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1. Background and rationale 
 
Cholera is an acute intestinal diarrhoeal disease with profuse watery diarrhoea, vomiting, 
rapid dehydration and high lethality in absence of adequate treatment. Current cholera 
outbreaks are caused by Vibrio cholerae 01 El Tor.  
 
Provision of safe water and proper sanitation are without doubt the long-term and only 
solution for cholera control. However, controlling cholera globally is far from being 
achieved; the disease burden is increasing with large-scale outbreaks reported in the past 
several years, such as those in Haiti and Zimbabwe. Current outbreak response 
interventions focus on case management and access to health care, as well as the immediate 
provision of safe water and hygiene promotion. However, current outbreak control 
activities have proven insufficient to avoid massive numbers of cases and deaths in recent 
large-scale outbreaks. The adequate treatment of cases for example, although crucial to 
decrease mortality, has a limited impact in controlling disease spread. Oral cholera vaccines 
(OCV), which have the potential to reduce the number of cases and minimize the spread of 
disease, could be an important addition to the cholera response arsenal.  
 
The World Health Organization (WHO) prequalifies the OCV Dukoral (SBL 
Vaccine/Crucell, Sweden) and Shanchol (ShantaBiotechnics, Hyderabad, India). Both are 
killed whole cell V cholerae O1 vaccines; Shanchol also contains V cholerae O139 and Dukoral 
the recombinant cholera toxin B subunit. The two vaccines share a good safety and efficacy 
profile with an estimated protection of 60–85% for 2–3 years. Although, recommended by 
WHO (including in response to outbreaks since 2010), their use as public health tools has 
been limited. Specifically, questions about the acceptability, feasibility, effectiveness, cost 
and potential diversion of resources have discouraged the use of OCV for outbreak control. 
 
Dukoral showed 84% short-term protection (six months) under field conditions, and has 
been successfully used both in Asia and Africa. Conversely, the effectiveness of Shanchol 
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under field conditions needs to be determined as the efficacy of the vaccine has been only 
measured under experimental conditions in Kolkata, India. Furthermore, as the trial was not 
designed to evaluate the short-term, but rather long-term protection (at two, three and five 
years), the protection offered by Shanchol within the first months after vaccination remains 
unknown. Shanchol has important difference compared with Dukoral; its price is 
considerably lower (1.85 vs. 5.25 US$ per dose), it does not require buffer and occupies 
lower storage volume, which reduces the logistic burden to implement mass vaccination 
campaigns. Evidence about the protection conferred by Shanchol in the first months after 
administration under field conditions is essential when considering its use for outbreak 
response. This is especially true at a time when WHO and its partners are in the process of 
creating a cholera vaccine stockpile for emergency use.  
 
In 2012, the Ministry of Health (MoH) of the Republic of Guinea, with the support of 
Médecins Sans Frontières (MSF), organized the first mass vaccination campaign using a 
two-dose oral cholera vaccine (Shanchol) as an additional control measure to respond to an 
on-going nationwide epidemic. This was also the first time that Shanchol was used in a 
mass vaccination campaign on the African continent. This project proposal aimed to gain 
evidence on the use of OCV to diminish cholera consequences in epidemic situations, trying 
also to identify critical elements for scaling up its use. Furthermore, it intended to enable the 
assessment of whether a reactive cholera vaccine intervention in selected, high-risk areas is a 
feasible, acceptable and effective strategy to reduce morbidity and mortality during future 
cholera outbreaks. 
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2. Objectives 
 
2.1. Overall Objective 
 
To evaluate the feasibility, acceptability and effectiveness of a mass vaccination campaign 
using the oral cholera vaccine Shanchol in response to an outbreak in order to identify 
critical elements for scaling up its use in real life situations. 
 
This overall objective was addressed through the following specific objectives: 
  
2.2 Specific Objectives 
 
 Feasibility assessment of the mass vaccination campaign  
o To describe the mass vaccination campaign procedures 
o To monitor number of doses administered, the time of administration, the 
vaccine wastage and the costs. 
 
 Assessment of the acceptability of the mass vaccination campaign by the population 
o To estimate the percentage of people vaccinated in the first and the second 
round of the mass vaccination campaign, by age group (1-4 years, 5-14 years 
and over 15 years old) 
o To estimate the percentage of people who received two doses of vaccine, by 
age group (1-4 years, 5-14 years and over 15 years old) 
o To estimate the dropout rate between the two rounds 
o To describe the reasons for not being vaccinated during the different 
vaccination opportunities 
o To describe the acceptability of the oral cholera vaccine used during the mass 
vaccination campaign. 
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 Surveillance of adverse events following immunization 
o To describe the adverse effects following immunization 
 
 Evaluation of the performance of the cholera rapid diagnostic test Crystal in 
vaccinated individuals 
o To estimate the proportion of positive results of a cholera rapid diagnostic 
tests in recipients of the cholera vaccine at different time points after 
vaccination  
o To estimate the mean time to become negative (in those with an initial 
positive test after vaccination 
 
 Estimate of the vaccine effectiveness 
o To estimate vaccine effectiveness of two complete doses of the oral bivalent 
cholera vaccine Shachol  
o To determine the presence or absence of bias related with the health seeking 
behavior that can affect the vaccine effectiveness estimates 
 
 
3. Material and Methods 
 
3.1 Feasibility of the mass vaccination campaign 
A descriptive analysis of mass vaccination procedures was conducted through direct 
observation and on-site recording of the following information in specific registers:  
 Composition and organization of vaccination teams and other participating 
personnel 
 Number of doses administered  
 Vaccine wastage 
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 Average time of administration and time spent in vaccination sessions 
 Logistical problems faced, including transportation and storage of vaccines and 
water 
 Availability of safe water 
 Waste managment 
 Overall direct costs incurred  
 
3.2. Acceptability of the mass vaccination campaign by the population 
We performed a cross-sectional cluster survey and implemented adverse event surveillance. 
The study population included individuals older than 12 months, eligible for vaccination, 
and residing in the areas targeted for vaccination (Forécariah and Boffa, Guinea). Data 
sources were household interviews with verification by vaccination card. 
 
3.3. Adverse events following immunization 
Surveillance of adverse events following immunization was implemented in the sites where 
the mass vaccination campaigns were carried out as well as in the health centers and health 
posts of the areas targeted by the mass vaccination campaigns for 14 days following each 
vaccination round. The following data were collected using a standardized form age, sex, 
pregnancy, history of allergies, vaccination date, consultation date, date of onset of the 
symptoms, type of symptoms, and clinical outcome (recovery, transfer or death). 
 
3.4. Performance of the cholera rapid diagnostic test crystal in vaccinated 
individuals  
A total of 108 vaccinated individuals, selected systematically among all persons older than 
one year, were included at vaccination sites and 106 were included in the analysis. Stools 
samples of this cohort of vaccinated participants were collected and tested with the rapid 
diagnostic test every day until the test was negative for two consecutive visits or for a 
maximum of 7 days. 
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3.5 Vaccine effectiveness 
We conducted a matched case-control study between May 20 and October 19, 2012. 
Suspected cholera cases were confirmed by rapid test, control subjects were selected among 
neighbors of the same age and sex as the case-patients. The odds of vaccination were 
compared between case-patients and control-subjects in bivariate and adjusted conditional 
logistic regression models. Vaccine effectiveness was calculated as 1-odds ratio per 100. 
 
4. Results 
We administered 312,650 doses of vaccine during two vaccination rounds in two coastal 
districts in Guinea. The feasibility, timeliness of implementation, and delivery cost were 
similar to those of other mass vaccination campaigns.  
 
In total 5,248 people were included in the household-based surveys, 3,993 in Boffa and 1,255 
in Forécariah. Overall, 89.4% [95%CI:86.4–91.8%] and 87.7% [95%CI:84.2–90.6%] were 
vaccinated during the first round and 79.8% [95%CI:75.6–83.4%] and 82.9% [95%CI:76.6–
87.7%] during the second round in Boffa and Forécariah respectively. The two dose vaccine 
coverage (including card and oral reporting) was 75.8% [95%CI: 71.2–75.9%] in Boffa and 
75.9% [95%CI: 69.8–80.9%] in Forécariah respectively. Vaccination coverage was higher in 
children. The main reason for non-vaccination was absence. No severe adverse events were 
notified. 
 
A total of 94.3% of cholera vaccine recipients had a positive test after vaccination; all except 
one of these positive results were reactive only with the O139 antigen. The mean time to 
become negative in those with an initial positive result after vaccination was 3.8 days. 
Overall, 40 case-patients and 160 control-subjects were included in the vaccine effectiveness 
study for the primary analysis between June 8 and October 19, 2012. Vaccination with two 
complete doses was associated with significant protection against cholera, in the crude 
analysis and after adjustment for potentially confounders (86.6%; 95% confidence interval: 
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56.7 to 95.8%; P value=0.001). In the sub-analysis including only cases that were culture 
and/or PCR confirmed, vaccination with two complete doses was also associated with 
significant protection against cholera (91.6%; 95% confidence interval: 58.6 to 98.3%; P 
value=0.002). 
 
5. Conclusions  
 The implementation of the first vaccination campaigns with a prequalified oral 
cholera vaccine in response to epidemics is a feasible strategy. 
 
 The vaccination campaign was well accepted by the population, and high 
vaccination coverage was achieved despite the short time available for preparation, 
the two-dose schedule, the remote rural setting, and the highly mobile population. 
 
 The oral cholera vaccine Shanchol is safe when administered in mass vaccination 
campaigns. 
 
 The rapid test Crystal can be used normally as soon as 24 hours after vaccination in a 
context of O1 epidemics, which represent the vast majority of cases, and after a 
period of five days in areas where V cholerae O139 is present. 
 
 The effectiveness of Shanchol when used in response to outbreaks is high, which 
supports the addition of vaccination as an outbreak response tool.  
 
This evidence should serve to strongly recommend the addition of OCV among the tools to 
be used in response to epidemics, alongside efforts to improve provision of safe water and 
sanitation and access to cholera treatment. In addition it served to support the creation of an 
oral cholera vaccine stockpile for emergency use by the World Health Organization (WHO) 
and partners. This work has been also considered by the Global Alliance for Vaccines and 
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Immunization (GAVI) in order to include the oral cholera vaccine among the vaccine 
supported for introduction in the next coming years. 
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1. Introducción y justificación 
 
El cólera es una enfermedad intestinal aguda que se presenta con diarrea acuosa profusa, 
vómitos, y deshidratación rápida, acompañado de una alta letalidad en ausencia de un 
tratamiento adecuado. Actualmente los brotes de cólera están causados principalmente por 
la cepa Vibrio cholerae 01 El Tor. 
 
El suministro de agua potable y un saneamiento adecuado son sin duda la única solución a 
largo plazo para el control del cólera. Sin embargo, el control del cólera a nivel mundial está 
lejos de ser una realidad, la carga de la enfermedad está aumentando con brotes de gran 
amplitud declarados en los últimos años, como los de Haití en 2010 y Zimbabue en 2009. Las 
intervenciones usuales de respuesta frente a los brotes epidémicos de cólera se centran en el 
manejo clínico de los pacientes y la mejora del acceso a la atención médica, así como en el 
suministro de agua potable y la promoción de medidas de higiene. Sin embargo, estas 
actividades han demostrado no ser suficientes para evitar un elevado número de casos y 
muertes en los últimos brotes epidémicos. El tratamiento adecuado de los casos por ejemplo, 
aunque crucial para reducir la mortalidad, tiene un impacto limitado en el control de la 
propagación de las epidemias. Las vacunas contra el cólera, que tienen el potencial de 
reducir el número de casos y reducir al mismo tiempo la propagación de la enfermedad, 
podrían ser una herramienta adicional al arsenal de respuestas a los brotes de cólera.  
 
La Organización Mundial de la Salud (OMS) precalifica actualmente dos vacunas contra el 
cólera: Dukoral (SBL Vacuna / Crucell, Suecia) y Shanchol (ShantaBiotechnics, Hyderabad, 
India). Ambas vacunas están compuestas por células enteras inactivadas de V cholerae O1; 
Shanchol también contiene V cholerae O139 y Dukoral una subunidad B recombinante de la 
toxina del cólera. Las dos vacunas comparten un buen perfil de seguridad y eficacia con una 
protección estimada de 60-85% durante 2-3 años. Aunque, recomendadas por la OMS, su 
uso como herramientas de salud pública ha sido muy limitado; dudas sobre la 
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aceptabilidad, el potencial desvío de recursos, el coste y la factibilidad de la implementación 
de campañas de vacunación en masa han desalentado su uso. 
 
Dukoral ha mostrado una protección a corto plazo (seis meses) del 84% utilizada en 
condiciones de campo tanto en Asia como en África. Por el contrario, la eficacia de Shanchol 
en condiciones de campo se desconoce aún ya que la eficacia de la vacuna se ha medido sólo 
en condiciones experimentales en Calcuta, India. Además, el ensayo clínico de Calcuta no 
fue diseñado para evaluar la protección a corto plazo, sino la protección a largo plazo (a los 
dos, tres y cinco años), por lo que la protección ofrecida por Shanchol en los primeros meses 
después de la vacunación sigue siendo desconocida.  
 
Shanchol tiene importantes diferencias en comparación con Dukoral, su precio es 
considerablemente más bajo (1,85 vs. 5,25 dólares EE.UU. por dosis), no requiere búfer y 
ocupa un volumen de almacenamiento menor, lo que reduce la carga logística para llevar a 
cabo campañas de vacunación en masa. Es por esto que la evidencia sobre la protección que 
confiere Shanchol en los primeros meses después de su administración en condiciones de 
campo es esencial para considerar su uso en la respuesta a brotes epidémicos.  
 
Este estudio pretende evaluar diferentes aspectos de la la primera utilización en respuesta a 
una epidemia de una vacuna oral contra el cólera precalificada por la OMS. Esta fue 
también la primera vez que Shanchol ha sido utilizada en el continente africano, donde se 
registra cada año el mayor número de muertes ligadas al cólera. En 2012, el Ministerio de 
Salud de la República de Guinea, con el apoyo de Médicos Sin Fronteras, organizó una 
campaña de vacunación en masa con  vacuna oral contra el cólera (Shanchol) como una 
medida de control adicional en la respuesta ante una epidemia de esta enfermedad. Con los 
diferentes estudios incluidos en este manuscrito buscamos obtener evidencia sobre el uso de 
vacunas orales para disminuir las consecuencias del cólera en situaciones epidémicas, 
tratando también de identificar los elementos críticos para extender su uso a otros contextos. 
Asimismo, buscamos evaluar si la vacunación contra el cólera en respuesta a brotes 
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epidémicos es una estrategia viable, aceptable y eficaz para reducir la morbilidad y la 
mortalidad durante futuras epidemias de cólera. 
 
 
2. Objetivos 
 
2.1. Objetivo general 
Evaluar la factibilidad, aceptabilidad y eficacia de una campaña de vacunación en masa con 
la vacuna oral contra el cólera Shanchol en respuesta a un brote epidémico con el fin último 
de identificar los elementos críticos para ampliar su uso en situaciones epidémicas reales. 
 
Este objetivo general fue abordado a través de los siguientes objetivos específicos: 
 
2.2  Objetivos Específicos 
 Evaluación de la factibilidad de la campaña de vacunación en masa 
o Describir los procedimientos para implementar la campaña de vacunación en 
masa 
o Estimar el número de dosis administradas, el tiempo de administración, la 
pérdida de vacunas  y los costes asociados. 
 Evaluación de la aceptabilidad de la campaña de vacunación en masa por la 
población 
o Estimar el porcentaje de personas vacunadas en las dos rondas de 
vacunación, por grupo de edad (1-4 años, 5-14 años y mayores de 15 años) 
o Estimar el porcentaje de personas que recibieron dos dosis de la vacuna, por 
grupo de edad (1-4 años, 5-14 años y mayores de 15 años) 
o Estimar la tasa de abandono entre las dos rondas de vacunación 
o Describir las razones para no vacunarse durante las diferentes oportunidades 
de vacunación 
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 Vigilancia de eventos adversos tras la inmunización 
o Describir los efectos adversos tras la vacunación 
 Evaluación del test rápido Crystal para el diagnóstico de cólera en individuos 
vacunados 
o Estimar la proporción de resultados positivos en las personas vacunadas 
contra el cólera a diferentes intervalos de tiempo después de la vacunación 
o Estimar el tiempo medio para la obtención de un resultado negativo (en 
aquellos con una prueba positiva inicial) después de la vacunación 
 Estimación de la efectividad de la vacuna 
o Estimar la eficacia de la vacuna oral bivalente contra el cólera (Shanchol) tras 
la administración de dos dosis completas 
o Determinar la presencia o ausencia de sesgo sobre las estimaciones de la 
eficacia de la vacuna relacionado con la búsqueda de tratamiento en caso de 
diarrea 
 
3. Material y Métodos 
 
3.1 Factibilidad de la campaña de vacunación en masa 
Se llevó a cabo un análisis descriptivo de los procedimientos de vacunación en masa 
mediante a partir de la siguiente información recogida en los puntos de vacunación 
mediante el uso de registros destinados a tal efecto: 
• Composición y organización de los equipos de vacunación y demás personal que 
participó en la campaña de vacunación  
• El número de dosis administradas 
• Proporción de vacunas perdidas 
• El tiempo medio de administración y el tiempo utilizado para completar las sesiones de 
vacunación 
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• Problemas logísticos que se encontraron, incluyendo el transporte, el almacenamiento 
de vacunas y la distribución de agua 
• Disponibilidad de agua potable 
• Gestión de residuos 
• Los costes totales directos  
 
3.2 Aceptabilidad de la campaña de vacunación en masa por la población 
Se realizó una encuesta transversal con muestreo en conglomerados. La población de 
estudio incluyó a individuos mayores de 12 meses, elegibles para la vacunación, y que 
residían en las zonas seleccionadas para la vacunación (Forécariah y Boffa, Guinea). Las 
fuentes de datos fueron las entrevistas realizadas en los hogares, con verificación de los 
carnets de vacunación. 
 
3.3 Eventos adversos tras la inmunización 
La vigilancia de eventos adversos tras la vacunación se llevó a cabo en los puntos de 
vacunación  donde se implementaron las campañas de vacunación en masa, así como en los 
centros de salud y puestos de salud de las zonas objeto de las campañas de vacunación 
durante los 14 días sucesivos a cada ronda de vacunación. Los datos a continuación se 
recogieron  a través de registros estandarizados: edad, sexo, embarazo, antecedentes de 
alergias, fecha de vacunación, fecha de consulta, la fecha de inicio de los síntomas, tipo de 
síntomas y severidad, y resultado clínico (curación, referencia a un hospital o muerte). 
 
3.4 Rendimiento del test de diagnóstico rápido de cristal de cólera (Crystal) en los 
individuos vacunados   
Un total de 108 personas vacunadas se incluyeron en dos puntos de vacunación. Los sujetos 
fueron sistemáticamente seleccionados entre todas las personas mayores de un año 
presentes en los puntos de vacunación. De los 108 individuos, 106 fueron incluidos en el 
análisis. Se recogieron muestras diarias de heces y se testaron con el test de diagnóstico 
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rápido para el cólera hasta que la prueba fue negativa durante dos visitas consecutivas o 
durante un máximo de 7 días. 
 
3.5 Efectividad de la vacuna 
Se realizó un estudio de casos y controles. Los casos sospechosos de cólera fueron 
confirmados por pruebas de diagnóstico rápido, se seleccionó una muestra de sujetos 
control entre los vecinos de la misma edad y sexo que los casos. Las odds de vacunación se 
compararon entre los caos y los controles con modelos de regresión logística condicional 
bivariados y ajustados por posibles factores de confusión. La efectividad de la vacuna se 
calculó como 1-odds ratio por 100. 
 
4. Resultados 
Durante las campañas de vacunación en masa en dos distritos litorales de la República de 
Guinea se administraron 312.650 dosis de la vacuna contra el cólera en dos rondas de 
vacunación. La factibilidad, el tiempo de implementación y el coste de la campaña son 
similares a los de otras campañas de vacunación en masa implementadas en respuesta a 
epidemias (como el sarampión y la meningitis). 
 
En total 5.248 personas fueron incluidas en las encuestas poblacionales: 3.993 en Boffa y 
1.255 en Forécariah. En general, el 89,4% [IC 95%:86.4-91 0,8%] y 87,7% [IC 95% :84.2-90 
0,6%] fueron vacunados en la primera vuelta y el 79,8% [IC 95% :75.6-83 0,4%] y 82,9% [ 95% 
CI :76.6-87 0,7%] en la segunda ronda en Boffa y Forécariah respectivamente. La cobertura 
de dos dosis de la vacuna (incluyendo la información verificada en carnet de vacunación y 
verbalmente) fue 75,8% [IC 95%: 71,2-75,9%] en Boffa y 75,9% [IC 95%: 69,8-80,9%] en 
Forécariah respectivamente. La cobertura de vacunación fue mayor en los niños. La razón 
principal para no vacunarse fue la ausencia durante la campaña de vacunación. No se 
notificó ningún evento adverso grave. 
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Entre las personas que recibieron la vacuna del cólera, un 94.3% tuvo un resultado positivo 
en el test de diagnóstico rápido para el cólera; todos estos resultados positivos excepto uno 
fueron exclusivamente positivos al antígeno O139. El tiempo medio para obtener un 
resultado negativo en los pacientes con un resultado positivo después de la vacunación 
inicial fue de 3,8 días. 
 
En total, 40 casos y 160 de controles fueron incluidos en el análisis principal de efectividad 
de la vacuna. La vacunación con dos dosis completas se asoció con una protección 
significativa contra el cólera en el análisis crudo y tras ajustar por potenciales factores de 
confusión (efectividad: 86,6%, IC 95%: 56,7-95,8%, valor p = 0,001). En el sub-análisis 
incluyendo sólo los casos que tuvieron un resultado positivo en el cultivo y / o en la PCR, la 
vacunación con dos dosis completas también se asoció con una protección significativa 
contra el cólera (efectividad: 91,6%, IC 95%: 58,6 a 98,3%, valor p = 0,002). 
 
5. Conclusiones 
 La primera utilización de una vacuna oral contra el cólera precualificada por la OMS 
en respuesta a una epidemia fue una estrategia viable. 
 
 La campaña de vacunacion fue bien aceptada por la población, y la elevada 
cobertura vacunal se logró a pesar del poco tiempo disponible para la preparación, la 
pauta de dos dosis, un entorno rural de difícil acceso y una población con gran 
movilidad. 
 
 La vacuna contra el cólera oral Shanchol es segura cuando se administra en las 
campañas de vacunación en masa. 
 
 El test diagnóstico rápido Crystal se puede utilizar normalmente tras la vacunación 
en un contexto de epidemias de V cholerae O1, que representan la gran mayoría de 
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los casos, y después de un período de cinco días en las zonas donde V cholerae O139 
está presente. 
 
 La eficacia de Shanchol cuando se utiliza en respuesta a los brotes es alta, lo que 
apoya la inclusión de la vacunación como una herramienta de respuesta situaciones 
epidémicas. 
 
La evidencia presentada en este trabajo sirvió para recomendar la incorporación de vacunas 
orales contra el cólera entre las herramientas de respuesta a las epidemias de cólera. Así 
mismo, sirvió a la creación por parte de la OMS y sus colaboradores de un stock de vacunas 
contra el cólera para uso en situaciones de emergencia sanitaria. Este trabajo ha sido 
considerado por la Global Alliance for Vaccines and Immunisation (GAVI) para incluir las 
vacunas contra el cólera entre las vacunas cuya introducción será apoyada en los próximos 
años.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
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1.1 History of cholera and global disease burden 
 
Cholera is an infectious disease that produces acute profuse watery diarrhea, vomiting, 
rapid dehydration and high mortality in absence of adequate treatment. Cholera is caused 
by the gram-negative bacteria Vibrio cholerae and it is one of the oldest diseases affecting 
humans [1–4]. The earliest reports of dehydrating diarrhea were recorded in Sanskrit in the 
5th century BC. Hippocrates also reported the symptoms of cholera in several documents. 
The disease has existed in the Indian subcontinent for centuries. The first contemporary 
reporting of epidemic cholera was from Garcia del Huerto, a Portuguese physician working 
in India. During the epidemic that affected London between 1849 and 1854, John Snow 
proposed that cholera was a communicable disease and that stool contained infectious 
material. He suggested that this infectious material could contaminate drinking water 
supplies, resulting in transmission of cholera. Filippo Pacini, working independently in Italy 
in 1854, was the first to observ comma-shaped forms under a microscope in cholera stools. 
In 1884, Robert Koch first isolated V cholerae in pure culture in Egypt and India. 
 
Six pandemics have been registered between 1817 and 1923. All of them started in the 
Ganges delta and were caused by V cholerae O1, Classical biotype. The ongoing 7th 
pandemic is caused by V cholerae O1, El Tor biotype, which was first reported in Indonesia 
in 1961, reached the Indian subcontinent in 1966 and then spread to the Middle East. It 
reached Africa in 1970 and extended rapidly throughout the continent, creating new 
endemic zones that had not been affected by cholera for over a century. It took another 20 
years for the 7th pandemic to reach the Americas: the first cases were reported in Peru in 
1991 and within one year the disease spread throughout Latin America. A new strain 
appeared in 1992: V cholerae O139 (Bengal). This new strain has in principle the potential to 
emerge as the 8th pandemic and to replace V cholerae O1 El Tor. 
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Although cholera has disappeared from the diseases affecting the high income countries, 
controlling cholera globally is far from being achieved and it remains one of the main causes 
of morbidity and mortality in the poorest areas of the world [5,6]. Moreover, the disease 
burden is increasing with large-scale outbreaks reported in the past several years, such as 
those in Haiti and Zimbabwe [7].. Every year an estimated 3 million cases of cholera and 
about 100,000 deaths occur worldwide [7]. The reported cholera case fatality rates remain 
high in many countries particurally among vulnerable groups and high-risk areas [8]. The 
burden of the 7th pandemic has shifted from South and Central America to the African 
continent. Currently African countries account for the highest proportion of cholera cases 
and deaths reported worldwide. However, it is likely that a high underreporting of cases 
occurs in Southern Asian countries 
 
 
1.2 Causal agent 
 
The Vibrio cholera, part of the family Vibrionaceae, is a Gram-negative, non-spore forming, 
comma-shaped bacterium, 1.4—2.6µm long. The V cholerae is capable of having both, a 
respiratory and a fermentative metabolism. The bacterium is oxidase-positive, reduces 
nitrate and is motile through a single, sheathed, polar flagellum [1,2,9]. The V cholerae has 
two circular chromosomes, with 4 million base pairs of DNA sequence and 3,885 predicted 
genes. Chromosome 1 has ~3 million base pairs and chromosome 2 has ~1 million base pairs 
[10]. The first chromosome contains the crucial genes for toxicity, regulation of toxicity and 
relevant cellular functions. The V cholerae contains a genomic island of pathogenicity called 
vibrio pathogenicity island (VPI) and is lysogenized with phage DNA that contains the 
genome of the cholera toxin (CT), which makes the bacterium pathogenic  [10]. 
 
The optimal growing conditions include salty water, alkaline media and warm 
temperatures. Although V cholerae can as well survive at low temperatures and it is able to 
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grow in water of low salinity if it is warm and rich in organic nutrients. The bacteria does 
not survive to acid media and boiling. The optimal  conditions for growing are found in 
estuarine environments, where zooplankton and shellfish are abundant [11,12] V cholerae 
enters in a viable but non-culturable form in water  [3,13,14] 
 
The serological classification of V cholerae is based in differences in the sugar composition of 
the heat-stable surface O-antigen (lipopolysaccharide). Currently, more than 200 different O 
serogroups have been described. Thus far, strains belonging to O group 1 (O1) are 
responsible for all the cholera pandemics. Strains that do not agglutinate with the O1-
antiserum are called non-O1; they can cause only sporadic infections and do not have the 
potential to cause epidemics. 
  
The strains of the serovar O1 consist of two biotypes, classical and El Tor. Antigenic factors 
allow further differentiating into serotypes. Both El Tor and Classic biotypes are divided 
into 3 serotypes: Ogawa (A and B antigens), Inaba (A and C antigens) and Hikojima (A, B 
and C antigens). The three serotypes can co-exist during an epidemic because of the 
flexibility of the bacteria to mutate between serotypes. Only recently, cholera infections in 
India and Bangladesh which subsequently were also reported in several parts of the Asia 
were caused by a novel non-O1 strain, the O139 Bengal [15,16]. The strain O139 Bengal 
closely resembles biotype El Tor of the serovar O1 and it most likely derived from V cholerae 
O1 El Tor by lateral transfer of a genomic island substituting the O139 for the O1 antigen  
[17–19].  
 
Although early isolates of V cholerae O1 were susceptible to most antibiotics, V cholerae O139 
and recent isolates of V cholerae O1 El Tor have acquired antibiotic resistance. Resistance to 
co-trimoxazole and streptomycin, which is  mediated by the acquisition of an SXT element, 
has been described in most of the isolates in the last decade  [20]. In the last year additional 
resistance has been described against tetracycline, erythromycin, ciprofloxacin, 
chloramphenicol, nalidixic acid or imipenem [21–25].  
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1.3 Pathogenesis 
 
The clinical characteristics of the disease caused by V cholerae O1 and O139 strains are 
equivalent. Both serogroups produce the clinical signs and symptoms by producing an 
enterotoxin that promotes the secretion of fluid and electrolytes into the lumen of the small 
intestine [9]. 
 
To reach the small intestine, the V cholerae needs to be ingested in enough quantity. Most of 
the bacteria are killed by the gastric acid, but some of them arrive at the small intestine, 
where they colonize the endothelium cells.  Therefore the use of antacids and histamine 
receptor blockers increases the risk of cholera infection and predisposes patients to more 
severe disease as a result of reduced gastric acidity. The same applies to patients with 
chronic gastritis secondary to Helicobacter pylori infection or those with gastrostomy. Retinol 
deficiency has been also associated with a higher risk of severe diseases [26,27]. As well, 
individuals with O blood group are prone to more severe diseases [28–31]. It has been 
suggested that virulence of V cholerae can be modulated by enteropathogenic bacteria and 
parasites [32,33]. 
 
The main virulence factors of V cholerae are the CT, a pilus that is required for colonization 
(toxin-coregulated pilus - TCP) and a membrane complex that regulates the production of 
TCP (ToxR).  The genes of the CT are encoded within the genome of a bacteriophage 
(CTXϕ) [34]. The classical and El Tor strains have different version of the CTXϕ. The surface 
receptor of the CTXϕ is the TCP. The genome of the TCP is encoded in a vibrio 
pathogenicity island (VPI)  [35,36]. 
 
The enterotoxin is a protein molecule composed of 5 B subunits and 2 A subunits  [37]. The 
B subunits are responsible for binding to a ganglioside (monosialosyl ganglioside, GM1) 
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receptor located on the surface of the cells that line the intestinal mucosa. The activation of 
the A1 subunit by adenylate cyclase is responsible for the net increase in cyclic adenosine 
monophosphate (cAMP). cAMP blocks the absorption of sodium and chloride by the 
microvilli and promotes the secretion of chloride and water  [38–40]. The result is an isotonic 
watery diarrhea. Unless the lost fluid and electrolytes are replaced adequately and rapidly, 
the infected person may develop shock from intense dehydration and acidosis from loss of 
bicarbonate [9]. 
 
 
1.4 Epidemiology 
 
Cholera is a disease of poverty and closely linked to poor sanitation and a lack of clean 
drinking water. Humans are the main natural host for V cholerae and constitute the main 
cholera reservoir. Nonetheless, V cholerae is naturally present in the environment and the 
existence of environmental reservoirs in association with copepods and other zooplankton 
has been documented in salty water and estuaries. The disease is transmitted by fecal-oral 
route.  
 
Cholera spreads both as an endemic disease and in epidemics. Endemic cholera has been 
defined by the World Health Organization (WHO) as the occurrence of fecal culture-
confirmed cholera diarrhea in a population in at least three of the past five years [7]. Cholera 
occurs endemically in south and south-east Asia and in Africa, where it may also cause 
major outbreaks. Young children living in endemic areas are the most frequently affected by 
the disease, but any age group may suffer cholera infection, especially during epidemics 
[41].  
 
John Snow, one of the founders of modern epidemiology, showed the importance of 
descriptive epidemiology in cholera epidemics, emphasizing the importance of the 
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consideration of space, to target prevention and control activities [42]. Today, resources and 
tools for mapping are available; however,  the description of place in cholera epidemics 
remains poor and examples of studies using spatial technologies in the medical literature 
are limited [43–51]. Some recent examples in cholera outbreaks where the spatial component 
was analyzed have shown the existence of “hotspots” where some sub-populations are 
exposed at higher risk of infection [52–55]. In addition, it has been suggested that these 
hotspots can contribute in a higher extent to the progression of the epidemics [56]. The 
identification of high risk areas is crucial to properly target prevention and control strategies 
(see Annex 1: related publications 1 and 2).  
 
The work conducted by John Snow in London in the 19th century also established 
contaminated water as the main route of cholera transmission  [40] . Nonetheless, since then 
John Snow himself and others have suggested that other routes of transmission are also 
important. Studies have shown the importance of the foodborne transmission in cholera 
outbreaks  [57,58] and the preventive effect of using acidifiers in food  [59]. Other means of 
transmission, such as certain burial practices, are also possible  [60], and secondary cases at 
household level can be involved thereby maintaining transmission(see Annex 1: related 
publication 3)  [61–64].   
 
The possibility of direct person-to-person transmission through poor hygiene, patients’ 
fluids or infected clothes has been considered less important due to the high infectious dose 
(>105 vibrios) needed to produce infection under laboratory conditions [65,66]. The 
infectious dose of V cholerae required to cause clinical disease varies by the mode of 
administration. Recent studies have suggested that V cholerae from human stool is 
hyperinfectious compared with laboratory-grown bacteria (700-fold increase), which means 
a lower infectious dose and therefore a higher probability of human-to-human transmission  
[67–69]. The incubation period varies from 12 hours to 5 days [17]. 
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1.5 Diagnosis 
 
Cholera diagnosis relies on the microbiological identification of the pathogen by stool 
culture, which remains the gold standard to confirm the diagnosis. However, this procedure 
requires laboratory infrastructure, adequate transport procedures and trained staff [70]. As 
rapid diagnostic tests (RDT) require less time, a minimum laboratory infrastructure and 
basic technical skills, they are used to confirm cholera outbreaks in places where high 
laboratory standards are difficult to obtain [71]. 
 
In 2003, the Institut Pasteur developed a cholera RDT based on the qualitative detection of 
the lipopolysaccharide (LPS) antigen of both, Vibrio cholerae O1 and O139 serogroups, from 
stool specimens. This test uses one-step, vertical-flow immunochromatography principle 
and monoclonal antibodies against the core and O-specific polysaccharides of each 
serogroup for capture and detection of antigens [72,73]. The O1 specific antigenic 
determinant is common to Ogawa and Inaba serotypes [73,74] and the one for O139 is 
common to both O139 capsular polysaccharide and LPS. This cross-reactivity between O139 
LPS and capsular polysaccharide explains that antibodies react with both encapsulated and 
non-encapsulated V cholerae O139 strains [75]. The RDT is produced by Span Diagnostics 
(Surat, India) under the trade name Crystal VC [70,76]. Several evaluations have shown 
good sensitivity, ranging from 92% to 100% [72,77,78]. In contrast, the specificity was lower 
and most evaluations in field conditions have shown specificities from 71% to 77% when 
compared with culture as the gold standard [76–79]. Nevertheless, the use of culture as gold 
standard may underestimate specificity, and re-analysis of the data using statistical methods 
for evaluation with an imperfect gold standard showed that the specificity could be around 
85% [80]. After these evaluations, the manufacturer SPAN changed the test presentation 
(order of the lines and addition of a dilution buffer), but the test in this new version has not 
been formally evaluated. This test is widely used for epidemiological purposes during 
outbreaks. However, given that the RDT Crystal VC detects the LPS antigens of V cholerae 
O1 and O139 in feces, which are also contained in the oral vaccine Shanchol, the stools of 
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vaccinated individuals could potentially become positive by the rapid test due to the 
vaccine only, in the absence of viable bacteria.  
 
 
1.6 Clinical features 
 
The typical presentation of cholera is a sudden onset of profuse painless watery stools, 
sometimes rice-water like, often accompanied by vomiting [81]. There is no fever. 
Dehydration appears within 12 to 24 hours. Cholera can cause as high as 20 to 50% mortality 
if case management is not adequate. Conversely, mortality is low (<2%) if well treated [9]. 
 
In moderate forms of the disease there are frequent watery stools but fluid loss and 
dehydration are moderate. In severe forms there is intense diarrhea and vomiting with 
significant fluid loss, more than 10 to 20 liters/day. Dry cholera is a rare condition which is 
characterized by  little diarrhea and/or vomiting and a rapid collapse due to severe acute 
dehydration and a high mortality rate. Death before arrival at the treatment center is 
frequent [82].  
 
The presentation of cholera differs between endemic and epidemic settings. In endemic 
settings, rates of asymptomatic V cholerae infection ranges from 40% to 80% [3], and cholera 
can present as a mild diarrhea indistinguishable from infection by other enteropathogens. 
The most severe cases of cholera in endemic settings are concentrated among young 
children and previously unexposed individuals. During an epidemic, severe disease occurs 
in adults as frequently as in children and it is associated with high case-fatality rates [83,84]. 
 
The degree of dehydration is graded according to the symptoms and signs that reflect the 
amount of fluid lost. Hypovolemic shock and death can occur quickly if rehydration 
therapy is not provided [85].  The degree of dehydration should be systematically evaluated 
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at admission and re-evaluated during the hospital stay. Patients are classified in three 
treatment plans according to the degree of dehydration (see table below)  [86]: 
 Plan A: No dehydration. Because clinical status may deteriorate rapidly, these 
patients may initially need to be kept under monitoring, especially when they live 
far from the treatment centre or when correct home treatment cannot be guaranteed.  
 
 Plan B: Moderate dehydration. Patients must be admitted to the treatment centre to 
receive treatment as indicated below and be monitored until diarrhea/vomiting 
stops. 
 
 Plan C: Severe dehydration.  Patients must be admitted to the treatment centre to 
receive treatment as indicated below and be monitored until diarrhea/vomiting 
stops. 
 
After dehydration, hypoglycemia is the most common lethal complication of cholera in 
children [87]. Hypoglycemia is the result of diminished food intake during acute illness. 
Acute pulmonary edema is related to over-hydration, due to excessive IV rehydration. It is a 
common risk among elderly, young children and severely anemic patients. Renal failure 
(anuria) is a rare complication that can occur when a shock is not rapidly corrected. Urine 
output normally resumes within 6 to 8 hours after starting rehydration [88,89]. 
Hypokalemia should be suspected if repeated episodes of painful cramps occur [89].  
 
 
1.7 Treatment 
 
In an epidemic situation, any patient with diarrhea and/or vomiting is a suspect cholera 
case. The most important element of cholera treatment is rapid replacement of the water 
and salts lost through diarrhea and vomiting. Most patients can be treated using oral 
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rehydration solution (ORS) alone [82,90]. Only severely dehydrated patients need the 
administration of intravenous fluid (IV). IV fluid might be also required in patients with 
profuse vomiting. Antibiotic therapy may reduce the volume of diarrhea and carriage time 
of V cholerae in severely ill patients; however antibiotic treatment is not strictly needed in 
most cholera patients. 
 
Patients without signs of dehydration and with moderate dehydration should be rehydrated 
orally using the standard WHO-ORS (plans A and B) [91,92], as more potassium, 
bicarbonate and glucose are available in ORS than in the IV fluids  [82,90]. IV is required in 
patients with severe dehydration, with IV needs around 200mL/Kg (plan C)  [86,93]. Ringer 
Lactate solution is the best option. It provides an adequate concentration of sodium, some 
potassium and enough lactate, which is metabolized into bicarbonate for the correction of 
acidosis. Oral rehydration should be started as soon as the patient is able to drink. The 
patient’s condition must be assessed every 30 minutes during the first 2 hours, then every 
hour for the next 6-12 hours. Monitoring is based on pulse and respiratory rates; and the 
frequency of urine, stool, and vomiting [86]. 
 
In severe cases, antibiotics can reduce the volume of diarrhea and carriage time of Vibrio 
[94]. Effective antibiotics shorten the duration of diarrhea and reduce the volume of stools 
losses, while they reduce the duration of shedding bacteria in stools. Most cholera patients 
are cured by rehydration and do not need antibiotics. Antibiotics are indicated for patients 
with severe dehydration and/or complications and are given after IV rehydration. Before 
introducing antibiotics, it is important to check sensitivity and adjust the antibiotic choice 
accordingly as resistance to different antibiotics has been documented worldwide [95–101]. 
 
Zinc supplementation after childhood diarrhea also reduces the incidence of subsequent 
episodes of diarrhea for several months [102,103]. WHO recommends zinc for children 
younger than 5 years of age with diarrhea. Children with diarrhea in developing countries 
also benefit from supplementation with vitamin A [104]. 
Introduction |  30 
 
 
 
 
1.8 Prevention 
 
Cholera prevention is based in access to safe water and proper sanitation as well as 
adhesion to safe food-handling practices [86]. In areas where the safety of water is not 
ensured, it is recommended to boil the water or treat it with a chlorine product before 
consumption, to store it in clean, covered containers and to bottle it with unbroken seals. 
 
Hygiene is also a pillar of cholera prevention. It is important to wash hands often with soap 
and safe water: before eating or preparing food, before feeding or cleaning children, after 
using the latrine or toilet and after taking care of someone ill with diarrhea. 
 
In order to limit the spread of the diseases it is important to use latrines or bury the feces 
and not defecate in any body of water. It is also important to clean latrines and surfaces 
contaminated with feces using a chlorine solution.  
 
Intense information, education and communication activities are required in order to 
achieve improvements in the quality of the water at the point of use, sanitation and hygiene 
practices. These activities require strong coordination from partners involved in cholera 
prevention and controls. Clear and easy to follow messages need to be provided to the 
population, especially during cholera outbreaks [105].  
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1.9 Cholera vaccines 
 
Widespread use of oral cholera vaccines (OCV) began in the 1960s. The vaccines then in use 
were composed of whole V cholerae O1 cells, killed using formalin, phenol or heat, and 
administered by injection. In the 1970s, the interest in these injected whole cell vaccines 
decreased [106], as it was perceived that they had a low efficacy (around 50%), provided 
only short-term immunity (3 to 6 months), and had an unacceptable rate of side effects. A 
Cochrane review, however, found that the duration and efficacy of the whole cell injected 
vaccines may have been underestimated; it was 54% at seven months (based on 18 trials) 
and 46% at one year (based on 14 trials). Protection waned by the second year in children 
under five, but persisted into the third year for those over the age of five years [107,108]. 
Nevertheless, injected vaccines are no longer in use or available, and attention is now 
focused on vaccines administered by the oral route. 
 
Vaccines work by stimulating immunity against a pathogen which has been killed, 
attenuated or otherwise rendered incapable of causing disease, in order to prevent or 
mitigate the effects of infection with the natural pathogen if it subsequently occurs. The 
route of administration of a vaccine may influence its immunogenicity and acceptability. 
Oral vaccines have the potential to stimulate local immunity within the mucosa of the gut, 
preventing the colonisation and multiplication of V cholerae. Since cholera is transmitted 
orally, oral vaccines may thus have more direct effect than injected vaccines which stimulate 
immunity in the blood. Oral vaccines are also potentially easier to administer, more 
acceptable to patients, and have a reduced risk of transmitting blood borne infections [109]. 
 
Two main types of oral vaccines have been investigated in clinical trials: inactivated 
vaccines (containing killed whole cells of V cholerae), and live attenuated vaccines 
(containing genetically modified, non-pathogenic strains of V cholerae). In addition, subunit 
vaccines have been tested which consist only of cell components (antigens). The live 
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attenuated vaccines are usually given as a single dose, whereas killed whole cell vaccines 
may require two or three doses at one to two week intervals to produce an adequate 
immunological response. Three vaccine formulations are currently available [4]: 
 
• WC-rBS (Dukoral): A monovalent inactivated vaccine containing killed whole cells of V 
cholerae O1 plus additional recombinant cholera toxin B subunit. Produced by SBL 
Vaccine/Crucell, Sweden. 
 
• BivWC (Shanchol): A bivalent inactivated vaccine containing killed whole cells of V 
cholerae O1 and V cholerae O139. Produced by Shantha Biotechnics, India. 
 
• BivWC (mORCVAX): A bivalent inactivated vaccine containing killed whole cells of V 
cholerae O1 and V cholerae O139. Produced by VABIOTECH, Vietnam and only available in 
Vietnam. 
 
Both WC-rBS (Dukoral) and BivWC (Shanchol) vaccines are prequalified by the WHO. 
 
1.9.1 Dukoral (WC-rBS) 
Dukoral was developed in Sweden and first licensed in 1991. It is licensed in more than 60 
countries, primarily as a vaccine for travelers to cholera-endemic areas. However, it has also 
been used in crisis situations in Indonesia, Sudan and Uganda, and in a demonstration 
project in an endemic area of Mozambique. Dukoral is a monovalent vaccine based on 
formalin and heat-killed whole cells (WC) of V cholerae O1 (classical and El Tor, Inaba and 
Ogawa) plus recombinant cholera toxin B subunit. The B subunit of cholera toxin was 
originally produced chemically (WC-BS) but is now produced by recombinant technology 
(WC-rBS). BS and rBS are practically identical in terms of immune response. To protect the 
toxin B subunit from being destroyed by gastric acid, the vaccine must be given with a 
bicarbonate buffer. The vaccine is provided in 3 ml single-dose vials together with the 
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bicarbonate buffer (effervescent granules in sachets). Vaccine and buffer are mixed in 150 ml 
of water (chlorinated or not) for persons aged >5 years and in 75 ml of water for children 
aged 2–5 years. The vaccine has a shelf life of 3 years at 2–8 °C and remains stable for 1 
month at 37 °C. 
 
Both prelicensure studies and postmarketing surveillance have demonstrated that Dukoral 
has a good safety profile, as has also been found safe in pregnant women and in HIV-
infected or other immunocompromised individuals. In clinical trials involving around 
240,000 participants, adverse events were no more common in vaccinees than in placebo 
recipients. The adverse events consisted primarily of mild abdominal discomfort, pain or 
diarrhoea, all of which were mainly attributed to the buffer solution given to both groups. 
Only 63 adverse reactions were associated with more than 1,000,000 doses of the vaccine 
sold in Scandinavia during 1992–2003. Dukoral stimulates the production of both 
antibacterial and antitoxin antibodies, including immunoglobulin A antibodies produced 
locally in the intestines. The vaccine has been tested in randomized placebo-controlled 
double-blind prelicensure efficacy trials in both Bangladesh and Peru.  
 
The Matlab trial in Bangladesh [110] involved 62,285 children aged 2–15 years and women 
aged >16 years. At the time of the trial, El Tor and classical cholera strains co-circulated in 
the study population. At 4–6 months following WC-BS immunization, the combined 
protective efficacy against El Tor and classical cholera for vaccinees aged >2 years was 85% 
(95% confidence interval [CI], 56–95%), dropping to 62% (95% CI, 46–74%) after 1 year of 
follow up [111]. During the second and third years of follow up, the protective efficacies 
were 58% (95% CI, 40–71%) and 18% (95% CI, 21–44%), respectively. The cumulative 
efficacy of the 2 doses over 3 years was 51% (95% CI, 40–60%) against El Tor and classical 
cholera combined; it was slightly lower against El Tor than against classical cholera [112].  
 
The Matlab results differed considerably among young children and older children and 
adults. Among children aged 2–5 years, the level of protection against El Tor and classical 
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cholera combined was 100% (95% CI, 80–100%) at 4–6 months following vaccination; it 
dropped to 38% (95% CI, 1–62%) at the end of 1 year, to 47% (95% CI, 4–71%) during the 
second year and to 0% thereafter [111]. The protective efficacy for people aged >5 years was 
78% (95% CI, 61–87%) at 1 year and 63% (95% CI, 41–77%) during the second year following 
immunization. Two doses of the WC-BS vaccine were as protective as 3 doses in people 
aged >6 years [112,113].During the first year of surveillance in Matlab, recipients of the 
vaccine made 26% fewer visits to treatment-centres for diarrhoea due to any cause and also 
had a 26% lower rate of mortality from all causes [113]. 
 
Studies of vaccine efficacy similar to the Matlab trials were conducted with Dukoral in Peru 
during the cholera epidemics in the 1990s. The vaccine conferred 86% protection against El 
Tor cholera among military aged 16–45 years during the first 4–5 months after vaccination 
[114]. In a trial in the outskirts of Lima, the vaccine showed no protection during the first 
year in any age group after 2 doses, but the study was criticized as lacking rigor during the 
observation period [115]. Following a booster dose given 10 months after the primary series, 
the vaccine conferred 61% (95% CI, 28–79%) protection in the second year against cholera 
and 82% (95% CI, 27–96%) against cholera requiring hospitalization [116]. 
 
During 2003–2004, the field effectiveness of Dukoral was studied in Beira, Mozambique, in 
an area where cholera is endemic and there is a high prevalence of HIV [117]. This case-
control study included 4 age-matched and sex matched neighbourhood controls for each of 
the 43 culture-confirmed cases; vaccine effectiveness at 1–6 months after vaccination was 
84% (95% CI, 43–95%) among people who received 2 doses; it was 78% (95% CI, 39–92%) 
among those who received 1 or 2 doses; it was 82% (95% CI, 19–98%) among children aged 
2–4 years who received 1 or 2 doses; and it was 67% (95% CI, 16–86%) among people aged 
≥5 years who received 1 or 2 doses. Furthermore, since the El Tor strain of V cholerae O1 that 
expresses the classical cholera toxin was responsible for all cases in this setting, the results 
show that Dukoral protects against this important El Tor variant. 
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1.9.2 Shanchol and mORCVAX 
The closely related bivalent OCV Shanchol and mORCVAX are based on serogroups O1 and 
O139. Unlike Dukoral, these vaccines do not contain the bacterial toxin B subunit . The 
original ORCVAX was licensed in Viet Nam in 1997. 
 
From 1998 to 2009, >20 million doses of this vaccine were administered to children in high-
risk areas of Vietnam, making ORCVAX the first oral cholera vaccine to be used primarily 
for endemic populations. In cooperation with the International Vaccine Institute in Korea, 
ORCVAX was significantly reformulated in 2004 to meet the requirements of WHO and 
good manufacturing practices. This involved replacing a high toxin-producing strain with 
the 2 V cholerae strains contained in the original Swedish vaccine and doubling the quantities 
of lipopolysaccharide antigen. Following successful phase II trials in India and Vietnam, this 
vaccine was licensed in 2009 as mORCVAX in Vietnam and as Shanchol in India; 
mORCVAX is currently intended for domestic use in Vietnam, whereas Shanchol is 
produced for Indian and international markets. Shanchol is provided in single-dose vials, 
mORCVAX in singledose and 5-dose vials. The vaccine has a shelf life of 2 years at 2–8 °C. 
(Stability tests at ambient temperatures are continuing). According to the manufacturer, 
Shanchol should be administered orally in 2 liquid doses 14 days apart for individuals aged 
≥1 year. A booster dose is recommended after 2 years. 
 
Shanchol and mORCVAX are considered safe and effective vaccines [118,119]. The original 
WC cholera vaccine included in the Bangladesh trials in the 1980s provided less short-term 
protection than Dukoral against El Tor and classical cholera, but at 2 years and 3 years of 
follow up the protection was equal to, or better than with Dukoral [112]. 
 
A modification of the original vaccine was evaluated 8–10 months after immunization in an 
open, controlled trial involving 334 000 residents of the Vietnamese city of Hue during an El 
Tor outbreak in 1992–1993. The protective efficacy of the vaccine for all ages after 2 doses 
was 66% (95% CI, 46–79%), and similar results were obtained in children aged 1–5 years and 
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adults [120]. The overall effectiveness of this vaccine 3–5 years after vaccination was 50% 
(95% CI, 9–63%) [121]. Following the addition of the O139 strain, the resulting bivalent 
vaccine was shown in non-inferiority trials to be safe and immunogenic against both O1 and 
O139 infection. In 2006, a cluster-randomized placebo-controlled double-blind phase III trial 
of Shanchol that includes 66 900 participants aged >1 year was conducted in slum districts of 
Kolkata, India. An interim analysis after 2 years of follow up showed an overall protective 
efficacy of 67% against culture-confirmed cholera among those who received 2 doses [122]. 
The vaccine was found to be protective in all age groups including in children aged 1–4 
years, and the protection showed no decline during the second year of follow up.12 Follow 
up will continue for 5 years. The cumulative protective efficacy at 5 years was 65% (95% CI, 
52-74%), and the study suggested no evidence of decline in protective efficacy over time 
[123]. 
 
1.10 Context: The Republic of Guinea 
The Republic of Guinea borders six countries and has a large coastline to the west (Figure 1). 
This coastal area has two main ports, one in the capital of Conakry, and the second in 
Kamsar. Guinea is divided into four natural regions: the coastal area (Lower Guinea or 
Maritime Guinea), the mountainous area of Middle Guinea, the savannah zone (Upper 
Guinea) and the equatorial forest zone (Forest Guinea). The population was estimated to be 
10 million in 2008, with a density of 38.5 inhabitants / km ². Population density is much 
higher in and around the capital Conakry, along the coastal strip and in Forest Guinea 
bordering Liberia and Sierra Leone. 
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Figure 1. Administrative map of the Republic of Guinea. Orange, Basse Guinée or Guinée 
Maritime; in blue Moyenne Guinée; in yellow Haute Guinée and in pink Guinée Forestière. 
Source: http://www.nozay44.com/guinee/ 
 
 
1.11 Cholera in Guinea 
1.11.1 Previous cholera outbreaks 
The 7th cholera pandemic began in 1961 with the cases reported from Africa in 1970. West 
Africa was affected including Guinea; where the first epidemic began in the capital city of 
Conakry and affected only two coastal prefectures, Conakry and Forécariah. Over the past 
fifty years, Guinea has suffered repeated epidemics interspersed with intervals without 
cases (Figure 2). In 1978 and 1986, cholera was reported only in the coastal prefectures. The 
largest reported epidemic occurred in 1994, with more than 30,000 cases and 670 deaths. In 
this epidemic, the continental (inland) prefectures were affected the first time; although the 
most affected areas remained the coastal prefectures and the islands [124].  
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Figure 2. Cholera cases, deaths and case fatality ratio (CFR) reported to the World Health 
Organization between 1970 and 2008. Source: World Health Organization. 
 
 
However, from 2003 to 2007, cholera outbreaks were reported each year, with increasing 
intensity. Maritime Guinea (and mainly the city of Conakry) and Forest Guinea were most 
affected. There was a clear association between weekly precipitation and number of cholera 
cases, with all epidemics peaking during the rainy season (July-August). In 2007, the 
outbreak began early in the year and was associated with a large number of reported cases. 
From 2008, only sporadic cases were reported, mainly in Kindia region of Maritime Guinea 
southwest of Conakry [125]. 
 
1.11.2 Cholera in Forecariah and Boffa 
Forecariah and Boffa prefectures are both located in Maritime Guinea. Forecariah prefecture 
is located in Kindia region and Boffa prefecture in Boké region (northeast of Conakry). 
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From 2003 to 2009, Forecariah prefecture reported 5.0% of cholera cases and 6.0% of deaths 
from Guinea. Forecariah has been affected by a cholera outbreak each year from 2004 to 
2007. It is part of a national priority area for cholera prevention and control, in particular the 
sub-prefectures of Kaback, Kakossa, Kalia and Benti [125].  
 
From 2003 to 2009, Boffa prefecture reported 4.7% of cholera cases and 4.6% of deaths from 
Guinea. During this period, epidemics were reported in 4 out of 7 years, with and overall 
attack rate of 36.9 per 10,000 inhabitants and a case fatality rate of 4.4%. In Boffa prefecture, 
the coastal sub-prefectures were the most affected, with attack rates ranging from 29.3 to 
81.6 per 10,000 inhabitants for this period. The coastal sub-prefectures (Tougnifily, Douprou, 
Boffa-centre et Koba) were considered as national priority areas for cholera prevention and 
control [125]. 
 
1.11.3 Cholera epidemic in 2012 
 
The first cases of cholera were reported in Forecariah in the region of Kindia. A total of 147 
cases and 13 deaths were reported from February 2nd to March 8th, 2012, followed by a 
decrease in the number of cases. On March 3rd, the first case was reported and confirmed in 
Conakry. After four years without cholera outbreak in Guinea, these local epidemics have 
emerged well before the rainy season signalling a high risk of large outbreak. A cholera 
outbreak was also on going in neighbouring Sierra Leone, with 13,934 cases and 232 deaths 
reported countrywide between January and August 2012 [126].  
 
The regional nature of the epidemic, the early notification of cases before the peak of the 
rainy season and the long interval without outbreaks, thereby increasing the number of 
susceptible individuals due to lack of prior exposure, all suggested the possibility of a large 
epidemic in Guinea in 2012. Case management, water, health education, hygiene and 
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sanitation interventions were implemented in response to the outbreak. In addition, non-
selective mass vaccination campaigns were implemented in the prefectures of Boffa and 
Forécariah (Figure 3) by Ministry of Health (MoH) of Guinea, with the support of Médecins 
Sans Frontières (MSF). This was the first cholera outbreak response in Africa using an OCV, 
and also the first time that Shanchol was used in a mass vaccination campaign on the 
African continent.  
 
 
 
Figure 3: Target areas for the non-selective mass vaccination campaigns, Guinea, 2012. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. JUSTIFICATION 
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Provision of safe water and proper sanitation are without doubt the long-term and only 
solution for cholera control [17,127]. However, controlling cholera globally is far from being 
achieved; the disease burden is increasing with large-scale outbreaks reported in the past 
several years, such as those in Haiti and Zimbabwe [7]. Current outbreak response 
interventions focus on case management and access to health care, as well as the immediate 
provision of safe water and hygiene promotion [17]. However, current outbreak control 
activities have proven insufficient to avoid massive numbers of cases and deaths in recent 
large-scale outbreaks [128]. The adequate treatment of cases for example, although crucial to 
decrease mortality, has a limited impact in controlling disease spread [7,17].  
 
Oral cholera vaccines, which have the potential to reduce the number of cases and minimize 
the spread of disease [56,129], could be an important addition to the cholera response 
arsenal [5,9,17]. The World Health Organization (WHO) prequalifies the OCV Dukoral (SBL 
Vaccine/Crucell, Sweden) and Shanchol (ShantaBiotechnics, Hyderabad, India). Both are 
killed whole cell V cholerae O1 vaccines; Shanchol also contains V cholerae O139 and Dukoral 
the recombinant cholera toxin B subunit. The two vaccines share a good safety and efficacy 
profile with an estimated protection of 60–85% for 2–3 years [17]. Although, recommended 
by WHO (including in response to outbreaks since 2010) [4], their use as public health tools 
has been limited. Specifically, questions about the acceptability, feasibility, cost and 
potential diversion of resources have discouraged the use of OCV for outbreak control [130]. 
 
Dukoral showed 84% short-term protection (six months) under field conditions, and has 
been successfully used both in Asia and Africa [110,117]. Conversely, the effectiveness of 
Shanchol under field conditions needs to be determined as the efficacy of the vaccine has 
been only measured under experimental conditions in Kolkata, India [122]. Furthermore, as 
the trial was not designed to evaluate the short-term, but rather long-term protection (at 
two, three and five years), the protection offered by Shanchol within the first months after 
vaccination remains unknown [122,131,132]. 
 
Justification | 43 
 
 
Shanchol has important differences compared with Dukoral; its price is considerably lower 
(1.85 vs. 5.25 US$ per dose [133]), it does not require buffer and occupies lower storage 
volume [134], which reduces the logistic burden to implement mass vaccination campaigns. 
Evidence about the protection conferred by Shanchol in the first months after administration 
under field conditions is essential when considering its use for outbreak response. This is 
especially true at a time when WHO and its partners are in the process of creating a cholera 
vaccine stockpile for emergency use [135].  
 
It is urgent to identify new tools and approaches for cholera control in Africa. The World 
Health Organization (WHO) has recommended that demonstration projects using OCV be 
performed in order to know whether, and in which circumstances, cholera vaccines may 
assist in the fight against cholera. 
 
This project proposal aimed to gain evidence on the use of OCV to diminish cholera 
consequences in epidemic situations, trying also to identify critical elements for scaling up 
its use. Furthermore, it intended to enable the assessment of whether a reactive cholera 
vaccine intervention in selected, high-risk areas is a feasible, acceptable and effective 
strategy to reduce morbidity and mortality during future cholera outbreaks. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. OBJECTIVES 
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3.1 Overall Objective 
 
To evaluate the feasibility, acceptability and effectiveness of a mass vaccination campaign 
using the oral cholera vaccine Shanchol in response to an outbreak in order to identify 
critical elements for scaling up its use in real life situations. 
 
This overall objective was addressed through the following specific objectives: 
  
3.2 Specific Objectives 
 
 Feasibility assessment of the mass vaccination campaign (see Annex 1: related 
publication 4) 
o To describe the mass vaccination campaign procedures 
o To monitor number of doses administered, the time of administration, the 
quantity of consumable and non-consumable materials used, the costs, the 
and vaccine wastage. 
 
 Assessment of the acceptability of the mass vaccination campaign by the population 
(see Annex 1: related publication 5) 
o To estimate the percentage of people vaccinated in the first and the second 
round of the mass vaccination campaigns, by age group (1-4 years, 5-14 years 
and over 15 years old) 
o To estimate the percentage of people who received two doses of vaccine, by 
age group (1-4 years, 5-14 years and over 15 years old) 
o To estimate the dropout rate between the two rounds 
o To describe the reasons for not being vaccinated during the different 
vaccination opportunities 
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o To describe the acceptability of the oral cholera vaccine used during the mass 
vaccination campaigns 
 
 Surveillance of adverse events following immunization (see Annex 1: related 
publication 5) 
o To describe the adverse effects following immunization 
 
 Evaluation of the performance of the cholera RDT Crystal in vaccinated individuals 
(see Annex 1: related publication 6) 
o To estimate the proportion of positive results of a cholera rapid diagnostic 
tests in recipients of the cholera vaccine at different time points after 
vaccination  
o To estimate the mean time to become negative (in those with an initial 
positive test) after vaccination 
 
 Estimate of the vaccine effectiveness (see Annex 1: related publication 7) 
o To estimate vaccine effectiveness of two complete doses of the oral bivalent 
cholera vaccine Shachol  
o To determine the presence or absence of bias related with the health seeking 
behavior that can affect the vaccine effectiveness estimates 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. MATERIAL AND METHODS 
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4.1 Study oversight and overall design 
This study was funded by MSF. The study protocol was approved by the Ethical Review 
Boards of the Republic of Guinea and MSF. Vaccine and treatment were provided free of 
charge and participation in the study was voluntary. Written consent was obtained from 
participants or their parents/guardians for the vaccine effectiveness study and oral informed 
consent was obtained for the acceptability assessment. 
 
The study design included five components: the feasibility assessment, surveillance of 
adverse events following immunization, the evaluation of the RDT in vaccinated 
individuals, a household based survey to assess acceptability and case-control study to 
estimate the vaccine effectiveness study. Figure 4 shows a summary diagram of the study 
design. 
 
 
Figure 4: Summary flow chart of the design 
 
4.2 Study population 
Non-selective mass vaccination campaigns were implemented in the prefectures of Boffa 
and Forécariah. In Boffa, the coastal part of the six sub-prefectures bordering the ocean 
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(Koba, Boffa-centre, Douprou, Tougnifily, and part of Mankountan and Tamita) were 
vaccinated from April 18 to May 14, and in Forécariah, the sub-prefectures of Kaback and 
Kakossa were vaccinated from May 27 to June 15 (Figure 3). During the second round, soap 
and a bottle chlorine solution was distributed by the Red Cross to all women of childbearing 
age presenting for vaccination.  
 
These campaigns targeted all residents in the targeted areas 1 year of age and older. The 
campaigns were organized by the MoH of Guinea, with the support of MSF. 
 
4.3 Feasibility assessment of the mass vaccination campaign  
A descriptive analysis of mass vaccination procedures was conducted through direct 
observation and on-site recording of the following information in specific registers (see 
Annex 2):  
 
 Composition and organization of vaccination teams and other participating 
personnel 
 Number of doses administered  
 Vaccine wastage 
 Average time of administration and time spent in vaccination sessions 
 Logistical problems faced, including transportation and storage of vaccines and 
water 
 Availability of safe water 
 Waste managment 
 Overall direct costs incurred  
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4.4 Assessment of the acceptability of the mass vaccination campaign by the 
population 
 
4.4.1 Study design 
A representative sample of the population in each of the survey sites (Boffa and Forecariah) 
was selected using cluster based sampling with population proportional to size [136]. The 
survey sample was selected among all resident older than one year at the time of the survey.  
Residents were defined as a persons living (sleeping and eating) in the area for at least two 
weeks. Ascertainment of vaccine status was done by examination of individual vaccination 
cards, as well as oral reporting of the vaccination status.  
 
Definitions 
 
 "Fully vaccinated" person was defined as an individual who received 2 complete 
doses of cholera vaccine (this was verified either by vaccination card or by 
interview). 
 
 "Incompletely vaccinated" was defined as an individual who took only one dose or 
who spitted out or vomited one of the two doses of vaccine (this was verified either 
by vaccination card or interview). 
 
 "Unvaccinated" was defined as an individual who had no vaccination card and who 
confirmed on interview that she/he received no dose.  
 
 "Unknown vaccination status" was defined as an individual who had no vaccination 
card and who was unable to describe their vaccination status.  
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4.4.2 Sample size calculation 
The sample size was calculated to obtain a representative estimate of the proportion of 
residents who received two doses of the OCV by age group. Children 1-4 years old 
represent the smallest proportion of the overall population, so the sample size was 
calculated to ensure a sufficiently precise estimate for this age group. 
 
The following assumptions were considered: 70% of residents received two doses of 
vaccine, alpha error of 5%, absolute precision of 7% for Boffa and 10% for Forecariah, design 
effect of 3 for Boffa and 1.5 for Forécariah (since the coverage was  expected to be more 
homogenous in the Forecariah islands).  
 
The sample size required was therefore 494 children aged 1 to 4 years for Boffa and 121 
children for Forecariah. Considering a 10% of missing data, it was planned to survey 543 
children aged 1 to 4 years in Boffa and 133 children in Forecariah. Taking into account the 
results of the Demographic and Health Survey of 2005, it was expected 0.7 children 1-4 year 
old per household in Guinea (6.1 individuals per household and 16% of the population 
under 5 years old). It is was planned to visit 776 households (60 clusters of 13 households) in 
Boffa and 180 households (30 clusters of 6 households) in Forecariah. 
 
 
4.4.3 Sampling procedure 
The clusters were allocated proportionally to the population size of the sub-prefecture, 
district and the sector. Within the selected sectors, the households were numbered. In order 
to select the first household of the cluster, a random number was chosen among the total 
number of households in the sector. Subsequent households were selected by proximity 
(first household to the left). 
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In urban area of Boffa and in Kaback Island of Forecariah satellite based sampling was used 
to select the starting point of the cluster. Cluster allocation was also  proportional to the 
population size, but a satellite photo was used to select randomly the starting point [137]. 
This alternative methodology was use in urban Boffa because of the large number of 
households to enumerate and in Kaback because of the absence of accurate population data 
per sector. 
 
A household was defined as a group of people sleeping under the same roof and sharing 
meals every day for at least the previous 2 weeks. Data concerning all the residents of the 
selected households eligible for the vaccination were collected.   
 
4.4.4 Recruitment methodology 
Prior to the beginning of the survey, all surveyors and supervisors were recruited locally 
and received a theoretical and practical training of three days. Training consisted of survey 
and interview methodology and a pilot implementation of the questionnaire.  
 
A total of 22 surveyors divided into 11 teams in Boffa and 4 surveyors in Forecariah 
conducted the survey. Each team consisted of two interviewers. In Boffa, each supervisor 
supervised 2 to 3 teams and 2 surveyors in Forecariah.  
 
The teams visited every selected household in each cluster. They conducted face-to-face 
interviews with the most senior adult household member. If the person was absent, the 
information was provided by the next most senior adult household member. Survey teams 
asked for the help of neighbours to trace absentees and re-visit empty (but not abandoned) 
households later in the day. If during the second visit the occupants could not be found or if 
they refused to participate, that household was skipped.  
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4.4.5 Data collection 
A standardized pre-piloted questionnaire (Annex 3) was used to collect the following data 
per each household member: 
 
- Demographic: age, sex, household size 
 
- Vaccination status: verbal and card confirmation 
 
- Reasons for non-vaccination: open question 
 
- Acceptability: side effects, taste and beliefs about the vaccine (only in participants older 
than 15 years). Acceptability was only collected in Boffa (first site where the mass 
vaccination campaign was implemented). 
 
Interviews were conducted in the local language (Soussou).  
 
4.4.6 Data entry and analysis 
 The main outcome was OCV coverage (single and full course) in each of the targeted 
locations for vaccination. Secondary outcomes included vaccine coverage by age group, and 
reasons for non-vaccination. Crude vaccination coverage estimates were obtained 
considering the survey design. The design effect was calculated to estimate the loss of 
precision due to the cluster based sampling strategy. Sampling weights were calculated at 
each level to account for the different cluster size.  
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4.5 Surveillance of adverse events following immunization 
 
4.5.1 Definition of side effects 
An adverse events following immunization (AEFI) was deﬁned as a medical occurrence 
detected by the vaccination site supervisor or a physician with an onset up to 14 days after 
receipt of a dose of vaccine [138]. 
 
4.5.2 Data collection and analysis 
AEFI surveillance was implemented in the sites where the mass vaccination campaigns 
were carried out as well as in the health centres and health posts of the areas targeted by the 
mass vaccination campaigns  for 14 days following each vaccination round. 
 
Data were collected either at the vaccination site by the medical team supervisor if the side 
effect was observed soon after taking the vaccine. Data were also collected in health posts 
and health centres if the side effect occurred with a larger delay and the person sought care 
in the health structure. 
 
The following data were collected using a standardized form (Annex 4): age, sex, 
pregnancy, history of allergies, vaccination date, consultation date, date of onset of the 
symptoms, type of symptoms, and clinical outcome (recovery, transfer or death). 
 
Patients who experienced a side effect after vaccination were described in terms of age, sex, 
time between intake of the vaccine and the onset of the side effect and symptoms. 
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4.6 Evaluation of the performance of the cholera rapid diagnostic test Crystal in 
vaccinated individuals 
 
4.6.1 Setting  and study design 
The study took place in Kabak (Forécariah Prefecture, Guinea) during the second round of 
the mass vaccination campaign carried out by the MoH and MSF in June 2012. The study 
population corresponded to the population targeted by the vaccination campaign (all 
residents of Kabak aged one year and above). Individuals were included if they were 
vaccinated and accepted to participate. They were excluded if they had watery diarrhea on 
inclusion (to exclude potential cholera cases) and/or a high probability of not being present 
for all the follow-up visits. The cohort of vaccinated participants meeting study criteria was 
followed-up prospectively. 
 
It was estimated that 96 individuals were needed to achieve a minimum precision of 10% 
around a proportion of 50% of positive RDT, as there were no data on the prevalence of 
positive tests in the vaccinated population. The sample size was increased to 106 to account 
for an expected 10% of loss to follow-up. A systematic sampling method (one every 10 
individual) was used in every vaccination site.  
 
4.6.2 Recruitment and follow-up procedures 
Participants were recruited in 4 of the 31 vaccination sites, selected arbitrarily, as 
vaccination sites were not thought to have any influence on the study outcomes.  
Demographic information was collected at inclusion through a face-to-face interview 
(mainly in Soussou, the local language) and information on stool production and basic 
clinical symptoms during follow-up visits using an individual standardized case report 
form (CRF). Participants were asked to collect stool in a pot provided by the study team. 
Participants’ homes were visited daily to collect stool specimens, complete a follow-up form 
Material and methods | 56 
 
 
and to provide them with a new pot for the next stool. The stools were transported to the 
laboratory and tested them with the RDT. Laboratory technicians completed the information 
with the RDT results. Follow-up was considered finalized when 2 consecutive negative RDT 
results were obtained or after 7 days. 
 
4.6.3 Field use of the rapid diagnostic test 
The stool samples were tested with the RDT at Kabak Health Center following the 
manufacturer’s instructions by a laboratory technician trained to the use of the test.  Crystal 
VC tests used were manufactured in 2011 and 2012 by Span Diagnostics Ltd., India 
(catalogue reference number 161C101-10). A small portion of stool was mixed with a buffer 
and 200 µL (4 drops) of the mix was placed in a test tube. The dipstick test was left in the 
tube for 20 minutes before reading. If only the control line appeared, the test was negative. If 
2 or 3 lines appeared, the test was positive for either V cholerae O139, O1, or both. If the 
control line was absent, the test was considered invalid and repeated once.  
 
4.6.4 Laboratory control of the rapid diagnostic test 
Ten by ten dilutions of the Shanchol vaccine were prepared using the dilution buffer 
provided in the RDT kit. Undiluted and diluted vaccine solutions up to a 109-fold dilution 
were tested with the RDT following the manufacturer’s recommendations.  
 
A bacterial suspension adjusted to an optical density at 600 nm (OD600nm) of 0.8 was 
prepared in the dilution buffer provided in the RDT kit from an overnight culture of V 
cholerae O1 and O139 strains. Such an OD value was previously estimated to correspond to 
2x108 V cholerae / mL by colony counting of 10-fold serial dilutions spread on agar plates and 
incubated over night at 37°C. This initial solution was used to prepare solutions at 2x107 and 
2x106 bacteria / mL using the dilution buffer provided in the kit, undiluted and diluted 
solutions were tested with the RDT following the manufacturer’s recommendations.  
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4.6.5 Data analysis 
Qualitative variables were described through their frequency and percentages. Continuous 
variables were described through their mean, median, standard deviation (SD) and 
percentiles (P25 and P75). The proportion of positive results for O1 or O139 for each day of 
follow-up was calculated including in the numerator the number of positive results and in 
the denominator the sum of the total number of tests performed and the number of cases for 
whom follow-up was stopped after obtaining two consecutive negative results. Missing data 
(absent or no stool sample) were excluded from this calculation. The 95% exact confidence 
intervals (95%CI) of the proportion estimate were calculated. To estimate the mean time to 
obtain a negative RDT result after vaccination (time to become negative), the number of 
days needed to obtain a first negative result was counted in the group of people who 
obtained previously a positive result for O1 or O139 after vaccination. Statistically 
significant differences by gender and age were assessed with a linear regression model. A p 
value <0.05 was considered significant.  
 
 
4.7 Vaccine effectiveness study 
 
4.7.1 Surveillance for cholera 
Cholera is one of the eight diseases under weekly surveillance in Guinea and included in the 
Early Warning System. Notifications are done every week from the peripheral health centres 
to the “Directions Préfectorales de la Santé”, from there to the “Directions Régionales de la 
Santé” and finally every Wednesday to the central level, the “Division de Prévention et de 
Lutte contre la Maladie”. 
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The epidemiologic surveillance system was reinforced in 2012 that included  supplementary 
training of the medical staff on the case definition, the importance of prompt and systematic 
notification of all suspected cholera cases and the use of specific registers for cholera. 
Medical staff was also trained on the use of rapid diagnostic cholera tests (RDT) and on the 
importance of consistent analysis of surveillance data.  
 
The reinforced surveillance system was established in the following sites: 
- In the prefecture of Boffa: in the six sub-prefectures targeted by the mass vaccination 
campaigns (Koba Tamita, Boffa, Douprou, Tougnifily and Mankountan). These six sub-
prefectures include a hospital, six health centres and 23 health posts. 
- In the prefecture of Forecariah: in the sub-prefectures targeted by mass vaccination 
campaigns (Kaback and Kakossa). These sub-prefectures include two health centres, three 
health posts and a cholera treatment centre. The health centres and health posts received 
cases arriving from the ports and quays located near the two islands (Mafarenyah health 
centre, and the health posts of Madinagbé and Mambala). 
 
The WHO cholera case definitions are used in Guinea. In agreement with the Provincial 
Divisions of Health, in the areas targeted by mass vaccination campaigns  the definition of a 
suspected cholera case in the 2012 epidemic was the following: anyone suffering from acute 
watery diarrhoea (at least 3 loose stools in 24 hours) with or without vomiting. A confirmed 
case was defined as any suspected case with a positive stool sample to Vibrio cholera O1 or 
O139 (by rapid test, culture or PCR). Systematic testing with RDT was done in the health 
centers and a sub-sample of stools was sent to the Institute Pasteur in Paris for culture and 
PCR analysis (see laboratory procedures bellow). A specific register was implemented in 
each surveillance structure beginning on April 14th 2012 in Boffa and May 26th 2012 in 
Forecariah. 
 
For each suspected case, the following data were collected: date of admission, date of 
symptom onset, age, sex, town or village of residence, state of hydration at admission, 
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vaccination status (number of cholera vaccine doses received), discharge date, discharge 
status (recovered, abandoned, transferred or death), and the result of RDT (negative / 
positive). 
 
4.7.2 Case–control studies 
The case subjects and controls were the residents of study areas. Case subjects with cholera 
were compared with controls who did not have diarrhoea. In an attempt to assess whether 
the results with respect to effectiveness could be attributed to bias, case subjects with non-
choleric diarrhea (negative result to the RDT) were also compared with controls who did 
not have diarrhea. Study staff who enrolled the case subjects and controls and who obtained 
information on vaccination status and other exposure variables were unaware of whether V. 
cholera was confirmed from the case subject and of how the information on vaccination 
status was to be used in the analysis. 
 
4.7.3 Definition and Selection of Case Subjects 
All suspected cholera cases seeking care in a health center of the study area between one 
week after the end of the vaccination campaigns and October 31, 2012, were eligible to be 
included as case-patients if they provided written informed consent (Annex 5) and fulfilled 
the following criteria: resident in the study area since April 16, 2012; older than 12 months; a 
positive cholera RDT; and their residence could be located after discharge. Only the first 
episode of acute watery diarrhea was included. 
 
To assess whether effectiveness results could be attributed to bias, case-patients with non-
choleric diarrhea (negative RDT result) were also compared with control-subjects that did 
not have diarrhea (indicator bias analysis) [117].  
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4.7.4 Definition and Selection of Controls 
A systematic selection procedure was used to recruit four neighbour controls for each case 
subject. Starting from every third house to the left of the case subject’s house, every 
consecutive house was visited until one eligible control was enrolled. The procedure was 
then repeated starting from every third house to the left of the control subject’s house until 
four controls were recruited. Only one control was recruited per household. A neighbour of 
the same sex and within the same age group (1 to 4, 5 to 9,   10 to 19,  20 to 29, 30 to 39 or 
more than 40 years of age) as the case subject was eligible to be a control if he or she had not 
sought treatment for diarrhea at the Cholera Treatment Center between January 1, 2012, and 
the date of onset of the matched case subject’s diarrheal illness and if he or she would have 
sought treatment at the Cholera Treatment Center if severe, watery diarrhea had developed. 
Eligibility for selection also required the same informed-consent, residency and age criteria 
as those applied to the case subjects. 
 
4.7.5 Ascertainment of Vaccination and Potentially Confounding Variables 
Receipt of the cholera vaccine during the mass immunization program was ascertained in 
face-to-face home interviews of the case subject and controls. Participants were asked 
whether they had been vaccinated and, if so, to show the vaccination cards distributed 
during the campaign. For those who reported that they had been vaccinated but were not in 
possession of a card, vaccination status and the completeness of dose ingestion were 
ascertained by oral reporting. Demographic, socioeconomic, and environmental variables 
were ascertained through special questionnaires administered to case subjects and controls 
(Annex 6). 
 
4.7.6 Laboratory procedures 
For each patient included in the study, a stool sample was collected and used to perform a 
RDT (Crystal-VC tests, SPAN Diagnostics, India, Lot numbers: 4000007832 and 4000008589). 
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The doctor/nurse in charge of the health centre performed the test according to the 
manufacturer's instructions for use, after training by the study team. Results were 
interpreted according to the manufacturer's instructions. If the control line did not appear, 
irrespective of other lines, the test was considered invalid and repeated once. 
 
In additional, for a sub-sample of a filter paper disc was dipped into fresh stool and placed 
into a microtube with 2 to 3 drops of normal saline solution (NaCl 0.9%). Tubes were kept at 
room temperature and sent to Institut Pasteur, Paris for isolation of V cholerae according to 
standard methods [139]. PCR was systematically performed on all specimens. Detection of 
the rfb was done as described by Hoshino et al. [140]. Presence of PCR inhibitors and 
bacterial DNA were respectively controlled by PCR amplification of an exogenous internal 
positive control (Applied Biosystems TaqMan) incorporated to each sample and 
amplification of the 16S rRNA gene. 
 
4.7.7 Statistical analysis 
The primary analysis assessed the protection conferred by the receipt of two completely 
ingested doses of vaccine against confirmed cholera by RDT. It was calculated that 90 cases 
and 360 controls (ratio 1:4) would be needed assuming 50% vaccine effectiveness, alpha 
error 5% and 80% power. The secondary analysis assessed the protection conferred by an 
incomplete course of vaccine (one complete dose or incomplete dose(s) due to spitting or 
vomiting part of a dose) against confirmed cholera by RDT. A sub-analysis was also 
conducted considering as case-patients: (i) those with presence of V cholerae confirmed by 
culture and/or PCR and (ii) those with diarrhea but with a negative result to the RDT 
(indicator bias analysis). 
The odds of vaccination between case-patients and control-subjects was compared 
conditional through logistic regression to account for the matching design; a model with 
indicator variables was fitted for non-vaccinated, incomplete and complete dosing. The level 
of vaccine protection was estimated as (1- odds ratio) x 100. 
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Demographic, environmental, and socioeconomic factors were compared between case-
patients and their matched control-subjects in order to assess their potential as confounders 
of vaccine protection. Variables with a P values <0.2  in the bivariate models were 
considered as possible confounders. Adjusted estimated of vaccine protection by co-
variables that significantly contributed to improve the likelihood of the model were 
calculated. All P values and 95% confidence intervals were two-sided. Statistical significance 
was determined as a P value less than 0.05.  
 
4.8 Data entry and data analysis tools 
Data entry was performed using EpiData 3.1 (EpiData Association, Odense, Denmark) in 
specific data entry mask created for each sub-study. Data analysis was performed using 
Stata 12.0 (College Station, TX, USA) for all the studies. Maps and geographical analysis 
were conducted using R 2.14 Statistical Package. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. RESULTS 
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5.1 Description of the cholera outbreak in Guinea in 2012 
In 2012, the first cholera case was reported in Forécariah (Maritime Guinea) on February 2. 
Both the Microbiology National Laboratory and the Institut Pasteur in Paris confirmed that 
the circulating strain was Vibrio cholerae O1 El Tor-Ogawa. Further studies based on genetic 
markers analysis showed that it was an hybrid El Tor strain possessing the classical B 
subunit cholera toxin gene (ctxB1 genotype) [141]. From February 2 to October 31, a total of 
7,350 cases including 133 deaths were reported to the WHO. This number of cases 
corresponds to an attack rate of 6.4 per 10,000 people. The case fatality ratio (CFR) per 100 
cases was 1.8 at country level. The peak of the epidemic was observed in week 34, in which 
1,152 cases were reported (MoH data, Figure 5). At country level, the vast majority of cases 
were reported during the rainy season. 
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Figure 5: Suspected cholera cases reported in Guinea in 2012 per week. 
 
Figure 6 shows a more detailed description of the geographical distribution of the epidemic. 
Four prefectures had attack rates over 15 cases per 10,000 individuals (Conakry, Dubréka, 
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Coyah and Fria); in Fria and Conakry the attack rate reached 27 and 26 cases per 10,000 
respectively. 
 
In the city of Conakry, 4,617 cases were reported, which represent 63% of the total number 
of cases at country level. The first case was declared in Conakry in week 22 (i.e. 17 weeks 
after the first notification in Forécariah). In Conakry, the peak of the epidemic was observed 
in epidemiological week 34 in which 727 cases were reported.  
 
 
Figure 6. Cholera attack rates per sub-prefecture in Guinea 2012. 
 
The median age of the patients was 25 years old (inter quartile range: 16-37). The number of 
reported cases was similar in men (49%) and women (51%). 
The epidemic evolved with a different dynamic in the vaccinated areas compared with the 
un-vaccinated areas (Figure 7). In the prefectures of Boffa and Forécariah, 283 and 344 cases 
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were respectively reported in 2012. In the country as a whole, 93% of the cases were 
reported after week 24, when the implementation of the vaccination campaigns ended. 
Conversely, in the vaccinated areas of Boffa and Forécariah the percentage of cases reported 
after the implementation of the vaccination campaigns was respectively 45% and 16% 
(Figure 7).   
 
 
 
Figure 7. Evolution of the outbreak in the country and in the vaccinated prefectures. 
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5.2 Feasibility assessment of the mass vaccination campaign 
 
5.2.1 Vaccine procurement, storage, and transport 
The bulk of the vaccine supply (320,000 doses) was shipped directly from the manufacturer 
in India, and 50,000 additional doses from MSF stock in Kampala, Uganda. The volume of 
the transport containers of vaccine was 29 m3. Vaccines were transported from Conakry's 
airport to the district capital in refrigerated trucks and stored in the field in refrigerated 
trucks or containers. Vaccines reached the field within 2 weeks of the order date. 
Vaccine was supplied in individual vials, either in secondary packing of 35 vials or in 
individual secondary packing inside tertiary packing of 10 vials (Figure 8). One vaccine vial 
in the 35-vial package had a volume of 13.5 cm3, about five times greater than a dose of 
measles vaccine. 
 
   Figure 8: Shanchol vaccine in 35 vials packing  or in individual secondary packing inside tertiary 
packing of 10 vials . 
 
5.2.2 Vaccination teams and training 
The identification of team members and team composition, as well as identification of 
each team leader was done by the MoH. Teams and team leaders were identified from each 
sous-prefecture for the work in their area. Team leaders were MoH medical staff, while the 
team members could be either medical staff or identified members of community, not 
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necessarily medical (mostly community health worker, or Red Cross volunteers – people 
already involved in public health activities). 
 
Each team was composed of 9 fixed team members in Boffa (1 team leader, 2 registrators, 2 
vaccinators, 2 preparators, 1 tally sheet, 1 log aid). In addition, community members were 
hired in Boffa and Forécariah on daily basis to assist at vaccination sites (crier, up to 4 
people to fill in vaccination cards, up to 6 people for crowd control). The total number of 
people working at vaccination sites varied between 9 and 20 in Boffa. In Forécariah, smaller 
teams of 5 people (1 team leader, 1 registration, 1 preparator, 1 vaccinator and 1 tally sheet) 
were used and between 2 and 8 daily workers were recruited in addition at each vaccination 
site. For the second round, Red Cross volunteer joined the team for the distribution of 
chlorine and soap. In total, 43 teams were created to comple the mass vaccination 
campaigns in Boffa and Forécariah (Figure 9). 
  
Figure 9: Vaccination team at work.  
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An initial training was organized before the first vaccination round to explain the basic 
rational of the intervention and vaccination. Another meeting was organized before the 
second round to take lessons learned and prepare the second round. Training included 
small introduction to cholera and cholera vaccination, set-up of vaccination session and 
role of each team member, as well as practical exercise. Before the second round, a short half 
day refresher session was organized. 
 
5.2.3 Choosing vaccination sites 
Preliminary selection was done together with district medical authorities, then refined in 
consultation with community leaders. An important criterion was to keep travel distances 
short so that all family members, including elderly people and mothers with small children, 
could reach the sites easily. Altogether there were 287 sites, one per village or settlement  
 
5.2.4 Mobilizing the population 
Due to the emergency nature of the intervention, the time period for social mobilization was 
short. The information was transmitted orally; modern media were not used, as local radio 
or television are not available in the area and the mobile network coverage is low. Public 
awareness messaging included detailed information about the rationale of the campaign, 
the vaccine and the importance of two-dose schedule, along with standard cholera control 
messages regarding the necessity and availability of treatment and prevention measures. 
Existing material was used to illustrate the standard cholera control messages, but no 
special material was designed for the vaccination due to the limited amount of time 
available. Medical, administrative, and traditional authorities were informed in advance. 
Each community was visited 2 days before vaccination day by a health promoter, who 
provided educational and awareness information via village leaders (Figure 10). In more 
populated areas, local outreach workers conducted door-to-door mobilization. 
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Figure 10: Public awareness campaing.  
 
5.2.5 Vaccination day 
Each team had a car (two in Boffa) or boat to reach the vaccination sites. Vaccines were 
transported and used at ambient temperature on vaccination day. Vaccines leftover at the 
end of vaccination day were returned to the cold chain and used first on the following day. 
Before administration, the vaccine vial monitor (VVM) was checked for stability; the vial 
was shaken, opened, and administered or self-administered under observation (Figure 11). 
All VVM remained valid during the campaign. 
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Figure 11: Vaccine administration. Image credit: David Di Lorenzo. 
 
To facilitate ingestion of the vaccine, safe drinking water was provided to each vaccinee 
(pre-packed 33 cl sachets from a Guinean manufacturer) (Figure 12). Each vaccinee also 
received a vaccination card during the first round and was asked to bring the card for the 
second dose. However, during the second round the vaccine was provided to those who 
had lost their card or were not previously vaccinated. 
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*  
Figure 12: Provision of safe water. Image credit: David Di Lorenzo. 
 
 
In Forecariah, the second vaccination round was accompanied by distribution of preventive 
items (soap and chlorine solution for household water treatment), targeting women of 
childbearing age. 
 
5.2.6 Number of doses administered and time 
A total of 143,039 doses were administered during the first round of vaccination, and 
117,139 during the second round in Boffa. The utilisation rate was 99,3%.  Few vials were 
lost during the manipulation of opening procedure, 4 vials were identified as having 
expired VVM and were removed. Also, few missing vials in the originally packed vaccine 
box were reported. 
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A total of 29,505 doses were administered during the first vaccination round and 26,567 
during second vaccination round in Forécariah.  
 
Teams vaccinated an average of 703 persons daily, up to 1,830 vaccinations/day/team. They 
spent several days in the larger villages but covered several smaller sites in one day. The 
complete campaign took 6 weeks from the decision to proceed until completion of the 
second round in Boffa (3-week interval between doses) and 5 weeks in Forecariah (2-week 
interval). 
 
5.2.7 Wate management  
All waste management was centralized in two site, one in Boffa and one in In Forecariah, 
where it was treated. 
 
Figure 13: Waste managment. 
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Paper and carton was incinerated. Glass was crushed with portative glass reducers and 
encapsulated.Aluminium covers of the vaccine were encapsulated at the same time in both 
sites. Maps of encapsulation areas were given to each health structure. Polystyrene, 
insulation sheets, thermal boxes were stocked in Conakry, in order to be used as building 
insulation. Thermal boxes were given to Boffa port and to the fishery/ port in Conakry. 
Waste management of water plastic bags was ensured by the provider who recuperated all 
plastics and recycle them. 
 
5.2.8 Costs 
Cost per dose of vaccine delivered was US$2.89, including $1.85 for the vaccine itself and 
just over $1 for direct delivery costs (especially transport of teams and material, and 
payment for teams and other staff). Table 1 lists all costs that were factored into this 
calculation. 
 
Table 1. Direct costs of mass vaccination campaign. Fixed administrative costs, MSF institutional 
costs and costs linked to operational   research are excluded.   
  Total % Total 
Vaccine (1.85 USD/dose) 585,063 64.0% 
Water sachets (0.036 USD/sachet) 10,626 1.2% 
Airfreight for vaccines 47,719 5.2% 
Transit cost for vaccines 9,574 1.0% 
Cold chain (truck rental, reparation of container in Boffa) 26,505 2.9% 
Vaccination, supervision and sensitisation teams payments 63,308 6.9% 
Training for the teams 4,899 0.5% 
Small vaccination material and stationary, vaccination cards 13,705 1.5% 
Logistic material, site preparation, waste management 13,333 1.5% 
Transport cost (cars, trucks, boats and fuel) 139,851 15.3% 
Total 914,582 100.0% 
Cost per dose delivered 2.89   
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5.3 Assessment of the acceptability of the mass vaccination campaign by the 
population 
 
 
The surveys were carried out May 20 to 25, 2012 in Boffa and June 16 to 20, 2012 in 
Forécariah (Figure 14).  
 
 
 
Figure 14: Timeline of the cholera vaccination campaigns and implementation of the field surveys in 
Guinea in 2012. Months are abbreviated as follows: F = February, A = April, M = May, J = June. 
 
 
In total, 851 households were visited in Boffa. Of these, 775 (91.1%) were included in the 
survey, 45 households (5.3%) remained empty after two visits, 3 households (0.4%) refused 
to participate and 23 (2.7%) were not residents of Boffa. All 180 visited households were 
included in Forécariah (Figure 15). 
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Figure 15: Study flow chart: Number of households visited, number of households included, number of 
individuals in the targeted age group (older than 12 months of age) residing in the households included 
in the survey and final number of individuals included in the study. 
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5.3.1 Household based survey in Boffa  
 
Description of the survey 
Overall, 3,993 individuals were included with an average of 5.5 (SD: 5.4) persons included 
per household. There were slight differences in the number of participants recruited by 
team; with an average of 327.8 individuals (SD: 114.7) recruited per survey team.  
 
Description of survey participants 
The median age of the participants was 15 years old (IQR: 5-30). There were slightly less 
males (47.6%) than females in the survey sample. The age pyramid shows no important 
asymmetries in children with an asymmetric shape in the active adult population and a 
classical shape of demographic expansion with a predominance of the youngest age groups 
(Figure 16). 
 
 
Figure 16. Age pyramid of the person included in the survey, Boffa prefecture, May 2012. 
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Regarding the sub-prefecture of origin, as expected the most populated areas were more 
represented in the sample (Table 2). 
 
Table 2. Number of people included in the survey by sub-prefecture. Boffa prefecture, May, 2012. 
 
Sub-prefecture N % 
Boffa 850 21.7 
Douprou 535 13.7 
Koba 957 24.5 
Tamita 203 5.2 
Tougnifili 811 20.7 
Mankountan 558 14.3 
  
 
Cholera vaccine coverage 
Overall, the vaccine coverage was 75.8% [95%CI: 71.2-79.9%, deff=10.1] with two doses 
(fully vaccinated), 17.6% [95%CI: 14.8-20.9%, deff=6.1] received only one dose (incompletely 
vaccinated) and 93.3% [95%CI: 91.1-95.0%, deff=5.9] either with one or two doses. The 
dropout rate between the first and second dose was 15.2% [95%CI: 12.2-18.7%, deff=7.0].  
 
Vaccination coverage varied with age (Figure 17). reaching over 80% for two doses (fully 
vaccinated) among children 1 to 15 years old, while fully vaccinated coverage was lower in 
adults, especially among males; at 66.0% [95%CI: 59.2-72.2%, deff=1.6].  
 
Results | 79 
 
 
 
Figure 17. Vaccine coverage by age group of the cholera mass vaccination campaign in Boffa 
prefecture, first round, second round and two doses (fully vaccinated), April-May 2012. 
 
The overall vaccine coverage was similar in both males and females; 76.6% [95%CI: 71.9-
80.7%, deff=5.5] of females and 75.0% [95%CI: 69.8-79.4%, deff=5.8] of males were fully 
vaccinated. Further details about the distribution of the vaccine coverage by age and sex are 
provided in Annex 9.  
 
No major differences were observed in the vaccination coverage by sub-prefecture, with the 
highest estimate in Mankountan and the lowest in Koba (especially in the second round) 
(Table 3). More details on the geographical variation of the vaccine coverage are shown in 
Annex 10 
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Table 3. Vaccine coverage by sub-prefecture of the cholera mass vaccination campaign in Boffa 
prefecture, first round, second round and two doses (fully vaccinated), April-June 2012. 
 
First round Second Round Full coverage (two doses) 
  n/N (%)* [95% CI] n/N (%)* [95% CI] n/N (%)* [95% CI] 
Boffa (n=850) 773/847 (91) [82-96] 692/847 (82) [74-89] 655/847 (78) [68-86] 
Douprou (n=535) 477/534 (88) [81-93] 428/534 (79) [70-86] 411/534 (76) [67-83] 
Koba (n=957) 835/949 (88) [83-92] 672/947 (71) [62-80] 645/946 (69) [59-77] 
Mankountan (n=577) 535/577 (93) [88-96] 506/577 (89) [82-93] 484/577 (84) [76-90] 
Tamita (n=203) 190/203 (93) [85-97] 165/202 (80) [71-87] 160/202 (78) [66-86] 
Tougnifili (n=811) 725/811 (88) [77-94] 676/811 (83) [73-89] 636/811 (77) [64-86] 
 
Overall, 73.9% [95%CI: 69.3-78.0%, deff=9.7] of participants showed vaccination cards. Card 
retention was higher in children than in adults, and higher in females than males. All 
groups showed card retention over 70% with the exception of adult males (64.5%). 
 
Among those vaccinated during the first round, 1.4% [95%CI: 0.8-2.2%, deff=2.9] reported 
spitting out or vomiting the vaccine; the same percentage was observed for the second dose. 
 
 
Reasons for non-vaccination 
Among non-vaccinated individuals (386 during the first and 779 during the second round), 
the reason for non-vaccination was obtained in 382 and 768 individuals respectively. The 
main reason for non-vaccination was absence during the campaigns for both the first (77.6% 
[95%CI: 69.2-84.2%, deff=3.0]) and the second round (71.2% [95%CI: 64.5-77.1%, deff=3.7]). 
The second most reported reason was “not having the time to go for the vaccination” for 
both rounds (6% and 10% respectively). The third most reported reason was to be sick 
during the campaign (4.9% and 4.4% respectively). (Table 4). The percentage of people 
reporting as the reason for non-vaccination any type of lack of information about the 
campaign was calculated as a standard quality indicator for campaign; this percentage was 
6.5% for the first round and 7.3% for the second round in Boffa prefecture.  
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Table 4. Reasons for non-vaccination among those not vaccinated. Boffa prefecture, May, 2012. 
 
 1st round 2nd round 
Raison N=382 % N=768 % 
Absent during the campaign 295 77.2 550 71.6 
The person did not have the time to be vaccinated 24 6.3 73 9.5 
Sick during the campaign 19 5.0 34 4.4 
Not informed about the campaign 12 3.1 22 2.9 
 Other 9 2.4 22 2.9 
The caregiver thought that the child was too young 8 2.1 8 1.0 
Vaccination site considered too far 3 0.8 5 0.7 
The person did not know the date of the campaign 3 0.8 21 2.7 
The person thought  that he/she was too old 2 0.5 2 0.3 
The person was hospitalized at the time of vaccination 2 0.5 2 0.3 
Refusal (link with cultural beliefs) 1 0.3 1 0.1 
Bad experience with previous vaccinations 1 0.3 1 0.1 
The person did not know the place of vaccination 1 0.3 2 0.3 
No explanation 1 0.3 5 0.7 
No vaccines available at the vaccination site 0 0.0 8 1.0 
Side effects during the first round 0 0.0 7 0.9 
The person thought that one dose was enough 0 0.0 2 0.3 
The vaccine was considered dangerous 0 0.0 1 0.1 
The vaccinator advise the person to not be vaccinated 0 0.0 2 0.3 
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Side effects (household survey results) 
In the retrospective household based surveys, a question about side effects after vaccination 
was asked to the adults who participated in the survey. Overall, 3.3% [95%CI2.4-4.7%, 
deff=3.1]) reported being sick after vaccination during the first round and 2.5% [95%CI: 1.7-
3.8%, deff=3.0]) during the second round. Among those reporting being sick after 
vaccination, the most frequently reported symptoms were diarrhea (34.0%) and fever 
(34.6%). Other symptoms reported included vomiting (8.3%), abdominal pain (10.3%), 
dizziness (9.0%) and weakness (7.1%). 
Among those reporting illness after vaccination 21.7% reported seeking care during the first 
round and 16.7% during the second round. 
 
Acceptability of the vaccine 
Regarding the awareness campaign, 95.7% of survey participants [95%CI: 94.2-96.8%, 
deff=1.7]) reported being informed about the campaigns. Concerning knowledge about the 
protection afforded by the vaccine, 94.2% [95%CI 91.3-96.1%, deff=3.8] of participants 
responded that full protection is obtained after two doses. However, 42.4% [95%CI 34.3-
50.9%, deff=10.5] of participants thought that only one dose afforded full protection.   
 
A small percentage of participants considered that the vaccine made them feel sick 3.9% 
[95%CI2.7-5.8%, deff=2.4]), similar to the proportion of participants reporting side effects. 
Most participants reported that the taste of the vaccine was bad (77.6% [95%CI 69.5-84.1%, 
deff=10.7]). However a very high percentage reported that they would be vaccinated again 
(98.9% [95%CI 97.8-99.5%, deff=2.3]) in a future cholera vaccination campaign. 
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5.3.2 Household based survey in Forecariah  
 
Description of the survey 
In total, 1,255 individuals included with an average of 7.0 (SD: 4.4) persons included per 
household. There were slight differences in the number of participants recruited by team; in 
average, 313.8 individuals (SD: 133.8) were recruited per team.  
 
 
Description of the survey participants 
The median age of the participants was 15 years old (IQR: 5-30). There were fewer males 
(44.1%) than females in the sample. The age pyramid shows no important asymmetries in 
children with an asymmetric shape in the active adult population and a classical shape of 
demographic expansion with a predominance of the youngest age groups (Figure 18). 
 
Figure 18. Age pyramid of the person included in the survey, Forecariah prefecture, May 
2012. 
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Regarding the sub-prefecture of origin, as expected more people were recruited from 
Kaback proportionally to its larger population size (Table 5). 
 
Table 5. Number of people included per Sub-prefecture. Forecariah-prefecture, May, 2012. 
 
Sub-prefecture N % 
Kabak 754 60.1 
Kakosa 501 39.9 
  
 
Cholera vaccine coverage 
Overall, the vaccine coverage was 75.9% [95%CI: 69.8-80.9%, deff=5.0] with two doses (fully 
vaccinated), 19.3% [95%CI: 15.5-23.8%, deff=3.3] received only one dose (incompletely 
vaccinated) and 94.9% [95%CI: 91.8-96.9%, deff=3.7] either with one or two doses. The 
dropout rate between the first and second dose was 13.6% [95%CI: 9.7-18.7%, deff=4.5].  
 
Vaccination coverage varied with age (Figure 19), reaching over 80% for two doses among 
children 1 to 14 years old. The coverage was lower in adults, especially among males; the 
coverage for two doses was 56.2% [95%CI: 45.1-66.7%, deff=1] in this group.  
 
The vaccine coverage was higher in females than in males. Overall, 79.4% [95%CI: 74.4-
83.6%, deff=2.1] of females and 71.4% [95%CI: 63.3-78.3%, deff=3.7] of males were fully 
vaccinated. Vaccine coverage among women in childbearing age (15–49 years old) was 
statistically higher than among men of same age in Forécariah (72.6% [95%CI: 65.4–78.8%] 
vs. 53.4% [95%CI: 41.6–64.8%], p<0.001). Further details about the distribution of the vaccine 
coverage by age and sex are provided in the Annex 9. 
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Figure 19. Vaccine coverage by age group of the cholera mass vaccination campaign in Forecariah 
prefecture, first round, second round and overall, May-June 2012. 
 
 
No major differences were observed in the vaccination coverage by sub-prefecture (Table 4). 
More details on the geographical vaccination of the vaccine coverage are shown in Annex 
10. 
 
 
Table 6. Vaccine coverage by sub-prefecture of the cholera mass vaccination campaign in Forécariah 
prefecture, first round, second round and two doses (fully vaccinated), April-June 2012. 
 
First round Second Round Full coverage (two doses) 
  n/N (%)* [95% CI] n/N (%)* [95% CI] n/N (%)* [95% CI] 
Kaback (n=754) 657/744 (87) [84-90] 605/744 (80) [72-86] 565/744 (74) [67-81] 
Kakossa (n=501) 447/501 (88) [80-93] 451/501 (88) [76-93] 88/501 (78) [68-86] 
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Overall, 78.9% [95%CI: 71.8-84.5%, deff=7.2] of the participants showed vaccination cards. 
The retention of cards was higher in children than in adults, and higher in females than in 
males. All groups showed card retention over 70% except adults males (65.7%) 
 
 
Reasons for non-vaccination 
Among the not vaccinated individuals (141 during the first and 189 during the second 
round), the reason for non-vaccination was obtained in 139 and 184 of them respectively. 
The main reason for non-vaccination was to be absent during the campaigns for both the 
first (78.4% [95%CI: 68.0-86.1% deff=1.6]) and the second round (70.0% [95%CI: 51.7-79.3%, 
deff=3.9]). (Table 7). The percentage of people reporting the reason for non-vaccination any 
type of lack of information about the campaign was 5.0% for the first round and 7.0% for the 
second round in Forecariah prefecture.  
 
Table 7. Reasons for non-vaccination among those not vaccinated. Forecariah prefecture, May, 2012. 
 
 1st round 2nd round 
Raison N=139 % N=184 % 
Absent during the campaign 115 81.0 122 64.9 
The person did not have the time to be vaccinated 6 4.2 8 4.3 
Sick during the campaign 5 3.5 8 4.3 
Not informed about the campaign 5 3.5 6 3.2 
Other 2 1.4 12 6.4 
The person did not know the date of the campaign   5 2.7 
The person thought  that he/she was too old 2 1.4 2 1.1 
The person was hospitalized at the time of vaccination 1 0.7 1 0.5 
Bad experience with previous vaccinations   7 3.7 
No explanation 3 2.1 4 2.1 
Waiting time too long   8 4.3 
Because of side effects during the first round   1 0.5 
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5.4 Surveillance of adverse events following immunization 
Overall, 48 individuals (28 in Boffa and 20 in Forécariah) spontaneously reported symptoms 
that were linked with the vaccine by the health personnel and considered as AEFI with 35 
after the first round and 13 after the second round.  In total, 29 were women (60%) and the 
median age was 27 years (IQR: 16–36 years);  8 (17%) were children 1 to 4 years.  Seven 
patients reported having a history of allergies (15%). The cause of the allergy was specified 
for two patients (quinine and chloroquine). The delay between vaccination and symptom 
onset is shown in Figure 20; the median delay was 7 hours (IQR: 1–24 hours). One quarter 
reported the symptoms in the following hour after vaccination.  
 
 
Figure 20. Box-plot of the delay in hours between the vaccine intake and the onset of the AEFI. The 
median time is represented by a red diamond. 
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The symptoms reported were mainly gastro-intestinal (Table 8): 28 (20%) diarrhea, 22 (16%) 
vomiting, 14 (10%) stomach ache and 12 (9%) nausea. In addition, 15 patients (11%) reported 
fever and general weakness. No patient was transferred to a hospital and no deaths were 
reported. Most of the patients (n=33, 69%) reported more than one symptom. 
 
Table 8. Symptoms reported by the forty-eight patients reporting adverse events following 
immunization.  
Symptom n = 139 % 
   Diarrhea 28 (20.1) 
Vomiting 22 (15.8) 
Stomachache  14 (10.1) 
Fever 15 (10.8) 
Weakness 15 (10.8) 
Nausea 12 (8.6) 
Dizziness 9 (6.5) 
Headache 5 (3.6) 
Borgorygms 2 (1.4) 
Anorexia 2 (1.4) 
Other 15 (10.8) 
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5.5 Evaluation of the performance of the cholera rapid diagnostic test Crystal in 
vaccinated individuals 
 
5.5.1 Recruitment and follow-up 
 
A total of 108 individuals were recruited during 2 days in 4 vaccination sites. Two 
individuals were excluded from the analysis (one was absent during all follow-up visits and 
for the other, follow-up was stopped accidentally by the study team).  
Follow-up of the remaining 106 participants is described in Figure 21. Study participants, 
exclusions and follow-up results, Kabak, June 2012.. Participants were followed for a 
median time of 5 days (minimum of 2 and 7 as maximum). Almost half of them (49.1%) 
were followed for 4 (23.6%) or 5 days (26.4%). 
 
 
Figure 21. Study participants, exclusions and follow-up results, Kabak, June 2012. 
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5.5.2 Participant’s characteristics, symptoms and delay in stool collection and testing 
Among the 106 participants, 79.2% (84) were females and the median age was 25 years (P25-
P75=2 – 80). The majority of participants were older than 15 (84.8%) and the proportion of 
children under five was 5.7%.  
 
In total, 18 participants declared having diarrhea during follow-up, and two reported 
vomiting. Other symptoms such as constipation, stomachache or headache were declared by 
37 participants.  
 
The average delay was 3.9 hours (SD=4.4) between stool production and collection and 6.6 
hours (SD=5.9) between stool collection and performance of the RDT (including collection 
and transport of samples to the laboratory) by the laboratory technicians. As a result, there 
was an average of 10.5 hours (SD= 6.6) between stool production and performance of the 
RDT. 
 
5.5.3 Proportion of positive tests after vaccination 
Of the 106 participants, 100 (94.3%) became positive with the O139 line after vaccination and 
6 never had a positive result. On the first day of follow-up (day 1) 71.1% were positive. On 
day 3, almost half of the tests remained positive (49.5%) and on day 5 and 6 this percentage 
decreased below 3% (Table 9).  
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Table 9. Results of the rapid diagnostic test Crystal VC in participants vaccinated against cholera by 
day of follow-up, Kabak, June 2012. 
 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day7 
A. Tests done 97 97 90 76 46 23 6 
a.1. Positive result (+) 69 80 47 20 2 1 0 
a.2. Negative result (-) 28 17 43 56 44 22 6 
B. Follow-up stopped after 2(-) 0 0 5 17 42 67 85 
C. Absent  1 0 0 1 1 4 5 
D. No sample available  8 9 11 12 17 12 10 
Total1 106 106 106 106 106 106 106 
        
Proportion2 of positives (%) 71,1 82,5 49,5 21,5 2,3 1,1 0,0 
IC 95% of the proportion 61.5-79.9 73.4-89.4 39.1-59.9 13.7-31.2 0.3-8.1 0.0-6.0 0.0-4.03 
1 The total is the sum of A+B+C+D 
2 The proportion is the result of (a.1/(A+B))*100 
3 97.5% Confidence Interval, one-sided 
 
Only one participant became positive with the O1 line (together with the O139 line) on the 
first day of monitoring, and both lines became negative subsequently. 
 
5.5.4 Time to become negative  
Of the 100 participants with at least one positive result, five could not be tested on day 7 as 
they were absent or did not produce stools, although they had a positive result with their 
last specimen collected (Figure 21). Among these 5 participants, 3 had their last positive 
stool on day 3, 1 on day 4 and 1 on day 5. For the remaining 95 cases with O139 positive 
tests, the time to become negative after vaccination was calculated.  
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For all participants, the mean time to become negative after vaccination was 3.8 days 
(SD=1.1) and the median time was 4 days (P25-P75= 3 - 5). For males, the mean time to become 
negative after vaccination was 4.3 days (SD=1.4) and 3.6 (SD=1) for females (p=0.03), with a 
median of 4 days for both males and females. A linear regression model showed that a 
longer time to become negative was associated to an older age (p=0.002) and to male sex 
(p=0.012) (Table 3). 
 
Table 10. Time to become negative by age and sex. Results of the linear regression model, Kabak, June 
2012. 
 Coefficient 95% Confidence Interval p 
Age 0.020 (0.008- 0.032) 0.002 
Sexe 0.669 (0.153- 1.186) 0.012 
 
 
5.5.5 Laboratory testing of the rapid diagnostic test 
The Crystal VC RDT gave positive results for both O1 and O139 when the strip was inserted 
directly into the vaccine solution prior to ingestion, and remained positive up to 104-fold 
dilutions of the vaccine. At a 105-fold dilution, only the O139 line remained positive and 
none of them were positive at higher dilutions.  
 
The RDT gave a positive signal with the O1 test line at bacterial concentration of 2x108 and 
2x107, but was negative at 2x106 bacteria/mL, while all dilutions of V cholerae O139 culture 
tested down to 2x106 bacteria/mL were positive for the O139 line.  
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Table 11. Results of Crystal VC rapid diagnostic test performed in Shanchol and bacterial suspension 
dilutions, Pasteur Institute, Paris, November, 2012. 
 
 Control line Line T1 O139 Line T2 O1 
Shanchol dilutions    
Tube 1 (10-fold dilution) +++ +++ +++ 
Tube 2 (102-fold dilution) +++ +++ +++ 
Tube 3 (103-fold dilution) +++ +++ ++ 
Tube 4 (104-fold dilution) +++ ++ + 
Tube 5 (105-fold dilution) +++ +  - 
Tube 6 (106-fold dilution) +++ - - 
Tube 7 (107-fold dilution) +++ - - 
Tube 8 (108-fold dilution) +++ - - 
Tube 9 (109-fold dilution) +++ - - 
O1 and O139 strains dilutions  +++   
O1 - Tube 1 (2x108bacteria/mL) +++ - +++ 
O1 - Tube 2 (2x107 bacteria/mL) +++ - ++ 
O1 - Tube 3 (2x106 bacteria/mL) +++ - - 
O139 - Tube 1 (2 x 108 bacteria/mL) +++ +++ - 
O139 - Tube 2 (2x107 bacteria/mL) +++ +++ - 
O139 - Tube 3 (2x106 bacteria/mL) +++ ++ - 
Intensity of the positive line: (+) very weak positive; (++) weak positive; (+++) positive 
Negative result: (-) 
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5.6 Estimate of the vaccine effectiveness  
5.6.1 Baseline Information 
From May 21 to October 31, 2012, 239 patients with acute, non-bloody diarrhea were treated 
at health centers in the study area (Figure 22); 5 died, yielding a case fatality ratio of 2%. 
Overall, 40 case-patients and 160 control-subjects were included in the primary analysis 
(Figure 23). None of the case-patients enrolled in the study died. The median age of 
participants was 28.0 years (inter-quartile-range: 16.5-39.0). There were fewer females 
(35.0%) than males (Table 1). Half of the cases sought care on the same day of symptom 
onset. Dehydration was present in 70% of cases at admission.   
 
Table 12. Characteristics of the case-patients and control-subjects included in the vaccine effectiveness 
study, Boffa and Forécariah, Guinea, 2012. 
 
 Controls Cases  
  n (%) n (%) P value 
Total included 160  40   
Males 104 (65.0) 26 (65.0)  
Female 56 (35.0) 14 (35.0)  
Age in years  (median and IQR*) 28 16-39 28 18-36  
Profession     0.18 
Trader 29 (18.1) 8 (20.0)  
Farmer 37 (23.1) 16 (40.0)  
Pupil / student 29 (18.1) 3 (7.5)  
Fisherman 10 (6.3) 3 (7.5)  
Housewife 10 (6.3) 1 (2.5)  
Unemployed 22 (13.8) 6 (15.0)  
Other 23 (14.4) 3 (7.5)  
Head of  household's educational attainment     0.13 
None 43 (27.2) 13 (32.5)  
Primary 5 (3.2) 4 (10.0)  
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Secondary 21 (13.3) 2 (5.0)  
University 5 (3.2) 0 (0.0)  
Literate 84 (53.2) 21 (52.5)  
Telephone     0.10 
No 32 (20.0) 13 (32.5)  
Yes 128 (80.0) 27 (67.5)  
Household size     0.063 
0-4 members 34 (21.3) 17 (42.5)  
5-7 members 40 (25.0) 7 (17.5)  
8-12 members 49 (30.6) 9 (22.5)  
>12 members 37 (23.1) 7 (17.5)  
Proportion of children attending school in the 
household     0.13 
None of them 33 (22.9) 14 (37.8)  
Less than half 42 (29.2) 11 (29.7)  
More than half 51 (35.4) 8 (21.6)  
All of them 18 (12.5) 4 (10.8)  
Distance to the closest health center     0.10 
Need of transport  107 (66.9) 31 (77.5)  
Walking distance 53 (33.1) 9 (22.5)  
Other cholera cases in the household     0.15 
No 155 (97.5) 37 (92.5)  
Yes 4 (2.5) 3 (7.5)  
Treatment of  drinking water†     0.15 
No 26 (16.3) 11 (28.2)  
Yes 34 (21.3) 5 (12.8)  
Eating food in a public space     0.02 
Never 72 (45.0) 11 (28.2)  
Sometimes 49 (30.6) 20 (51.3)  
Everyday 39 (24.4) 8 (20.5)  
Usual place of defecation     0.12 
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Latrine 81 (50.6) 17 (42.5)  
Pit in the yard 56 (35.0) 14 (35.0)  
In the ground 23 (14.4) 9 (22.5)  
Sharing the latrine with someone suffering from 
cholera     0.001 
No 131 (96.3) 24 (80.0)  
Yes 5 (3.7) 6 (20.0)  
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Figure 22. Acute diarrhea cases reported in the study areas after the starting date of the study (week 20 
in Boffa prefecture, panel A; and week 24 in Forécariah prefecture, panel B). The cholera cases 
confirmed by rapid test (RDT) included in the study are represented in red and the non-cholera cases 
(RDT negatives) included in the indicator bias analysis are represented in green. 
 
Of 36 case-patients included in the primary analysis for whom a specimen was sent for 
culture and PCR analysis, 18 (50%) were positive for V cholerae O1, El Tor-Ogawa; 13 were 
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positive for culture and PCR and 5 PCR positive but culture negative. All the 36 samples 
showed a weak amplification signal of the 16S rRNA gene. Among the 18 negative 
specimens, 5 had an almost undetectable amplification signal.  
 
In addition, 43 watery diarrhea case-patients with a negative RDT result and 172 control-
subjects were recruited for the indicator bias analysis (Figure 23). 
 
 
Figure 23. Study flow chart: number of case-patients with a positive result to the rapid diagnostic test 
(RDT) included in the primary analysis, number of case-patients with a negative result to the RDT 
included in the indicator bias analysis, and number of case-patients included in the sub-analysis with 
culture and/or PCR positive cases. Four matched control-subjects were selected for each case-patient. 
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5.6.2 Analysis of confounders and effect modifiers 
Table S1 shows the socio-economic characteristics and the exposure to different risk factors 
for cholera among case-patients and control individuals. A statistical association was 
observed between being a case-patient and eating in public places and sharing the latrine 
with a cholera case. The potential confounding effect of factors with P values lower than 0.2 
was assessed in the multivariate conditional logistic regression analysis. 
 
Table S2 shows the socio-economic characteristics and the exposure to different risk factors 
for cholera among non-cholera watery diarrhea case-patients and control-subjects included 
in the indicator bias analysis. The non-cholera watery diarrhea case-patients and the 
matched control-subject showed similar socio-economic characteristics and had similar 
exposure to different risk factors for cholera infection (Table S2). 
 
5.6.3 Vaccine Effectiveness Analysis 
 
Vaccination with two complete doses was associated with significant protection against 
cholera, in the crude analysis and after adjustment for potential confounders (86.6%; 95% 
confidence interval: 56.7 to 95.8%; P value=0.001) (Table 13). The precision of the vaccine 
effectiveness estimate for an incomplete course of vaccine was inconclusive (42.8%; 95% 
confidence interval: -83.6 to 82.2%; P value=0.35).  
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Table 13. Vaccine effectiveness estimates and 95 percent confidence interval (95%CI) of a complete (two doses) and an incomplete vaccine 
course. Boffa and Forécariah, Guinea, 2012. 
                 
Vaccination status Controls Cases VE* 95%CI P value  aVE† 95%CI P value 
  N (%) N (%) %      %     
Unvaccinated 23 (14.4) 15 (37.5) Ref      Ref     
Incomplete course‡ 36 (22.5) 14 (35.0) 38.9% (-55.2% - 76.0%) 0.30  42.8% (-83.6% - 
82.2%
) 
0.35 
Full course (two 
doses) 
101 (63.1) 11 (27.5) 84.0% (59.7% - 93.6%) <0.001  86.6% (56.7% - 
95.8%
) 
0.001 
Total 160 (100.0) 40 (100.0)            
                
* VE: crude vaccine effectiveness estimates, calculated as 1-odds ratio. 
† AVE: adjusted vaccine effectiveness. Adjusted by: number of individuals living in the household, treatment of water before 
consumption and sharing the latrine with a cholera case  
‡ Incomplete course: individuals who took only one dose or who spitted out or vomited one of the two doses of vaccine 
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Table 14. Vaccine effectiveness estimates and 95 percent confidence intervals (95%CI) in the sub-
analysis containing only culture and/or PCR confirmed cases and in the sub-analysis using watery 
diarrhea cases with negative RDT result. Boffa and Forécariah, Guinea, 2012. 
 
Vaccination status Controls Cases VE* 95%CI  P value 
  N (%) N (%) %         
Culture-PCR sub-analysis† 
     Unvaccinated 10 (13.9) 8 (44.4) Ref     
     Incomplete course‡ 17 (23.6) 6 (33.3) 66.2% (-53.0% - 92.6%) 0.16 
     Full course (two doses) 45 (62.5) 4 (22.2) 91.6% (58.6% - 98.3%) 0.002 
     Total 72 (100.0) 18 (100.0)       
Indicator bias analysis§          
     Unvaccinated 9 (5.2) 4 (9.3) Ref     
     Incomplete course‡ 35 (20.4) 7 (16.3) 48.1% (-177.1% - 90.3%) 0.44 
     Full course (two doses) 128 (74.4) 32 (74.4) 25.2% (-225.2% - 82.8%) 0.70 
     Total 172 (100.0) 43 (100.0)           
          
* VE: crude vaccine effectiveness estimates, calculated as 1-odds ratio. 
† In this sub-analysis only cholera cases confirmed by culture and/or PCR were included in the 
analysis. 
‡Incomplete course: individuals who took only one dose or who spit out or vomited one of the two 
doses of vaccine. 
§ In this sub-analysis case-patients with non-choleric diarrhea (negative RDT result) were also 
compared with control-subjects that did not have diarrhea in an attempt to assess whether the results 
with respect to effectiveness could be attributed to bias. 
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In the sub-analysis including only cases that were culture and/or PCR confirmed, 
vaccination with two complete doses was also associated with significant protection against 
cholera (91.6%; 95% confidence interval: 58.6 to 98.3%; P value=0.002) (Table 3). 
 
The odds of vaccination between non-cholera watery diarrhea cases and control-subjects did 
not vary between these two groups (Table 14). 
 
5.6.4 Sensitivity analysis of the vaccine coverage estimates considering the uncertainty 
about the vaccination status. 
 
In Scenario 1 of the sensitivity analysis individuals reporting vaccination but without cards 
are considered as unvaccinated and in Scenario 2 are considered as vaccinated 
Table 15. Sensitivity analysis of the vaccine effectiveness (VE) considering the uncertainty of 
vaccination status among those reporting vaccination but without vaccination cards.  
 
Controls Cases VE 95%CI P value 
 N (%) N (%) %         
Vaccination status 
              Unvaccinated 23 (14.4) 15 (37.5) 
          Incomplete course (with card) 22 (13.8) 7 (17.5) 
          Incomplete course (without card) 14 (8.8) 7 (17.5) 
          Full course (with card) 68 (42.5) 6 (15.0) 
          Full course (without card) 33 (20.6) 5 (12.5) 
     Scenario 1: those without cards as unvaccinated 
              Unvaccinated 70 (43.8) 27 (67.5) Ref 
         Incomplete course (with card only) 22 (13.8) 7 (17.5) 11.8% (-140.1% - 67.6%) 0.80 
     Full course (with card only) 68 (42.5) 6 (15.0) 81.9% (49.2% - 93.6%) 0.001 
Scenario 2: those without cards as vaccinated 
              Unvaccinated 23 (14.4) 15 (37.5) Ref 
         Incomplete course (with and without card) 36 (22.5) 14 (35.0) 38.9% (-55.2% - 76.0%) 0.30 
     Full course (with and without card) 101 (63.1) 11 (27.5) 84.0% (59.7% - 93.6%) <0.001 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. DISCUSSION 
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6.1 Feasibility of the mass vaccination campaign 
A mass vaccination campaign with a 2-dose OCV was successfully conducted at the 
beginning of a cholera epidemic in a large and remote geographical area in Africa with a 
highly mobile population and difficult access. Overall, the implementation of the campaign 
did not differ compared to other mass campaigns used for outbreak response despite the 2-
dose schedule. The volume of vaccines and therefore cold chain capacity required was large, 
but the fact that vaccines could be delivered at ambient temperature on the vaccination day 
by non-medical staff greatly facilitated the implementation.  
The population in the midst of a cholera epidemic was eager to receive the vaccine; despite 
the short mobilisation and awareness activities, the vaccination coverage was high.  Both 
provision and attention of resources to other preventive interventions remained strong as it 
was possible to use vaccination sites to deliver other prevention messages and items. While 
vaccination remains a costly intervention, it allowed for a significant reduction of inputs 
needed for curative activities in the following weeks. The funding of an OCV stockpile is 
currently being addressed by WHO and its partners in an attempt to improve the 
availability of OCV for countries facing outbreaks (12).   
The 6 week implementation time lag for finishing the campaign was relatively long, 
partially due to the 2-dose schedule (given between two to three weeks apart in our case) 
but should be compared with the average time needed to organize mass vaccination 
campaigns against meningitis or measles, using single dose vaccines, which may be as long 
with variations depending on the implementing agency and other constraints. 
Immunological studies have suggested that partial protection after one dose of vaccine can 
be obtained (13), but whether the immunological response after one dose is enough to 
confer clinical protection or not needs to be demonstrated.  Similarly, a herd protection 
effect of OCV has been reported (14, 15), but its extent is still unclear and needs to be 
confirmed in additional settings. 
This experience demonstrated that mass campaigns with a two-dose OCV can be conducted 
successfully at the beginning of a cholera epidemic, even in a large, difficult-to-access area 
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in Africa with a highly mobile population, and with little time for preparation of the 
campaign and social mobilization. Potential obstacles that discouraged earlier campaigns 
either failed to materialize or were quite manageable; in particular, the population was 
eager to get vaccinated during the outbreak, and logistical issues were resolved. 
 
In many ways our campaign was “over-resourced,” due to the anticipated obstacles. 
Vaccination teams in Boffa were over-sized (half-sized teams in Forecariah vaccinated the 
same number of people per day), which increased transportation needs. Transportation of 
water sachets was logistically challenging; although use of water is not necessary according 
to the manufacturer, it was provided to facilitate the intake of the salty-tasting vaccine. 
Vaccination cards were used only to verify vaccination status during the coverage survey. A 
simplified strategy without use of water and vaccination cards would reduce personnel and 
transport needs, and therefore related costs. 
 
Another potential simplification relates to vaccine vial presentation and packaging. The 
vaccine package as single-dose vaccines are voluminous, due partly to bulky secondary 
packaging. Additionally, the vaccine vial design is not ideal for oral use: single-dose vials 
are tiny, with metallic caps that are difficult to open. 
 
There may also be potential to reduce cold chain needs. Although the vaccine is equipped 
with VVM 14 and considered temperature-stable, current labeling requires the vaccine to be 
stored in the cold chain. Documentation of thermostability is needed for future campaigns 
to be conducted using vaccines at ambient temperature. 
 
A single-dose vaccine would also greatly simplify OCV campaigns. Studies in India found 
that partial immune response is achieved after a single dose [14], but whether this response 
is sufficient to confer clinical protection is not yet known. Similarly, a herd protection effect 
of Dukoral has been reported [15] [16], but its extent needs to be confirmed for Shanchol in 
additional settings. 
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Perhaps the most serious obstacles to wider use of reactive OCV campaigns are cost and 
limited supply of Shanchol. These constraints led us to drastically limit the target 
population to a small subset of those at risk; the full at-risk population includes everyone 
living along the coast of Guinea, including the capital (Conakry) with two million 
inhabitants, areas that were highly affected once the epidemic began. Funding for an OCV 
stockpile will be critical for the timely implementation of larger campaigns, an issue 
currently being addressed by WHO and its partners in an effort to improve OCV access for 
countries facing cholera outbreaks [17]. 
 
6.2 Acceptability of the mass vaccination campaign by the population  
 
The high coverage and good acceptability of the campaigns, conducted in a rural mobile 
population in Guinea, is encouraging. The percentage of people reporting AEFIs was low 
and almost all participants reported that they would be vaccinated in a future campaign. 
However, more evidence is needed about the feasibility of reactive campaigns from densely 
populated urban scenarios where cholera burden is high and cholera outbreaks evolve 
faster [52,142–145]. Also the acceptability of target campaigns in such a context should be 
assessed from a political, public health and community point of view. Determining the 
short-term protection given by the first dose is a clear priority as an effective one-dose 
regimen would facilitate the ease and timeliness of reactive campaigns in all contexts. 
 
There are several key limitations of note. Despite the short time span between the 
vaccination campaign and the data collection for the surveys, it was not possible to card-
confirm the vaccination status for 25% of the participants and as a result some information 
bias may be present. Considering those individuals as not-vaccinated (worst-case scenario), 
two-dose coverage would decrease to 61% in Boffa and 64% in Forécariah. Second, the 
precision of estimates was better than expected because the number of participants recruited 
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was higher (linked with the household size composition) than originally planned. However, 
population estimates in the surveyed areas are likely to be inaccurate. In most areas, no 
major differences were observed between administrative and survey coverage, but in 
Kaback an important deviation was observed. Inaccuracies in the population data could 
have caused some imbalances in the allocations of clusters; as described, spatial sampling 
was used in Kaback to avoid this problem. 
 
An additional limitation concerns the use of a quantitative approach to explore campaign 
acceptability. Although reasons for non-vaccination were specifically collected using an 
open question, it cannot be excluded the possibility that the population may not have 
understood certain awareness and education messages. A qualitative assessment would aid 
in understanding better the reasons for non-vaccination, elucidate possible solutions and 
provide a better understanding of the perception of the vaccination campaigns by the 
population. 
There are few examples where OCVs have been used as public health tools. Dukoral was 
used pre-emptively in refugee camps in Uganda and Darfur [146,147] and in endemic areas 
(Zanzibar and Mozambique) [148,149]. Shanchol has been recently used in Haiti in a pilot 
campaign [150]. To our knowledge there are only two published examples of reactive 
campaigns using OCV, and both were conducted in Asia [151,152] using vaccines not 
prequalified by the WHO. The coverage and acceptability of these campaigns varied 
depending on the setting and the approach (pre-emptive vs. reactive). High coverage was 
obtained in Uganda, Darfur and Micronesia [146,147,151] and lower coverage was obtained 
in Mozambique, Zanzibar and Vietnam [148,149,152]. In Guinea, 76% coverage was 
obtained for two doses and 93% of the population received at least one dose, which 
represents, to our knowledge, one of the highest coverage ever reached [146–149,151,152]. 
The high coverage obtained is a promising outcome considering that this was one of the 
largest campaigns conducted in terms of number of doses administered, the specificities of 
the population (rural and mobile), and the short time available for preparation of the 
campaign, which has been one of the major arguments against outbreak response with OCV 
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.There are several factors that likely influenced the population to participate in the 
campaign: first, the campaign was conducted in response to an outbreak and the possibility 
of even partial protection  against a frightening disease was motivating.  Second, the 
population may have been reassured by the involvement of the MoH, public health 
authorities and MSF; as an example, the vaccination campaign was inaugurated in Boffa 
with the presence of the Minister of Health. This involvement was also crucial to mobilize 
human resources and to organize the campaign considering the local specificities. Finally, 
both the awareness campaign and the vaccination strategy itself (decentralized with sites 
organized in each village or settlement) involved the communities. This aimed to ensure 
awareness and provide vaccination opportunities to remote places and difficult to reach 
population which likely contributed to this high coverage. Vaccination activities started 
early in the morning and finished late in the afternoon to maximize the opportunities for 
workers in the main fishing ports. Despite these efforts, the lowest coverage was obtained in 
adult males.  
 
Significant differences where observed by sex in Forécariah, especially in individuals 
between 15-49 years old.  The vaccination campaign in Forécariah coincided with an intense 
period in agriculture activities, which was a barrier for the participation in the campaign, 
especially for the male adults. In addition, the Red Cross Society of Guinea distributed soap 
and a bottle of chlorine solution to women of childbearing age in Forécariah during the 
second round of vaccination, which likely increased the coverage in this group. Distribution 
of soap and chlorine was one of the control measures implemented by the MoH in response 
to the outbreak in the affected places, but this activity was successfully integrated in 
Forécariah within the vaccination sites. This suggests that synergies among different 
preventive approaches is an element to consider in future campaigns both to provide a more 
comprehensive message on cholera prevention and to improve the vaccine coverage itself. 
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6.3 Adverse events following immunization 
The number of AEFI reported through the surveillance system was low, without severe 
AEFI reported. Only a small proportion of non-vaccinated individuals during the second 
round of vaccination reported AEFI as a cause of non-vaccination. This result is coherent 
with previous publications on vaccine safety where mild symptoms (mostly not requiring 
medical attention) have been reported [122,153]. The proportion of vaccinated individuals 
reporting AEFIs was lower in our study than in the cluster randomized clinical trial 
conducted in Kolkata (15 vs. 76 per 100,000) [122]. This difference is probably explained by: 
first, our surveillance system was passive compared with the active case finding 
implemented in Kolkata; and second, access to health care was likely more difficult in the 
vaccinated area in Guinea (remote rural area) than in the urban context of Kolkata.  
 
With respect to the proportion of vaccinees vomiting or spitting out the vaccine after intake, 
it was observed a higher percentage than previously documented with Dukoral (no data 
available for Shanchol) [148]. For administration of Dukoral, the vaccine has to be diluted in 
water containing a buffer solution. Although administration with water is not necessary for 
Shanchol, water was offered after vaccine intake. Most vaccinated individuals did not like 
the taste of the vaccine and offering water may have contributed to fewer incomplete 
vaccine courses. Additional information should be collected in future campaigns using 
Shanchol, considering that providing water considerably increased the logistic complexity 
of the campaign. 
 
6.4 Performance of the cholera rapid diagnostic test crystal in vaccinated 
individuals 
To our knowledge, this is the first study showing that healthy individuals vaccinated with 
the oral vaccine Shanchol become positive with the cholera rapid test Crystal VC in the first 
days following vaccination. The proportion of vaccinated individuals positive for the 
Crystal VC test after vaccination was high (94.3%) for the O139 component of the test, but 
Discussion | 110 
 
 
low with the O1 component. This proportion of O139-positive tests decreased rapidly to half 
on the third day after vaccination and to one-fifth on the fourth day of follow-up. The 
median duration required to have a negative result for those cases presenting a previous 
positive test was 4 days. 
 
Almost all positive tests (except for one) were positive only for O139 line, despite the fact 
that the Shanchol vaccines contains the two strains V cholerae O1 and O139, with a higher 
amount of O1 (1500 Elisa units of V cholerae O1 LPS and 600 Elisa units of V cholerae O139 
LPS for a dose of 1.5 mL) [18]. This could be due to a higher sensitivity of the RDT for the 
O139, as suggested by the results of sensitivity against bacterial cultures showing that the 
O139 line was reactive with higher bacterial dilutions than the O1 line. Such results were 
already reported by Nato et al. [7] when evaluating the initial version of the RDT, but are in 
contradiction with those observed by Mukherjee et al. [13] with the first version of the 
Crystal VC test, which was reactive at 106 bacteria/mL for V cholerae O1 and 107 bacterial/mL 
for V cholerae O139. These differences of analytical sensitivity between the different versions 
of the RDT emphasize the need for a proper diagnostic performance evaluation of each new 
version of the test. 
 
Including pre-vaccination stool status of our study population as well as unvaccinated 
participants could have provided useful information on the magnitude of potential false 
positive reactions due to factors unrelated to vaccination, i.e. non-specific reactions, which 
could have been expected considering the reported moderate specificity of the test  [4, 11-
13], or positivity due to asymptomatic carriers. The sharp increase and subsequent decrease 
in the proportion of O139 positive tests after vaccination are not in favour of such 
assumptions and suggest that the positive results were due to the vaccine alone. Of the 75 
tests done after day 5, only three (4%) were positive for O139, and overall only one test was 
positive for O1 which is lower than the number of false positives that could be expected 
based on the test specificity. However, it should be noted that this study was conducted in 
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people without cholera symptoms while the previous evaluations were conducted in 
suspected cholera cases. 
 
There are several limitations worth noting. First, women and adults were overrepresented 
in our study sample. Although women were more vaccinated than men were during the 
vaccination campaign carried out in Kabak, the proportion of women in our study (79.3%) 
was clearly higher than the vaccinated population (59.5%) [19]. This is likely due to the fact 
that  the majority of men presented early at the vaccination site and were more likely to be 
excluded given their potential absence for work during the follow-up period. However, 
although there was a small difference in the mean time to become negative between men 
and women (4.3 days vs. 3.6), the median was the same for both sexes (4 days) thereby not 
likely affecting the results presented here. The median age in the study was 25 years 
compared to 15 for the vaccinated population [19]. Considering that the time to become 
negative was longer for the older participants, it is likely that the time to become negative 
was slightly overestimated. Nonetheless, the differences by age were small in magnitude 
(0.2 days per 10 years of age) and they do not change the interpretation of the results neither 
our recommendations regarding the use of the cholera RDT in vaccinated areas. Second, it 
was not possbile to conclude on five cases who had a positive result with their last specimen 
collected, and for whom further samples could not be collected because they were absent or 
unable to produce stool samples. When designing the study, it was decided to limit the 
follow-up period to 7 days, based on the expected time for gastrointestinal transit of the 
killed bacteria. Although extending the follow-up of participants until they became negative 
for the rapid test would have been useful for concluding on these 5 individuals, this limit 
was considered reasonable in the absence of any other data. In addition, even considering 
that these five people were still positive at day 7, the percentage of positive tests would be 
still low (5.2%), lower than the expected for non-cholera cases considering the specificity of 
the test. Third, culture was not performed to exclude participants with possible cholera or 
asymptomatic carriage of V cholerae. Although initially planned in the protocol for 
participants with diarrhea or with a positive RDT at the end of follow-up (day 7), no culture 
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was performed since symptoms were found unreliable and none of the specimens tested on 
the seventh day of follow-up were positive. Finally, specimens were tested on average ten 
hours after stool production and without the possibility of storage at 4°C due to the lack of 
electricity in Kabak. This delay seems reasonable given the difficulties to collect the samples 
immediately after production, although it is unclear the degree to which antigens degrade 
during this period, which could potentially affect the RDT results. 
 
6.5 Vaccine effectiveness  
The results presented here show high effectiveness of two complete doses of Shanchol when 
administered as part of the response to a cholera epidemic in Africa. Our results represent 
an estimate of the short-term protection of Shanchol and are in line with previous results 
with Dukoral [117]. This is highly relevant considering the fact that oral vaccines have 
shown low levels of protection in low-income African settings in the past [154–156]. 
 
This study was carried out under real field conditions during a cholera outbreak with 
several limitations to note. The outbreak response immunization was part of the control 
strategy implemented by the Ministry of Health with the support of MSF in response to the 
epidemic; thus, the exposure in the population was not controlled. Overall, 316,250 vaccines 
were delivered  and 48 non-severe adverse events following immunization were notified; 
the vaccine coverage was high [157], ranging from 69% in Koba to 84% in Makountan sub-
prefectures. High vaccination coverage reduces transmission in vaccinated communities 
(herd protection) [158–160],  thereby directly and indirectly reducing the risk of cholera. In 
the past, this has limited opportunities to measure effectiveness [161] due to difficulties in 
recruiting case-patients. In our study, most of the cases were recruited from Koba (Boffa 
prefecture) where a small local outbreak was reported (August-October 2012). This area 
showed the lowest vaccination coverage [157] and borders Dubreka where high 
transmission (overall attack rate 17 per 10,000) was reported. It is important to mention that 
the small sample size did not translate into low power (99%) as the observed effectiveness 
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was higher than the assumption considered for the sample size calculation. However, the 
small sample size limited the possibility of conducting stratified analyses by age and to 
estimate single dose effectiveness with sufficient precision. This latter figure although not 
significant, was substantially lower than the protection conferred by two doses, and the 
point estimate was in line with previous findings with other OCV [117,122,160]. 
Despite the wide and systematic distribution of vaccination cards and the short time span 
between the vaccination campaign and the data collection, 25% of the vaccinated people 
interviewed were not able to provide their vaccination card at the time of the study. As 
vaccination status for all participants was not confirmed, some information bias may be 
present. Nevertheless, even if we consider all the individuals who were unable to find their 
vaccination card as not-vaccinated (worst-case scenario), the vaccine effectiveness would 
still reach 82%. 
 
Further, case-control studies of vaccine effectiveness may also be prone to bias related to 
differences in health seeking behavior. In order to measure this potential bias a 
supplementary analysis was conducted, measuring the odds of vaccination among non-
cholera watery diarrhea cases and a sample of matched control-subjects (indicator bias 
analysis). As the odds of vaccination did not vary significantly between these two groups, 
this finding was interpreted as absence of large health seeking behavior bias. 
 
Despite difficulties inherent in assessing effectiveness under field conditions, precise 
estimates of the short-term protection (first six months) of Shanchol were obtained in Africa 
where the impact of OCV is expected to be the highest in reducing mortality [5,7] and where 
problems with the protection provided by oral vaccines have been documented in the past 
[156]. The crude and the adjusted effectiveness estimates were similar after exploring the 
effect of a large number of well-described possible confounders, as well as when using only 
PCR or culture confirmed cases. The low proportion of PCR positive samples could be 
related to the small amount or the poor quality of biological material, as assessed by the 
weak amplification signal of the 16S rRNA gene. False positive RDT results cannot be 
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excluded [80,162]; this non-differential misclassification would have underestimated the 
vaccine effectiveness.  
 
The results presented here suggest that the short-term protection of Shanchol can be higher 
in the first six months than the protection remaining two years post-vaccination (67% 
estimate reported by Sur et al.) [122], probably as a result of waning immunity. It is possible 
that this difference is also partially explained by the fact that some non-vaccinated 
participants may have naturally acquired immunity, as cholera is endemic in Kolkata. In 
addition, our estimate might include some indirect protection, although indirect effects 
were minimized through the matched design [158,159]. 
 
An aspect that does not seem to have decreased the short-term protection provided by 
Shanchol is the cold chain strategy used in Guinea, where vaccines were stored under cold 
chain, but were transported and used at ambient temperature on the vaccination day. The 
vial temperature monitor was checked for stability before administration (all remained 
valid). These results are not surprising considering the good heat stability of Dukoral [4], 
but this requires more robust documentation which will allow for more flexible delivery 
strategies in the future. Another aspect that can substantially simplify the use of OCV in 
outbreak settings is a single dose regimen. Our study was underpowered to provide precise 
estimates of the one-dose protection. Determining the short-term protection given by one 
dose is a clear priority towards the implementation of efficient and timely reactive 
campaigns. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. CONCLUSIONS AND RECOMMENDATIONS 
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7.1 Feasibility of the mass vaccination campaign 
 
- Our experience demonstrates the feasibility of implementing OCV mass campaigns 
at the onset of major epidemics.  
 
- The difficulties found were similar to the campaigns with other vaccines used 
reactively (e.g., measles).  
 
- The main difficulties were associated to the two doses schedule, cold chain needs 
and provision of water for vaccine intake 
 
- A simplified strategy without use of water and vaccination cards would reduce 
personnel and transport needs, and related costs. 
 
7.2 Acceptability of the mass vaccination campaign by the population  
 
- High vaccine coverage can be reached within a few weeks, even in remote rural 
areas.  
 
- The campaigns were well accepted by the population.  
 
- Good documentation of these interventions is essential to elucidate the strategies 
leading to successful outcomes as well as key implementation barriers.  
 
- Synergies between different axes in cholera control interventions should be pursued  
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- Other examples of integrated cholera response than the one presented here should 
serve also to determine the best use of vaccines for cholera prevention and control. 
 
7.3 Adverse events following immunization 
-  The safety profile of Shanchol is good when used in reponse to outbreaks 
 
- No severe adverse event following immunization were document 
 
- Few mild adverse event were reported, with mainly ganstrointestinal symtoms 
associated. 
 
7.4 Performance of the cholera rapid diagnostic test crystal in vaccinated 
individuals 
 
- The rapid test Crystal VC can become positive in persons recently vaccinated against 
cholera. 
 
- The rapid test Crystal VC can become positive only with the O139 line, probably 
linked to its higher analytical sensitivity.  
 
- The tests become negative rapidly and five days after vaccination the proportion of 
positive tests among vaccinated is less than 3%.  
 
- As the current global pandemic is almost exclusively caused by Vibrio cholerae O1, 
our results suggest that the current Crystal VC kit can be used normally as soon as 
24 h after receiving Shanchol in a context of V cholerae O1 epidemic, and after a 
period of five days in areas where V cholerae O139 is present.  
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- Other cholera rapid diagnostic tests based on the LPS detection are available in the 
market and could also become positive in recently vaccinated individuals. Thus, an 
evaluation of other tests or future versions of the Crystal VC test is recommended if 
they are to be used in the context of oral cholera vaccination campaigns.  
 
- Tthe diagnostic performances of the current modified version of the Crystal VC test 
should be evaluated with respect to the different sensitivities of the O1 and O139 
lines. 
 
7.5 Vaccine effectiveness  
- The estimates on the short-term effectiveness of Shanchol is high when used in 
response to epidemics  
 
- The hihg effectiveness documented here is a key and essential information to 
improve the current strategies for outbreak prevention and control.  
 
- This evidence supports the current WHO recommendation of exploring the role of 
OCV in response to cholera outbreaks. 
 
- This evidence should serve to recommend strongly the addition of OCV among the 
tools to be used in response to epidemics. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. ACHIEVEMENTS AND WAY FORWARD 
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This evidence served to strongly recommend the addition of OCV among the tools to be 
used in response to epidemics, alongside efforts to improve provision of safe water and 
sanitation and access to cholera treatment. In addition it served to support the creation of an 
oral cholera vaccine stockpile for emergency use by the WHO and partners. This work has 
been also considered by the Global Alliance for Vaccines and Immunization (GAVI) in order 
to include the oral cholera vaccine among the vaccine supported for introduction in the next 
coming years. 
 
The next research areas were considered as priorities to improve the feasability, 
acceptability, effectiveness and impact when used in respose to outbreaks: 
 
1. To determine the level of protection of a one dose schedule. 
2. To stablished the termostability of the vaccine when used out of the cold chain 
3. To determine the safety profile when administered to pregnant women 
4. To analyise the possible interference with the co-administration of the oral polio 
vaccine 
5. To assess the the feasibility and acceptability of reactive campaings in urban contexts 
6. To determine the overall impact of oral cholera vaccine in response to epidemics in 
terms of deaths and cases adverted  
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Five different project are ongoing to adress the above mentioned research questions: 
 
1. A phase II clincial trial that will serve to determine the immune response to one dose 
schedule and the thermostability of the vaccine 
 
2. A cohort study to measure pregnacy outcomes in vaccinated and unvaccinated 
pregnant women 
 
3. A phase II clinical trial to analyise the possible interference with the co-
administration of the oral polio vaccine 
 
4. A demostration project of the use of cholera vaccine in urban African scenarios 
 
 
5. Modeling work to estimate the impact of reactive vaccinations 
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Abstract
Background: As resources are limited when responding to cholera outbreaks, knowledge about where to orient
interventions is crucial. We describe the cholera epidemic affecting Guinea-Bissau in 2008 focusing on the geographical
spread in order to guide prevention and control activities.
Methodology/Principal Findings: We conducted two studies: 1) a descriptive analysis of the cholera epidemic in Guinea-
Bissau focusing on its geographical spread (country level and within the capital); and 2) a cross-sectional study to measure
the prevalence of houses with at least one cholera case in the most affected neighbourhood of the capital (Bairro Bandim)
to detect clustering of households with cases (cluster analysis). All cholera cases attending the cholera treatment centres in
Guinea-Bissau who fulfilled a modified World Health Organization clinical case definition during the epidemic were included
in the descriptive study. For the cluster analysis, a sample of houses was selected from a satellite photo (Google EarthTM);
140 houses (and the four closest houses) were assessed from the 2,202 identified structures. We applied K-functions and
Kernel smoothing to detect clustering. We confirmed the clustering using Kulldorff’s spatial scan statistic. A total of 14,222
cases and 225 deaths were reported in the country (AR= 0.94%, CFR= 1.64%). The more affected regions were Biombo,
Bijagos and Bissau (the capital). Bairro Bandim was the most affected neighborhood of the capital (AR = 4.0). We found at
least one case in 22.7% of the houses (95%CI: 19.5–26.2) in this neighborhood. The cluster analysis identified two areas
within Bairro Bandim at highest risk: a market and an intersection where runoff accumulates waste (p,0.001).
Conclusions/Significance: Our analysis allowed for the identification of the most affected regions in Guinea-Bissau during
the 2008 cholera outbreak, and the most affected areas within the capital. This information was essential for making
decisions on where to reinforce treatment and to guide control and prevention activities.
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Introduction
Although cholera has disappeared among the diseases affecting
developed countries, it remains one of the main causes of
morbidity and mortality in the poorest areas of the world [1,2].
The burden of cholera is underestimated or non-estimated and
many countries face recurrent epidemics [1,3]. Sub-Saharan
African countries are especially affected, with 95% of reported
cholera cases and 98% of deaths [4]. Cholera emerges under poor
hygiene and sanitary conditions; thus, the lack of basic services and
disorganized urbanization in many Sub-Saharan African countries
constitutes the perfect culture medium for cholera [1].
John Snow, one of the founders of modern epidemiology,
showed the importance of descriptive epidemiology in cholera
epidemics, emphasizing the importance of ‘‘place’’, or the
consideration of space, to target prevention and control activities
[5]. Today, although resources and tools for mapping are
available, the description of place in cholera epidemics remains
poor and examples of studies using spatial technologies in the
medical literature are limited [6–15].
The objective of this study was to describe the cholera epidemic
affecting Guinea-Bissau from May 2008 to January 2009 focusing
on place in order to guide prevention and control activities. We
also conducted a cluster analysis to obtain more detailed
information about the distribution of cases in the most affected
area of the capital (Bairro Bandim) with the same aim.
Methods
Context
The Republic of Guinea-Bissau is one of the smallest nations in
continental Africa; it is divided into 8 regions (Bafata, Biombo,
Bissau, Bolama, Cacheu, Gabu, Oio, Quinara and Tombali) and
the capital, Bissau, (Sector Auto´nomo de Bissau (SAB)). The SAB
is the smallest geographical region in the country but the most
densely inhabited. Around 27% of the total population of the
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19005
country lives in this area. Although the country has experienced
several years of stability and development since the end of the civil
war in 1998, the life expectancy at birth is 47 years, and 203
children die before the age of five per 1 000 live births [16].
Descriptive epidemiology
Data sources. Daily official data from the Public Health
General Direction (DGS) registers was used to describe the
epidemic for the entire country in terms of time and place.
For SAB, we put in place a comprehensive data collection
system to describe the epidemic from 05/05/2008 to 20/10/2008.
These data came from the registers of the Cholera Treatment
Center (CTC) in the Hopital Nacional Simao Mendes and the five
Cholera Treatment Units (CTU) set up in 5 Health Care Centers
(Bandim, Bairro Militar, Ajuda, Antula and Plaque). The collected
data included age, sex, place of residence (bairro and area sanitaria),
center where the patient was treated, and clinical outcome (dead
or alive).
Population data (denominators) used for rate estimations were
obtained from the 1991 census of Guinea-Bissau. A specific growth
rate was applied to the different Sanitary Areas (SA) to account for
population growth and migration (provided by the Epidemiolog-
ical Department of the DGS (SE-DGS)). Age and sex distributions
were obtained from the annual SE-DGS census projections.
Case definitions, laboratory procedures and statistical
analysis. A modified WHO clinical case definition was used for
suspected and confirmed cases of cholera [17]. A suspected case was
defined as any person suffering from acute watery diarrhea with or
without vomiting. A confirmed case was defined as any suspected
case with a positive stool sample to Vibrio cholera O1 or O139.
Stool samples were analyzed in the National Laboratory of
Microbiology (NLM) in Bissau to confirm the cholera outbreak
and to determine the current circulating strain and its antibiotic
sensitivity by culture [18]. Additional samples were sent to the
Pasteur Laboratory in Dakar for the same purpose.
We describe the cholera outbreak in Guinea Bissau in terms of
time and place. For SAB, we describe the epidemic in terms of
time, place and person. Central tendency (mean and medians) and
dispersion parameters (standard deviation and interquartile range)
were calculated for continuous variables, percentage and 95%
confidence intervals for categorical variables. To adjust attack
rates by age and sex, we used a Poisson regression model.
Survey: cluster analysis
We conducted a cluster analysis to identify areas at high risk of
infection in the Bairro Bandim Health District of SAB. Bandim
was selected because this neighborhood reported the highest attack
rates and the most cases within SAB.
Sample size. To calculate the sample size, we assumed that
20% of the households would have at least one case. We aimed to
detect statistical differences for areas with at least 30% of households
with one case. Considering a power of 80% and an alpha error of
0.05, the required sample size was 626 households. Assuming 10%
of households would be either refusals or absences, the sample size
was 678 households. We randomly selected 140 houses from the
2,202 structures identified in the satellite photo obtained from
Google EarthTM. To do so, we assigned a number to each house.
We then used a random number, using the random generator
function implemented in Rß Statistical Software [19], for selection.
For field teams to locate houses, coordinates (WGS 84) of the
randomly selected houses were introduced into a handheld GPS
(Garmin XL). The team carried out an active search of cases in the
selected household and in the four closest households (defined by the
field teams) in order to reach the desired sample size in a reasonable
time without loosing precision due to the design effect [20]. Thus,
the final sample frame was 700 households.
Figure 1. Weekly number of cholera cases and case fatality ratio (CFR%) in Guinea-Bissau 2008–2009.
doi:10.1371/journal.pone.0019005.g001
Spatial Description of Cholera in Guinea-Bissau
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Statistical analysis. Our spatial point pattern consisted of
locations with at least one cholera case and houses without cases.
Thus, the data represented a typical example of a marked point
pattern. We analyzed whether or not the observed cholera cases were
clustered over and above the level that would be expected under
natural environmental heterogeneity. We calculated the K-functions
for both the houses without cases and those with at least one case, and
the difference was used to detect the extra propensity of the
households with cases to cluster. We calculated the standard error for
the difference of the K-functions and the 95% confidence intervals in
order to know if the observed difference was different from zero,
meaning clustering occurred [21]. Next, we computed the probability
of finding a house with at least one case using a Kernel smoothing
technique [22]. The significance of departure from randomness was
assessed by random labeling performing 1000-time simulations to
establish upper and lower confidence limits. These analyses were
performed using in Rß Statistical Software [19]. We confirmed the
clustering using Kulldorff’s spatial scan statistic using SatScan
software [23]. We performed 9999 Monte Carlo replications to
obtain estimates of P values and confidence intervals.
Ethical considerations
As this study was conducted during the emergency response to
the cholera outbreak and was designed to provide information to
orient the public health response, ethical approval was not sought
prior to the survey. We sought retrospective approval from the
National Ethical Review Board (ERB) of Guinea-Bissau and from
the MSF ERB. The MSF ERB considered that since the purpose of
the study was to guide prevention and control activities, it could be
considered good public health practice rather than research. The
National ERB of Guinea-Bissau granted retrospective approval.
Privacy, confidentiality and rights of patients were ensured
during and after the conduct of the study. Oral informed consent
was obtained in each visited household after detailed explanation
of the existence of an outbreak, the objective of study and the
planed use of the information. Moreover, health education was
carried out in each household regarding cholera transmission and
prevention. The information was entered and analyzed anony-
mously. The study was implemented in collaboration with the
Ministry of Health after obtaining authorization to carry out the
survey.
Results
Descriptive epidemiology
The first cholera case was declared in Guinea-Bissau on 5 May
2008 (week 19). The epidemic was officially declared in July. Both
the NLM and the Pasteur Laboratory in Dakar confirmed that the
circulating strain was Vibrio Cholera O1 El Tor-Ogawa. A total of
Figure 2. Geographical distribution of the crude cholera attack rate by region and sub-regions in Guinea- Bissau, 2008–2009.
Coordinates expressed in sexagesimal degrees.
doi:10.1371/journal.pone.0019005.g002
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14,228 suspected cases and 225 deaths were declared in the whole
country. This number of cases corresponds to an attack rate of
0.94 (AR) per 100 people. The reported case fatality ratio (CFR)
per 100 cases was 1.58. The weekly average number of cases was
395.2 (SD 454.6) and the median 176.0 (IQR=15.5–764.0). The
weekly number of cases varied between a minimum of 2 cases and
a maximum of 1,376 cases. The peak of the epidemic was
observed after 22 weeks of reported cases, which corresponds to
epidemic week 40. After the peak, fourteen consecutive weeks with
decreasing numbers of cases were observed (Figure 1).
Figure 2 shows a more detailed description of the geographical
distribution of the epidemic. There were several sub-regions with
AR over 2% (SAB; Quinhamel and Prabis in Biombo; Bubaque
and Uno in Bijagos) and two of them (Ondame in Biombo and
Caravelas in Bijagos) reached 4%.
The SAB reported 67% of the total number of reported cases
in the country. The first case was declared 5 weeks after the first
notification in Tombali. Finally, 9,394 cases and 73 deaths were
reported in the SAB, which corresponds to an AR of 2.33%.
The reported CFR was 0.78%. The peak of the epidemic was
observed in epidemiological week 40. Until the 20 October 2008
(period with individual data collection), a total of 7,749 cases
were reported in the CTC and 5 CTUs of SAB. Most cases
were treated at the CTC (68.4%, n= 5300/7749). Regarding
the CTUs, the Bandim CTU received the most patients (9.8%).
Most patients were between 15 and 49 years old (68.6%). This
group showed the highest attack rate, almost 3.5 times higher
than in the youngest age group. The number of reported cases
was similar in men (48.6%) and women, with similar attack
rates.
We obtained information about the SA of residence from 7,294
patients (94.1%). Bandim was the SA with the highest number of
patients in absolute numbers (24.1%) but also in relative numbers
(AR=3.9%). Compared with Ajuda, people living in Bandim were
2.5 times more affected (Table 1). There was not a clear spatial
pattern in the SAB, but all neighborhoods located in the southwest
had ARs over 1.5% (Figure 3).
Cluster analysis
From the 140 structures randomly selected, we were able to
assess 136. Of the 4 structures not included in the analysis, 2 were
not households (one was a cinema and the other a carpentry) and 2
houses were uninhabited. As we also assessed the four closest
households to those randomly selected, a total of 616 households
were included in the analysis. We found at least one case in 140
households (22.7%; 95%CI: 19.5%–26.2%).
We computed the K-functions for the 476 houses without cases
and the 140 houses with at least one case. We also computed the
difference between both K-functions and the 95% confidence
intervals as explained previously [21]. This comparison showed
that the houses with cases were more clustered than houses
without cases (p,0.001) (Figure 4). Next, we computed the
probability of finding a house with at least one case using a Kernel
smoothing technique. Two clusters were identified in the study
area using both random labeling and the Kulldorff’s spatial scan
statistic (Figure 5).In the most affected areas (clusters), we
estimated that 30% of the houses had at least one case and the
least affected only 1% (Figure 5).
Discussion
Our analysis allowed for the identification of the most affected
regions in Guinea-Bissau during the 2008 cholera outbreak, and
the most affected areas within the capital where 67% of cases were
reported. This information was essential for making decisions
about where to reinforce treatment and to guide control and
prevention activities. As resources are usually limited when
responding to cholera outbreaks, knowledge about where to orient
interventions is crucial.
Although this analysis provided critical information, this study
has limitations. As was the case here, most descriptions of cholera
epidemics are a posteriori. Comprehensive data collection began one
week before the peak of the epidemic and only in the SAB. The
description was limited principally due to time and resource
constraints as well as the trade-off inherent in emergencies where
close concerns and simple analyses are more important than distal
and complex analyses [24,25]. We focused only on one affected
area of the city and did not establish statistical associations with
environmental, social or cultural risk factors. Strengthening local
capacity in surveillance of diseases of epidemic potential remains
an ongoing need in countries like Guinea Bissau. Further work
should also focus on identifying risk factors that may help orient
future interventions. Moreover, we simplified the cluster analysis
in the sense that we did not count all the cases in a house; we only
classified the households as with or without cases. Thus, the cluster
analysis captures the spatial distribution of the risk of primary
infections (all houses have at least one) but this can limit the
identification of clustering due to factors different from the
household location (i.e. secondary transmission at household level).
Table 1. Number of cases, population, attack rate per 100
people (AR%), risk ratios (RR) and adjusted risk ratios (ARR) by
age, sex and sanitary area.
Variable Cases Population AR% RR ARR
Gender
Female 3 960 203 946 1.94 Ref.
Male 3 744 199 052 1.88 0.97 0.98
Age (years)
0–14 1 632 189 409 0.86 Ref.
15–49 5 312 174 337 3.05 3.54 3.54
.50 798 39 252 2.03 2.36 2.27
Sanitary Area
Ajuda* 160 10 429 1.53 Ref.
Antula* 640 30 778 2.08 1.36 1.37
Bandim* 1 756 44 718 3.93 2.56 2.61
Bairro Militar* 932 65 274 1.43 0.93 0.94
Belem 306 17 263 1.77 1.16 1.18
CIM** 154 14 985 1.03 0.67 0.68
Cuntum 857 45 482 1.88 1.23 1.24
Luanda 219 25 236 0.87 0.57 0.58
Missira 516 38 838 1.33 0.87 0.87
Pefine 306 14 808 2.07 1.35 1.37
Plaque* 380 27 633 1.38 0.90 0.89
Quelele 472 28 898 1.63 1.06 1.08
Sintra_Nema 348 21 451 1.62 1.06 1.08
Santa Luzia 248 17 204 1.44 0.94 0.96
Total 7 749 402 998 1.92 - -
*Cholera treatment unit set up in this area.
**Cholera treatment centre set up in this area.
Sector Auto´nomo de Bissau, 2008.
doi:10.1371/journal.pone.0019005.t001
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There are some examples in the literature using spatial
techniques to establish associations with environmental variables,
but most of these studies are retrospective and come from
Bangladesh. Long-term surveillance in Bangladesh, annually
affected by cholera, has allowed for research activities regarding
the vaccine and etiology of cholera disease. The examples in Africa,
where most of the cases occur [4], are scarce and there is a real need
for more accurate spatial information. One study in Lusaka,
Zambia used a similar methodology to describe the epidemic in one
of the most affected neighborhoods of the city [7]. In eastern
Democratic Republic of Congo (Kivu provinces) a geographic
information system was established, and the authors identified
relationships between environmental variables and the number of
cholera cases [15]. This analysis allowed the identification of some
cities, located on Lake Kivu and Lake Tanganyika, which serve as
the main sources of cholera epidemics. Another study in Kumasi,
Ghana, analyzed the association of cholera with proximity to refuse
dumps [6]. However, in many other countries currently affected by
large cholera outbreaks like Zimbabwe, Angola, Mozambique or
other west African countries (among those Guinea-Bissau), the
spatial epidemiology remains poorly described.
The epidemic prior to 2008 in Guinea-Bissau was in 2005. The
same strain (Vibrio Cholera O1 El Tor-Ogawa) was circulating
during that epidemic and most natural immunity acquired during
2005 had probably vanished during the three-year inter-epidemic
period. The AR was higher in 2005 (1.75% vs 0.94%), with a
similar CFR. The current outbreak started in May, one month
earlier than the outbreak of 2005, but the peak was reached after
22 weeks, thereby doubling the pre-peak period. The first area
affected was also different, the current epidemic started in
Tombali, but in 2005, the outbreak was first reported in SAB.
In both epidemics, the transmission of cholera within SAB
facilitated the rapid spread to other regions of the country, and
the more affected areas were Bijagos, Biombo and the Sector
Autonomo de Bissau in both epidemics.
In all regions, the CFRs were higher at the beginning of the
epidemic. This is likely due to the implementation of improved
case management and under notification of non-severe cases
during the first weeks of the epidemic. Especially high CFRs have
been observed in Quinara and Bafata (9.2% and 8.2%
respectively), where again the combination of a poor case
management and under-notification of non-severe cases likely
explain these figures.
The SAB reported 67% of all reported cases. The area with the
highest AR was Bandim, playing an important role in the dynamic
of the epidemic within the city. Other areas in the southwest of the
Figure 3. Age and gender adjusted cholera attack rates (%) by Sanitary Area in Sector Auto´nomo de Bissau, 2008–2009. Coordinates
expressed in sexagesimal degrees. * Sanitary area with a cholera treatment centre. + Sanitary area with a cholera treatment unit.
doi:10.1371/journal.pone.0019005.g003
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city such as Quelele, Cuntum, Ajuda or Belem also showed higher
ARs than other areas. Within big areas like Bairro Militar, it is
likely that the distribution of the AR was not homogeneous with
some sub-areas more affected, but we could not test this hypothesis
because of the lack of smaller spatial scale population data. We
focused our investigation in Bandim because of the high AR and
the high percentage of total number of cases reported from this
neighborhood. This area is close to the markets and the main
road, so it may be important not only because of its disease burden
but also because of its potential role in the circulation of cholera in
the whole city. Nonetheless, it is important to consider that
Bandim has been the site of demographic surveillance system with
a focus on infectious diseases. It is possible that the extended
presence of these activities in the community leads people to seek
treatment promptly, and may therefore account in part for the
high attack rate in Bandim [26].
The cluster analysis identified two areas within Bandim at
higher risk of finding houses with cases. One was the surroundings
of the Caracol market. Different factors potentially explain this
higher risk. The first is the market itself; people living in this area
are more likely to be in contact with other cholera cases because
the market has a large inflow of people. There were also plausible
foodborne cases originated in the market, which may disporpor-
tionaly affect people living in the surrounding area. Another factor
is the large amount of waste around the market and garbage in the
streets. Moreover, an open drain passed through the market
gathering solid waste and dirty water. Within the market, sanitary
conditions were inadequate. The number of latrines was
insufficient; there were no hand washing points and the control
over the food items sold was insufficient. These factors combined
undoubtedly facilitate transmission. As a result of this analysis, the
authorities cleaned the market and established washing point and
installation of additional latrines. In markets, customers tend to
touch, taste and/or smell aliments; this reinforced the need for
focused behavioral changes together with sanitation measures
around markets.
The other affected area also has a high level of crowding and
the confluence of two factors that can increase risk: crowding –this
area is crossed by of one of the main streets in Bandim– and an
area where runoff accumulates waste. Moreover, the altitude of
this zone is almost at sea level. It is likely that the freatic
(groundwater) level in this area were higher, which implies less
filtration and higher probability of contamination under assump-
tion that the source of drinking water is from local boreholes.
General water and sanitation systems and hygiene condition
must be improved to avoid further outbreaks. Nonetheless, these
improvements take time and investment and preparedness plans
must be developed since outbreaks will continue to occur. Our
analysis is useful to orient these plans, and we recommend focusing
the preparedness activities in three regions: the Sector Autoˆnomo
de Bissau, Biombo and Bijagos, as these areas were the most
affected in the 2008 epidemic, and in 2005. The early detection of
the outbreak and the control plans are especially important in the
capital, Bissau, where most cases and deaths occur. One of the
Figure 4. Differences of K-functions and 95% confidence intervals between households with cholera cases and households without
cases in Bairro Bandim (Bissau), 2008–2009. A homogeneous set of points in the plane is a set that is distributed such that approximately the
same number of points occurs in any circular region of a given area. A set of points that lacks homogeneity is spatially clustered. The k-function is
defined as the expected number of points within a distance s of an arbitrary point, divided by the overall density of the points. Due to variations in
the spatial distribution of the population at risk, a k-function computed only for cases may not be informative. Instead, the k-function calculated for
cases can be compared with the one calculated for non-cases, with the difference between the two functions representing a measure of the extra-
aggregation of cases over and above the observed for the non-cases. This difference is represented in the figure above, showing extra-aggregation of
cases.
doi:10.1371/journal.pone.0019005.g004
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activities that should be planned in advance is the management of
the Caracol market and, depending on resources available, the
other markets. A cleaning routine should be established, a food
safety assessment implemented and latrines and washing points set
up. Education and awareness activities are key points to reinforce
in order to reduce the impact of future epidemics. These activities
are most important in some neighborhoods of the capital: Bandim,
Antula, Quelele, Cuntum and Ajuda. Another point to consider
among potential control activities are mass vaccination campaigns
with the oral cholera vaccine. Feasibility and effectiveness of mass
vaccination campaigns in specifically targeted settlements or
populations have been demonstrated in endemic areas
[27,28,29] and their use in targeted locations of Guinea-Bissau,
like Bandim, should be considered seriously both as a preventive
and a reactive strategy. There is an urgent need to identify new
strategies, which are feasible, acceptable and cost-effective to
prevent or quickly stop epidemics. Use of oral cholera vaccines
might be one of the solutions and its role during outbreaks should
be explored.
In conclusion, our study shows the importance of the
consideration of space for making decisions about where to
reinforce treatment and to guide control and prevention activities
in cholera outbreaks. The results of this study also highlight the
need for geographical descriptions of cholera epidemics in Africa.
Available tools for spatial analysis should be integrated into
existing surveillance systems in order to improve preparedness and
control of cholera epidemics.
Acknowledgments
This outbreak investigation was carried out in close collaboration with the
Servic¸co de Higiene e Epidemiologia de la Direcc¸ao Geral de Sau´de of
Guinea-Bissau and the World Health Organization. In particular, Dr.
Alvarenga and Dr Nogueira, from the Preparedness and Response Unit of
the WHO country office, were close partners in this investigation. We also
want to thank the Me´decins San Frontie`res team in Bissau their
information, help and support in all activities carried out during this work.
We would like to acknowledge the enthusiasm and dedication of the field
assistants, Carlos Co´, Fidel Manque, Celestino Co´, Lino Co´ and Carlos
Fredy. We thank the entire Bandim Health Project for their accessibility
and support of this work. We are also grateful to Vivian Bremer and
Brigitte Helynck (EPIET programme) for their critical lecture of the
manuscript.
Author Contributions
Conceived and designed the experiments: FJL CNB DR PPP EB RFG.
Performed the experiments: FJL CNB DR. Analyzed the data: FJL CNB
DR. Contributed reagents/materials/analysis tools: FJL CNB DR. Wrote
the paper: FJL CNB DR PPP EB RFG.
References
1. Zuckerman JN, Rombo L, Fisch A (2007) The true burden and risk of cholera:
implications for prevention and control. Lancet Infect Dis 7: 521–530.
2. Griffith DC, Kelly-Hope LA, Miller MA (2006) Review of reported cholera
outbreaks worldwide, 1995–2005. Am J Trop Med Hyg 75: 973–977.
3. Deen JL, von SL, Sur D, Agtini M, Lucas ME, et al. (2008) The high burden of
cholera in children: comparison of incidence from endemic areas in Asia and
Africa. PLoS Negl Trop Dis 2: e173.
4. WHO (2006) Cholera, 2005. Wkly Epidemiol Rec 81: 297–307.
5. (2004) 150th Anniversary of John Snow and the pump handle. MMWR Morb
Mortal Wkly Rep 53: 783.
6. Osei FB, Duker AA (2008) Spatial dependency of V. cholera prevalence on open
space refuse dumps in Kumasi, Ghana: a spatial statistical modelling. Int J Health
Geogr 7: 62.
7. Sasaki S, Suzuki H, Igarashi K, Tambatamba B, Mulenga P (2008) Spatial
analysis of risk factor of cholera outbreak for 2003–2004 in a peri-urban area of
Lusaka, Zambia. Am J Trop Med Hyg 79: 414–421.
Figure 5. Geographical distribution of the probability of finding a house with at least one cholera case in Bairro Bandim (Bissau) in
percentage and areas over the 95% confidence interval. Coordinates expressed in sexagesimal degrees. Figure 5a shows the Google EarthTM
picture and the overimposed image of the risk surface (probability of finding a house with at least one cholera case). The figure 5b shows the risk
surface and the two areas with statistically significant higher risk (black bold line). The same two clusters were detected (dashed blue circles) using
the Kulldorff’s spatial scan statistic (cluster A: Log likelihood ratio = 9.95, P = 0.029; cluster B: Log likelihood ratio = 8.81, P = 0.05).
doi:10.1371/journal.pone.0019005.g005
Spatial Description of Cholera in Guinea-Bissau
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19005
8. Osei FB, Duker AA (2008) Spatial and demographic patterns of cholera in
Ashanti region - Ghana. Int J Health Geogr 7: 44.
9. Ali M, Goovaerts P, Nazia N, Haq MZ, Yunus M, et al. (2006) Application of
Poisson kriging to the mapping of cholera and dysentery incidence in an
endemic area of Bangladesh. Int J Health Geogr 5: 45.
10. Chevallier E, Grand A, Azais JM (2004) Spatial and temporal distribution of
cholera in Ecuador between 1991 and 1996. Eur J Public Health 14: 274–279.
11. Ali M, Emch M, Donnay JP, Yunus M, Sack RB (2002) The spatial
epidemiology of cholera in an endemic area of Bangladesh. Soc Sci Med 55:
1015–1024.
12. Ali M, Emch M, Donnay JP, Yunus M, Sack RB (2002) Identifying
environmental risk factors for endemic cholera: a raster GIS approach. Health
Place 8: 201–210.
13. Myaux J, Ali M, Felsenstein A, Chakraborty J, de FA (1997) Spatial distribution
of watery diarrhoea in children: identification of ‘‘risk areas’’ in a rural
community in Bangladesh. Health Place 3: 181–186.
14. Waldman EA, Antunes JL, Nichiata LY, Takahashi RF, Cacavallo RC (2002)
Cholera in Brazil during 1991–1998: socioeconomic characterization of affected
areas. J Health Popul Nutr 20: 85–92.
15. Bompangue D, Giraudoux P, Piarroux M, Mutombo G, Shamavu R, et al.
(2009) Cholera Epidemics, War and Disasters around Goma and Lake Kivu: An
Eight-Year Survey. PLoS Negl Trop Dis 3: e436.
16. World Health Organization - Regional Office for Africa (2008) Country Health
System Fact Sheet 2006 Guinea-Bissau. WHO.
17. World Health Organization (2004) Cholera outbreak: assessing the outbreak
response and improving preparedness.
18. World Health Organization (2008) Cholera in Guinea Bissau. WHO. Available:
http://www.who.int/csr/don/2008_09_24/en/print.html.
19. R Development Core Team (2008) R: A language and environment for
statistical computing, reference index version 2.6.0. R Foundation for Statistical
Computing, Vienna, Austria. Available: http://www.R-project.org.
20. Working Group for Mortality Estimation in Emergencies (2007) Wanted: studies
on mortality estimation methods for humanitarian emergencies, suggestions for
future research. Emerg Themes Epidemio 1: 4–9.
21. Diggle PJ, Chetwynd AG (1991) Second-order analysis of spatial clustering for
inhomogeneous populations. Biometrics 47: 1155–1163.
22. Diggle P (1985) A kernel method for smoothing point process data. Applied
Statistics 34: 138–147.
23. Kulldorff M: SaTScan Version 9.0.1. (2010) Software for the spatial and space-
time scan statistics Information Management Services, Boston, MA, USA.
24. Coulombier D, Pinto A, Valenciano M (2002) Epidemiological surveillance
during humanitarian emergencies. Med Trop (Mars) 62: 391–395.
25. Medecins San Frontieres (2004) Cholera Guidelines. Paris: Medecins San
Frontieres.
26. Aaby P (1997) Bandim: an unplanned longitudinal study. In: Das Gupta M,
Aaby P, Pison G, Garenne M, eds. Prospective community studies in developing
countries. Oxford: Clarendon. pp 276–296.
27. Lucas ME, Deen JL, von SL, Wang XY, Ampuero J, et al. (2005) Effectiveness of
mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 352:
757–767.
28. Cavailler P, Lucas M, Perroud V, McChesney M, Ampuero S, et al. (2006)
Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine
in an urban cholera-endemic setting in Mozambique. Vaccine 24: 4890–4895.
29. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, et al. (2009) Efficacy and
safety of a modified killed-whole-cell oral cholera vaccine in India: an interim
analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet
74(9702): 1694–1702.
Spatial Description of Cholera in Guinea-Bissau
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19005
Urban Cholera Transmission Hotspots and Their
Implications for Reactive Vaccination: Evidence from
Bissau City, Guinea Bissau
Andrew S. Azman1, Francisco J. Luquero2, Amabelia Rodrigues3, Pedro Pablo Palma4, Rebecca F. Grais2,
Cunhate Na Banga3, Bryan T. Grenfell5,6, Justin Lessler1*
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 2 Epicentre, Paris, France, 3National
Public Health, Ministry of Health, Bissau City, Guinea-Bissau, 4Me´dicos Sin Fronteras, Barcelona, Spain, 5Department of Ecology and Evolutionary Biology, Princeton
University, Princeton, New Jersey, United States of America, 6 Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America
Abstract
Background: Use of cholera vaccines in response to epidemics (reactive vaccination) may provide an effective supplement
to traditional control measures. In Haiti, reactive vaccination was considered but, until recently, rejected in part due to
limited global supply of vaccine. Using Bissau City, Guinea-Bissau as a case study, we explore neighborhood-level
transmission dynamics to understand if, with limited vaccine and likely delays, reactive vaccination can significantly change
the course of a cholera epidemic.
Methods and Findings: We fit a spatially explicit meta-population model of cholera transmission within Bissau City to data
from 7,551 suspected cholera cases from a 2008 epidemic. We estimated the effect reactive vaccination campaigns would
have had on the epidemic under different levels of vaccine coverage and campaign start dates. We compared highly
focused and diffuse strategies for distributing vaccine throughout the city. We found wide variation in the efficiency of
cholera transmission both within and between areas of the city. ‘‘Hotspots’’, where transmission was most efficient, appear
to drive the epidemic. In particular one area, Bandim, was a necessary driver of the 2008 epidemic in Bissau City. If vaccine
supply were limited but could have been distributed within the first 80 days of the epidemic, targeting vaccination at
Bandim would have averted the most cases both within this area and throughout the city. Regardless of the distribution
strategy used, timely distribution of vaccine in response to an ongoing cholera epidemic can prevent cases and save lives.
Conclusions: Reactive vaccination can be a useful tool for controlling cholera epidemics, especially in urban areas like Bissau
City. Particular neighborhoods may be responsible for driving a city’s cholera epidemic; timely and targeted reactive
vaccination at such neighborhoods may be the most effective way to prevent cholera cases both within that neighborhood
and throughout the city.
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Introduction
With the introduction of inexpensive, easy to administer, and
effective oral vaccines against cholera, vaccination in response to
an epidemic (reactive vaccination) may be an effective supplement
to conventional control measures. Two safe and internationally
licensed oral cholera vaccines are currently available, Dukoral and
Shanchol. Both protect against clinical cholera two or more years
after vaccination, but neither confers long lasting immunity [1–4].
On an epidemic timescale, these vaccines have efficacies ranging
from 66 to 86% [2,5].
Vaccination against cholera has been used preventatively [3,6–
8], but before 2012, we know of only two instances, in The
Federated States of Micronesia in 2000 and Vietnam in 2008,
where vaccination commenced during an epidemic [4,9]. Vaccine
efficacy estimates ranged from 76 to 80%, however, no analysis on
how vaccination affected the course of the epidemic was reported
for either case [4,9].
New data on vaccine performance and the changing epidemi-
ology of cholera prompted the WHO’s Strategic Advisory Group
to recommend in 2010 that reactive vaccination be considered in
specific areas [10]. In order to facilitate rapid procurement and
deployment of an oral cholera vaccine, some have proposed the
creation of a revolving global stockpile [11,12]. While discussions
of the global stockpile proceed, countries that use reactive
vaccination must contend with a limited supply that may arrive
after a significant delay.
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Spatial heterogeneities may influence how cholera vaccine can
best be distributed in a reactive campaign. The effectiveness of a
campaign and optimal allocation strategy will depend upon local
cholera transmission dynamics, vaccine supply, and logistical
delays [12,13]. Human movement, water and sewerage infra-
structure, and natural waterways facilitate cholera transmission
across a city. Within neighborhoods, there can be marked
variation in the efficiency of transmission.
One country that may benefit from reactive vaccination is
Guinea-Bissau, where outbreaks have occurred every three to four
years since 1994. Sector Auto´nomo de Bissau (SAB), or Bissau
City, the capital, consistently reports the most cholera cases within
the country (unpublished data, Guinea-Bissau Ministry of Health).
In 2008, 67% of reported cases occurred in SAB while only 25%
of the national population live within its boundaries [14]. Reactive
vaccination in SAB may be possible in future epidemics given the
concentration of cases within the city and the Ministry of Health’s
experience with vaccination campaigns.
Here, we explore the possible effectiveness of different reactive
vaccination strategies using SAB as a case study. We fit a
neighborhood-based meta-population model to the 2008 cholera
epidemic. Using this model, we characterize the spatio-temporal
dynamics of cholera transmission within the city and estimate the
impact that different reactive vaccination strategies could have had
on the course of the epidemic.
Methods
Data Sources
During the 2008 epidemic, the Guinea-Bissau Ministry of
Health, the WHO, and Me`decins Sans Frontie`res implemented a
clinic-based cholera surveillance system, which has been described
previously [15]. In brief, upon arrival at either the cholera
treatment center in the Hospital National Simao Mendes or one of
five cholera treatment units (Figure 1C and 1D), health care
providers entered patients into a surveillance registry. A patient’s
age, sex, area of residence, treatment facility, date of presentation,
and clinical diagnosis were recorded.
Modified WHO cholera case definitions were used [15]. A
suspected case was any person suffering from acute watery
diarrhea, and a confirmed case was a suspected case with a
positive stool sample containing Vibrio cholerae O1 or O139. We
included all suspected and confirmed cases with complete
information on their presentation date and home sanitary area
in this analysis. The population for each sanitary area within the
city was extrapolated from 1991 census data using a constant
linear growth rate estimated by the Direcc¸a˜o-Geral Sau´de. To
estimate the population density in each sanitary area we traced the
residential areas using Google Earth (v6.0.3.2197), then divided
each sanitary area’s population by its estimated residential area.
Model of Cholera Spread in SAB
We fit a discrete-time Susceptible-Infectious-Recovered meta-
population model to the confirmed and suspected cases reported
during the 2008 epidemic with each of 14 sanitary areas in SAB
treated as a distinct population. We assume the epidemic follows a
first-order Markov process with a fixed generation time of five
days. At each time step, the incidence in each area follows a
Poisson distribution with a mean determined by the number
infected in the last time step in all areas and the proportion of the
area’s population remaining susceptible. After infection, individ-
uals were assumed to remain immune for the duration of the
epidemic (See Text S1 for model details).
We considered models of cholera transmission with and without
seasonality assuming (A) equal transmission coefficients between
and within all areas of SAB; (B) different transmission coefficients
within each area and equal transmission coefficients between all
areas; (C) different transmission coefficients within each area and
unique symmetric transmission coefficients between each pair of
areas; and, (D) different transmission coefficients within each area
and unique asymmetric transmission coefficients between each
pair of areas in the city. We chose the best model based on
Deviance Information Criteria (Text S1). To assess fit we
simulated 300,000 epidemics predicting five, fifteen, and fifty
days ahead drawing new parameters from the posterior distribu-
tion every 1000 simulations.
Posterior distributions were approximated using Markov Chain
Monte Carlo methods using JAGS 3.1.0 and R 2.14.0 with non-
informative priors [16,17]. We ran 3 chains of 400,000 iterations
with a burn in of 50,000, and assessed convergence using the
potential scale reduction factor and through visual inspection [18].
Vaccination
We assume every vaccinated individual receives two doses in a
vaccine campaign over a 20 day period and that 75% are fully
protected (VEs~0:75 [19]) [3,5,6,20]. In our model vaccinees get
no protection until 10 days after the second dose [21,22]. Hence,
75% of the susceptible vaccinees are considered immune starting
30 days after their first dose, with no protection before (Table 1).
We considered campaigns with 50,000, 75,000, or 100,000
doses (i.e. 25,000, 37,500, and 50,000 individuals vaccinated) and
targeted vaccination at one, two, three, or all (14) areas (Table 3).
When the proposed number of vaccinees in a specific area
exceeded the population size, we distributed vaccine to the other
vaccination areas or, in the campaigns with one vaccination area,
we dispersed the vaccine throughout the city with each person
having equal probability of getting vaccinated. We varied the
starting time of the vaccination campaign between 20 and 120
days after the first case was detected.
We considered targeted and diffuse (city-wide) campaigns. In
diffuse campaigns, vaccine was distributed throughout all areas of
SAB. In targeted campaigns, we considered three different
Author Summary
Cholera remains a major public health threat, causing 3–5
million cases and 100,000–120,000 deaths each year. In
2010, data on vaccine performance and the changing
epidemiology of cholera prompted the WHO’s Strategic
Advisory Group to recommend that reactive vaccination
be considered in specific areas. We built a spatially explicit
stochastic model of cholera transmission and fit it to data
from a 2008 epidemic in Bissau City, Guinea Bissau. Using
this model we examined the potential effectiveness of
reactive vaccination for controlling cholera transmission in
Bissau City, comparing strategies for distributing limited
vaccine. In simulations, early targeting of a single
transmission ‘‘hotspot’’, Bandim, was the most effective
strategy, and led to the greatest reduction in cases both
within Bandim and in areas where no vaccine was
distributed. This finding has implications for cholera
control in urban settings in general: public health officials
will often know which areas of a city were hotspots of
cholera transmission in the past or where conditions
promote efficient transmission. When there is limited
vaccine, our work suggests that targeting reactive vacci-
nation at these areas will lead to the greatest reduction in
cases both in these areas and elsewhere in the city.
Cholera Transmission in Bissau City, Guinea Bissau
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strategies to select vaccination areas. In the population-based
strategy, we selected the areas with the largest population. In the
connectivity-based strategy, we vaccinated in areas estimated to be
most ‘‘connected’’ to other areas. In the attack rate-based strategy,
we chose the areas with the highest attack rate in the 2008
epidemic. We allocated vaccine proportional to population size in
all simulations.
Simulation Studies
For each vaccination scenario we ran 5,000 simulations
calculating the difference between the final epidemic size with
and without vaccination. Epidemics were assumed to follow the
observed 2008 epidemic course until 30 days after the first dose. In
each simulation we drew new parameters from the joint posterior
distribution. As a sensitivity analysis, we ran simulations with
Figure 1. The 2008 cholera epidemic in SAB. Panel A (solid line) shows suspected and confirmed cholera cases reporting to cholera treatment
centers/units (shown as circles and triangles) throughout all areas of SAB aggregated in 5-day intervals. The dashed line below (B) shows 5-day
aggregated cases from Bandim, the area with the highest attack rate (40.6 per 1000). Panel C illustrates the day of the first reported case for each area.
Attack rates (per 1000) for each area are shown in D.
doi:10.1371/journal.pntd.0001901.g001
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different generation times (3–10 days) and vaccine efficacies (65%–
85%). Additional simulation study details are available in Text S1.
Ethics Statement
Original data collection was approved by the Me`decins Sans
Frontie`res ERB and the National Ethical Review Board of
Guinea-Bissau [15]. The analyses presented in this article were
conducted on de-identified data and deemed to be non-human
subject research by the Johns Hopkins Bloomberg School of Public
Health IRB.
Results
The 2008 Cholera Epidemic
The first case in SAB was reported on June 5, 2008 in Bairro-
Militar, the most populated area of the city (Figures 1A, 1B), one
month after the first reported case in Guinea-Bissau. Within three
weeks, all 14 areas had reported cases (Figure 1C). The Ministry of
Health officially declared an epidemic one month after the first
case report from SAB. The National Laboratory of Microbiology
and the Pasteur Laboratory in Dakar, Senegal identified all
positive specimens analyzed as Vibrio cholerae O1 El Tor Ogawa.
Nationally, 14,226 suspected cases and 228 deaths were
reported with 67% (9,393) of cases and 32% (73) of deaths
reported in SAB. The last case in the country was reported in SAB
on January 11, 2009. Individual-level data in SAB was collected
between June 5, 2008 and October 28, 2008, over which time
8,024 (85%) suspected and confirmed cases were reported. These
analyses focus on 7,551 suspected and confirmed cases with
complete information on date of presentation, home area, and
clinical diagnosis (Figure S1).
In SAB, weekly incidence ranged from 14 to 755. Within-area
attack rates ranged from 9.1 to 40.6 per 1,000 (Table 2, Figure 1D),
with Bandim having both the most cases (1,816) and the highest
attack rate.
Spatial Spread of Cholera in SAB
The final model fit both the overall and area-specific epidemic
curves well, even when predicting as far as 50 days (i.e. 10 time
steps) ahead (Figures 2A,2B). To understand how transmission
varied through time, we calculated the odds that an incident case
was caused locally (i.e. attributable to transmission between people
in the same area) for each area throughout the course of the
epidemic (Figure 3). Only Bandim, Plaque, and Santa-Luzia have
an odds consistently greater than 1, suggesting internally driven
epidemics in these areas.
Table 1. Overview of assumptions related to vaccination and
immunity.
Vaccine efficacy 75%
Doses per individual 2
Immunity before second vaccine dose None
Duration of vaccination campaign 20 days
Time from second vaccine dose to complete
protection
10 days
Proportion immune after natural infection 100%
Length of immunity from natural infection or
successful vaccination
Duration of the epidemic
Main assumptions used in primary analysis related to vaccination and immunity.
Additional details are provided in the methods section and Text S1.
doi:10.1371/journal.pntd.0001901.t001
Table 2. Overview of sanitary areas in SAB.
Sanitary Area Population
Suspected and
Confirmed Cases
Attack Rate
(per 1,000)
Barrio-Militar 65,274 944 14.5
Bandim 44,718 1,816 40.6
Cuntum 45,482 890 19.6
Missira 38,838 532 13.7
Antula 30,778 662 21.5
Quelele 28,898 493 17.1
Plaque 27,633 396 14.3
Luanda 25,236 229 9.1
Sintra Nema 21,451 355 16.5
Belem 17,263 322 18.7
Santa-Luzia 17,204 261 15.2
CIM 14,985 161 10.7
Pefine 14,808 324 21.9
Ajuda 10,429 164 15.7
All SAB 402,997 7,549 18.7
Estimated 2008 population for each sanitary area projected from 1991 census
data (second column). Suspected and confirmed cases with complete location
and time data and attack rate during 2008 cholera epidemic (third and fourth
columns).
doi:10.1371/journal.pntd.0001901.t002
Table 3. Vaccination scenarios.
Vaccination Strategy
Areas Vaccinated Population Connectivity Attack Rate Vaccination Start Day Doses
1 Area Bairro Militar (1.00) Missira (1.00) Bandim (1.00) 20–120 50,000–100,000
2 Areas Bairro Militar (0.59) Missira (0.69) Bandim (0.75) 20–120 50,000–100,000
Cuntum (0.41) Santa-Luzia (0.31) Pefine (0.25)
3 Areas Bairro Militar (0.42) Missira (0.46) Bandim (0.50) 20–120 50,000–100,000
Cuntum (0.29) Santa-Luzia (0.21) Pefine (0.16)
Bandim (0.29) Plaque (0.33) Antula (0.34)
For each scenario we chose the top 1, 2, and 3 areas that met the vaccination strategy criteria. The number of vaccinees in each area were weighted (shown in
parenthesis) to ensure that vaccines were allocated proportional to population size in all simulations.
doi:10.1371/journal.pntd.0001901.t003
Cholera Transmission in Bissau City, Guinea Bissau
PLOS Neglected Tropical Diseases | www.plosntds.org 4 November 2012 | Volume 6 | Issue 11 | e1901
We define the effective internal basic reproductive number (Rint) as
the expected number of cases caused within a given area by one
infected individual, within the same area, at the beginning of the
epidemic. Only areas with Rintw1 can sustain an epidemic absent
infections introduced from other areas. The strength of internal
epidemics varied with estimates of Rint ranging from 0.01 (95%
Credible Interval (CI) 0.00–0.07) in Ajuda to 1.17 (95%CI 0.99–1.33)
in Bandim (Figure 4). We found no significant correlation between
Rint and either estimated population size or population density.
Bandim is the only area where we estimate Rintw1, and it
appears to have played a necessary role in driving the epidemic.
With Bandim removed, simulated introductions of cases fail to
cause epidemics. In contrast, city-wide epidemics occur with
removal of any other single area.
In simulated epidemics based upon our best-fit model, we find
that, on average, at least 10% of cases in each area are caused by
cases in other areas (Figure 2C, Text S1). External transmission
coefficients represent epidemic connectivity between areas, and
Figure 2. Cholera transmission model overview. 10-step ahead (50 day) predictions for all of SAB (A) and Bandim (B) with 95% predictive
interval bands. The arrows in Panel C illustrate the proportion of cases estimated to be caused in each area (head of arrow) by another (tail end of
arrow). Panel D illustrates the mean effective internal reproductive number (Rint) for each area (colors), and the proportion of each areas epidemic
estimated to be caused by Bandim (arrows). Arrow size and transparency are scaled by the magnitude with a minimum of 10% shown.
doi:10.1371/journal.pntd.0001901.g002
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our estimates suggest heterogeneity in inter-area transmission
(Text S1). Based on simulations, we estimate that Bandim
contributed over 10% of the cases to over half (7/13) of the other
areas (Figure 2D), highlighting the crucial role it played in the
epidemic.
The sum of the external transmission coefficients for any area
provides an estimate of the effective external basic reproductive
number (Rext). This number is the estimated number of cases a
single infectious case in that area would cause in all other areas of
SAB given the pre-epidemic level of population immunity.
Estimates of Rext ranged from 0.37 (95% CI 0.16–0.71) in Belem
to 7.32 (95% CI 6.29–8.37) in Missira (Figure 4).
Reactive Vaccination Simulations
Vaccination in the area(s) with the highest attack rate leads to
larger reduction in cases than all other targeted and city-wide
campaigns at all starting times. Targeting vaccination at Bandim
only, the area with the highest attack rate, within the first 80 days
of the epidemic averts more cases than other strategies regardless
of vaccine quantity (Figure 5). Targeted vaccination in Bandim
Figure 3. Odds of internally caused case over time by area. Odds of a case being caused internally (i.e. as a result of other cases in that area)
vs. externally for all areas throughout the epidemic, sorted by attack rate (top to bottom). Red represents those values in support of an internally
driven epidemic and blue represents those supporting an externally driven epidemic. The observed epidemic curve is shown above in grey for
reference.
doi:10.1371/journal.pntd.0001901.g003
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starting on day 20 is expected to reduce the final size of the
epidemic by 41% (95% Predictive Interval (PI) 0.21–0.69), 56%
(95% PI 0.30–0.85), and 67% (95% PI 0.40–0.89) with 25,000,
37,500, and 50,000 vaccinees, respectively. In comparison, a city-
wide campaign starting on the same day is expected to reduce the
epidemic size by 21% (95% PI 0.07–0.34), 30% (95% PI 0.17–
0.44), and 40% (95% PI 0.27–0.55) for 25,000, 37,500, and 50,000
vaccinees (Tables 4,S1,S2).
We found wide variability in the outcomes using different targeting
strategies, with the differences diminishing as vaccination is delayed
(Figure 5). Under the population-based strategy, only a targeted
campaign in the three most populated areas averts more cases than a
city-wide campaign (Figure 5, Table 4). Targeting the areas estimated
to be most ‘‘connected’’ to others averts fewer cases than city-wide
campaigns regardless of vaccination starting time and doses.
Starting day has a profound impact on the effect of all
vaccination campaigns: the sooner vaccination begins, the more
cases are averted. With 37,500 vaccinees, each day delay in
vaccination results in an average of 39.5 (95% CI 37.7–44.2) fewer
cases averted when targeting based on attack rate. Increasing the
size of a vaccination campaign early on in the epidemic can
significantly improve case prevention, however, the marginal
benefit of additional vaccine diminishes as vaccination is delayed.
On average, each additional person vaccinated as part of a
targeted campaign in Bandim starting on day 20 averts 7.5 cases
compared to 1.7 cases averted per vaccinee in campaigns starting
two months later.
In simulations, early targeted vaccination leads to fewer cases both
within the targeted area and throughout the citywhen compared to diffuse
campaigns. When starting vaccination on day 20 (Figure 6A),
targeting Bandim averts more cases both in Bandim (1,173) and in all
the other areas combined (2,265) when compared to a city-wide
campaign (341 averted in Bandim and 1,741 in all other areas). As the
vaccination campaign is delayed, these differences shrink (Figure 6).
Figure 4. Mean Rint, Rext and 95% credible intervals. Sorted from top to bottom by Rint.
doi:10.1371/journal.pntd.0001901.g004
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Figure 5. Vaccination results by strategy and start time. Each plot shows the median (diamonds) and 95% predictive interval for the
proportion of cases averted by vaccination start time for (A) attack rate-based, (B) population-based, and (C) connectivity-based targeting strategies.
The colored lines represent the different number of areas vaccinated. Estimates made from simulations starting at the time of vaccination with 37,500
individuals vaccinated (75,000 doses). Purple lines (14 vaccination areas) are the same in each panel.
doi:10.1371/journal.pntd.0001901.g005
Table 4. Vaccination scenario results summary.
Vaccination Campaign Start Time
Distribution
Strategy
# Areas
Vacc. Day 20 Day 60 Day 80 Day 100
Cases % Cases % Cases % Cases %
Attack Rate 1 area 4228 0.56 2342 0.30 970 0.12 345 0.04
2263,6424 0.30,0.85 1195,3392 0.16,0.41 197,1732 0.03,0.21 2186,887 20.02,0.10
2 areas 3954 0.53 2266 0.29 986 0.13 379 0.05
2142,6214 0.29,0.82 1156,3258 0.16,0.40 238,1732 0.03,0.21 2146,928 20.02,0.11
3 areas 3422 0.46 2025 0.26 975 0.12 433 0.05
1903,5174 0.27,0.69 1021,2993 0.14,0.36 222,1708 0.03,0.20 271,964 20.01,0.11
Population 1 area 1804 0.24 1272 0.16 777 0.10 359 0.04
558,3250 0.08,0.41 254,2276 0.03,0.28 27,1565 0,0.19 2166,897 20.02,0.10
2 areas 1974 0.26 1405 0.18 859 0.11 396 0.05
824,3355 0.12,0.42 432,2361 0.06,0.29 102,1633 0.01,0.19 2120,936 20.02,0.11
3 areas 3019 0.40 1928 0.25 996 0.13 414 0.05
1727,4534 0.24,0.59 976,2902 0.13,0.35 269,1739 0.04,0.21 292,941 20.01,0.11
Connectivity 1 area 666 0.09 476 0.06 322 0.04 181 0.02
2363,1742 20.05,0.22 2404,1372 20.05,0.17 2436,1102 20.06,0.13 2349,716 20.04,0.08
2 areas 1258 0.17 827 0.11 566 0.07 326 0.04
154,2375 0.02,0.3 262,1741 20.01,0.21 2129,1322 20.02,0.16 2198,863 20.03,0.10
3 areas 1792 0.24 1255 0.16 828 0.10 427 0.05
603,3032 0.09,0.39 339,2243 0.05,0.27 104,1574 0.01,0.19 274,967 20.01,0.11
Diffuse/City-Wide 14 areas 2271 0.30 1521 0.20 872 0.11 421 0.05
1170,3450 0.17,0.44 658,2464 0.09,0.30 150,1623 0.02,0.19 271,947 20.01,0.11
Median count and percent of cases averted by targeting strategy (indicated by left-most column) and vaccination start day (epidemic day) for 75,000 doses (37,500
vaccinees). Values were estimated from simulations starting from the first time period where any vaccinee gained protective immunity. 95% predictive intervals (PIs) are
shown below each median value. Differences were calculated from time that the first vaccinated individuals are protected.
doi:10.1371/journal.pntd.0001901.t004
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Discussion
Using a simple spatially explicit model of cholera transmission,
we captured the essential dynamics of the 2008 cholera epidemic
in SAB, Guinea-Bissau. This model suggests that there was
significant transmission between areas in SAB and that one area,
Bandim, drove the epidemic. Our simulations show that early
distribution of vaccine is the most important determinant of the
number of cases prevented. For example, vaccinating 25,000
individuals in Bandim on epidemic day 20 would have averted
more cases (3,109, 95% PI 1,475–5,198) than vaccinating 50,000
in the same area just 40 days later (2,732, 95% PI 1,630–3,738).
Our simulations suggest that an early vaccination campaign
targeted at Bandim alone would have outperformed distributing
the same vaccine quantity throughout the city. Not only are more
cases prevented overall, but more are prevented in areas outside of
Bandim.
Our results suggest that rapid small-scale vaccination may be
more effective than a delayed larger-scale vaccination campaign.
For example, on average, each day delay results in an additional
39.5 cases when targeting 37,500 people in the areas with the
highest attack rate. Applying the average case fatality ratio from
the 2008 epidemic (1.58 per 100 cases [15]) we estimate that each
week delay in vaccination would have resulted in an average of 4.4
cholera-related deaths.
Transmission hotspots for other infectious diseases have been
exploited to devise novel prevention and control approaches
[23,24]. For example, targeted interventions in hotspots may be
Figure 6. Comparison of cumulative cases within (red) and outside (blue) Bandim under targeted and diffuse vaccination. Dashed
lines represent the median number of cases in simulations with vaccination, and the solid lines represent the median number of cases in uncontrolled
epidemic simulations (no vaccination). Each row (panels A–C) represents simulations with vaccination started at the epidemic day denoted on the
right hand side (e.g. Day 20). Simulations were started from the reported number of cases in the first 5 days of the epidemic.
doi:10.1371/journal.pntd.0001901.g006
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key to effective malaria control and elimination [24]. Similarly,
cholera hotspots can serve as targets for both reactive and
preventative interventions. Identification of hotspots during an
epidemic may be challenging. In the case of SAB, Bandim is an
area which has had high attack rates in previous epidemics and
few improvements in water and sanitation infrastructure. Such
historical information may be useful in targeting vaccination;
however, more research on combining historical and real-time
surveillance data is needed.
In our model, vaccination campaigns lasted 20 days, but in
reality the duration will vary by the number of vaccinees targeted
and the vaccine used. If Shanchol were used with the
recommended inter-dose period of 14 days, the campaign would
likely exceed 20 days. While this suggests that our results
underestimate the speed by which Shanchol vaccination would
occur, these differences would be offset by partial immunity
conferred before a second dose [22].
As the time to distribute vaccine doses increases, we expect to
avert fewer cases. However, there is some evidence that a single
dose of oral cholera vaccine may be sufficient for reactive
vaccination [22,25]. If one dose is sufficient to elicit a strong
protective response for the time-scale of an epidemic, more people
could be vaccinated quickly.
Cholera’s generation time is not well characterized and varies
widely with the concentration of bacteria in the environment, its
survival rate, and the route of transmission [26–28]. We ran analyses
with alternate generation times of 3, 7, and 10 days and got the same
qualitative results (Figures S3, S4, S5, S6, S7, S8 and Tables S3, S4,
S5). We also found that varying the vaccine efficacy to 65% and 85%
changed the number of cases averted, but preserved the relative
performance of each strategy over time (Figure S2 and Tables S7,S6).
There are a number of limitations to this work. We focus on a
single epidemic in Guinea-Bissau. A longer time series would
provide insight into variability in transmission across epidemics.
The data came from an intensified surveillance effort from both
Me`decins Sans Frontie`res and the Guinea-Bissau Ministry of
Health, however suspected cases that presented after October 28,
2008 were only captured by the national surveillance system
without details on timing and home sanitary area.
There are several possible alternative explanations for the elevated
attack rate in Bandim. The cholera case definition used is not 100%
specific, and some cholera cases may be false positives. People may be
more likely to seek care if their neighbors do, hence clinic visits may
cluster even if cholera does not. In addition, Bandim has been the
location to several surveillance programs and public health interven-
tions through the Bandim Health Project [29], perhaps leading to
increased awareness. However, if these phenomena were consistent
throughout the epidemic they would not lead to elevated estimates of
the local transmission rate under our algorithm.
We found that how rapidly vaccine can be distributed during a
cholera epidemic is the most important determinant of the
effectiveness of a reactive vaccination program; and that a single
area of SAB was an essential driver of the epidemic. Hence, early
targeting of this area would have been the most effective way to
reactively distribute vaccine. These results may apply to urban
cholera epidemics more generally. It seems reasonable that cholera
epidemics in other urban settings, particularly in Africa, may be
disproportionally driven by specific parts of the city. If these
hotspots can be identified, targeted reactive vaccination may be an
effective way to prevent cases both within that area and
throughout the city, especially when vaccine supply is limited.
Regardless of the distribution strategy used, timely distribution of
vaccine in response to an ongoing cholera epidemic can prevent
cases and save lives.
Supporting Information
Figure S1 5-day aggregated case counts for all sanitary
areas during the 2008 epidemic. Data collected from cholera
treatment center and cholera treatment units throughout the city
from June 5, 2008 to October 28, 2008.
(TIF)
Figure S2 Vaccine efficacy sensitivity analysis.Compar-
ison of proportion of epidemic averted with different 65%, 75% (as
in main analysis), and 85% vaccine efficacy over different
vaccination starting times. All scenarios shown use attack rate
based targeting.
(TIF)
Figure S3 Comparison of transmission parameters
with different generation times. Posterior means and
standard deviation for transmission coefficients, (log(b)’s on
diagonals and log(a)’s on off-diagonals) with 3, 5, and 7 day
generation times.
(TIF)
Figure S4 Comparison of internal and external effective
reproductive numbers for different generation time
aggregations.
(TIF)
Figure S5 Proportion of cases caused in each area by
others from 3, 5, 7, and 10-day generation time models.
The sum of each row is equal to one, representing 100% of the
area’s epidemic.
(TIF)
Figure S6 Vaccination simulation results with 3-day
generation time, 75% vaccine efficacy, and 75,000 doses.
(TIF)
Figure S7 Vaccination simulation results with 7-day
generation time, 75% vaccine efficacy, and 75,000 doses.
(TIF)
Figure S8 Vaccination simulation results with 10-day
generation time, 75% vaccine efficacy, and 75,000 doses.
(TIF)
Table S1 Vaccination simulation results with 50,000
doses and 75% vaccine efficacy. Proportion and number of
cases averted in 5,000 simulations under different vaccination
strategies (Median and 95% Predictive Interval).
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Table S2 Vaccination simulation results with 100,000
doses and 75% vaccine efficacy. Proportion and number of
cases averted in 5,000 simulations under different vaccination
strategies (Median and 95% Predictive Interval).
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Table S4 Vaccination simulation results from 7-day
generation time model, 75,000 doses. Proportion and
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SUMMARY
Two community-based density case-control studies were performed to assess risk factors for
cholera transmission during inter-peak periods of the ongoing epidemic in two Haitian urban
settings, Gonaives and Carrefour. The strongest associations were: close contact with cholera
patients (sharing latrines, visiting cholera patients, helping someone with diarrhoea), eating food
from street vendors and washing dishes with untreated water. Protective factors were: drinking
chlorinated water, receiving prevention messages via television, church or training sessions, and
high household socioeconomic level. These ﬁndings suggest that, in addition to contaminated
water, factors related to direct and indirect inter-human contact play an important role in cholera
transmission during inter-peak periods. In order to reduce cholera transmission in Haiti intensive
preventive measures such as hygiene promotion and awareness campaigns should be implemented
during inter-peak lulls, when prevention activities are typically scaled back.
Key words: Cholera, risk factors, endemic, epidemic, Haiti, prevention, transmission,
Vibrio cholerae.
INTRODUCTION
Since October 2010 Haiti has been experiencing a cho-
lera epidemic for the ﬁrst time in over 100 years [1]. As
of March 2013, the epidemic has resulted in more than
650000 cases and 7441 deaths [2]. Immunological
naivety of the population to the cholera agent and
the contamination of river waters explain most of
the high attack rate [3]. Several epidemic peaks have
occurred, all during the rainy seasons. The ﬁrst peak
(October–December 2010) was explosive, with very
rapid transmission throughout the country; the second
peak (May–July 2011) was lower than the ﬁrst in some
places, and higher in others. Since then, peaks have
occurred twice a year corresponding to the rainy
season. Between peaks a low but persistent number
of cholera cases are reported.
Waterborne transmission was clearly identiﬁed as
the main transmission route during the peak periods
[4–6]; however, other factors may increase in
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importance during the inter-peak periods. Here we
present ﬁndings from two studies which investigated
the risk factors associated with clinical cholera cases
that occur during the lull in transmission, factors
that therefore may contribute to the maintenance of
cholera transmission in urban settings.
METHODS
Study design and settings
The two studies were community-based density case-
control surveys, with cases and controls matched by
age and gender. The ﬁrst study was conducted in
Gonaives, a city of 230000 inhabitants [7] and capital
of the Artibonite department, from 23 March 2011 to
30 May 2011. The second study was conducted in
Carrefour (a suburb of the capital Port-au-Prince;
430000 inhabitants) [7] from 22 July 2011 to 22
August 2011 (Fig. 1). At the time of the study,
Carrefour still sheltered ∼40000 displaced people in
camps as a consequence of the January 2010 earth-
quake [8]. Data were collected from individuals as
well as from household observations.
Gonaives was chosen because it was among the
ﬁrst and most affected towns; Carrefour was chosen
to explore additional risk factors related to the post-
earthquake conditions of the survivors and because
of the high incidence reported in previous epidemic
waves.
Case and control deﬁnitions
A case was deﬁned as a person (1) living in Gonaives
or Carrefour since the beginning of the cholera out-
break in October 2010; (2) aged >5 years; (3) pre-
senting with symptoms of acute watery diarrhoea;
and (4) with a cholera diagnosis conﬁrmed by a
rapid test (Crystal VC® Rapid Dipstick test, Span
Diagnostics, India) for Vibrio cholerae O1 or O139.
In Gonaives, cases were included from the cholera
treatment centre (CTC) managed by Médecins Sans
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Fig. 1. Location of the towns of Gonaives and Carrefour and periods of participants’ interviews in relation to the
epidemic curves of the communes, where the towns are located, Haiti, 2011.
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Frontières (MSF). In Carrefour, cases were included
from two CTCs: one managed by MSF and another
by Save the Children. Participation in the study was
proposed to all eligible patients upon admission to
the CTC. Written consent was sought after patients
tested positive by Crystal VC test and before inclusion
in the study.
Two controls of the same sex and age group were
selected for each case. Age groups were 5–9, 10–14,
15–19, 20–29, 30–39, 40–49 and550 years. A control
was deﬁned as a person (1) living in Gonaives or
Carrefour since the beginning of the epidemic in
October 2010; (2) who had not experienced acute
watery diarrhoea since that time; and (3) reported
that they would have sought treatment at the CTC if
they had developed acute watery diarrhoea.
Controls were selected using spatial random
sampling [9]. Two polygons were ﬁrst drawn to
deﬁne the urban areas of Gonaives and Carrefour.
Points were then drawn randomly within the polygons
and superposed onto Google Earth® maps. Points
coinciding with a house were retained; two points
were randomly attributed to each case as locations
to ﬁnd controls. Investigators located the correspond-
ing houses using GPS devices and veriﬁed the presence
of a household member eligible for participation as a
control. If none was eligible, investigators continued
to the nearest house, and so on, until they found a
willing control.
Sample size was determined based on the hypoth-
esis that the presence of free chlorine in drinking
water stored at home would result in a 2·5-fold
decrease in the risk of transmitting cholera. This
hypothesis was tested with an alpha risk of 5%, a stat-
istical power of 80% and an estimated loss of 10%,
resulting in a sample of 90 cases and 180 controls
for each study.
Data collection and management
Trained investigators conducted face-to-face inter-
views with all cases and controls aged 516 years; for
participants aged <16 years, interviews were con-
ducted with the child’s guardian. A locally tailored
questionnaire was written in French and translated
into Creole, and then back-translated for veriﬁcation.
Patients who agreed to participate were interviewed
either on the day of admission to the CTC or the fol-
lowing day, depending on the severity of their clinical
condition. On the day of a case’s interview, investi-
gators visited his/her household to assess the hygiene
conditions of the latrine (presence of hand washing
soap at latrine; overall latrine condition) and to con-
duct chemical and biological tests of the household’s
drinking water. The interview and the household
assessment of controls were carried out on the same
day as, or the day following, the matched case
interview.
During the interview, data was collected on the
following variables of potential relevance to cholera
transmission: origin and quality of food and water,
hygiene and sanitation habits, contact with cholera-
infected patients, knowledge of transmission and pre-
vention measures, and socioeconomic status.
Evaluating quality of drinking water
The level of free chlorine in households’ drinking
water was measured with a HANNA HI 701
Checker® HC spectrophotometer (HANNA Instru-
ments®, UK). Properly chlorinated water was
deﬁned as being above a threshold of 0·2 mg/l free
chlorine [10]. The presence of Escherichia coli
was assessed using chromogenic medium Aqua-
CHROM™ (CHROMagar™, France). After adding
a ﬁxed dose of chromogenic medium to a 100 ml
water sample, the sample was incubated at room
temperature for 24 h. The sample appearance was
interpreted as follows: green or blue-green=presence
of E. coli; yellow=presence of non-E. coli coliforms;
colourless=absence of E. coli and non-E. coli coli-
forms.
Statistical methods
Data were entered using EpiData v. 3.1 (EpiData,
Denmark) and analysed using Stata v. 11 (Stata-
Corp, USA).
Matched odds ratios (ORs) were calculated using
conditional logistic regression as a measure of cholera
risk. Matched ORs, 95% conﬁdence intervals (95%
CIs) and P values were estimated with the case/control
status as outcome variable and with exposure vari-
ables as explanatory variables, and interpreted with
a bilateral test. Statistical signiﬁcance was deﬁned as
P<0·05.
A score for socioeconomic status was constructed
by determining whether or not the family owned
speciﬁc items (radio, television, refrigerator, oven,
washing machine, water storage recipient, car, ani-
mals), and by education level of the interviewee and
the head of the family (main provider of household
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income). Details on how this score was determined are
presented in the supplementary online Appendix.
Multivariate conditional logistic regression analysis
was performed as described by Hosmer & Lemeshow
[11]. Models incorporated those variables that showed
a signiﬁcance level of P<0·2 in univariate analysis, as
well as those generally considered to have public
health relevance for cholera (level of free chlorine
and presence of E. coli in home-stored drinking
water). The likelihood-ratio test was used to evaluate
the contribution of each variable to the model; rel-
evant ﬁrst-degree interactions were also analysed.
Ethics
The two studies were implemented in collaboration
with the Haitian Ministry of Public Health and
Population and they adhered to the principles govern-
ing biomedical research involving human subjects, as
deﬁned by the Declaration of Helsinki. Protocols
were validated by the Haitian Ethics Committee.
Written consent was obtained from participants or
a parent/guardian. Privacy and conﬁdentiality of
data was ensured during and after conducting the
surveys.
RESULTS
Univariate analysis
Direct and indirect contacts with cholera patients
Compared to controls, cases in Carrefour (but not
Gonaives) had more frequent exposure to direct con-
tact with cholera patients (living with, visiting or car-
ing for). Sharing latrines with someone suffering from
diarrhoea was signiﬁcantly associated with the risk of
getting cholera for both locations (Table 1).
Water and food consumption
Most households in both locations had access to
drinking water from protected water sources such as
the town water system or private vendors. No signiﬁ-
cant difference was found in terms of household
drinking-water source between cases and controls
(Table 1); however, always drinking chlorinated
water was protective in both studies (signiﬁcantly
associated in Gonaives and almost signiﬁcantly associ-
ated in Carrefour).
Eating a meal away from home at least once during
the week before illness was signiﬁcantly more frequent
on cases than controls in both studies (OR 7·6 and 2·5
in Gonaives and Carrefour, respectively) (Table 1).
This was a frequent risk factor as it was reported
by 42·2% and 47·8% of cases in Gonaives and
Carrefour, respectively. In Gonaives, the most com-
mon location of these meals were school, street ven-
dors, and parents’/friends’ houses. Investigators
collected detailed information about the types of
food consumed over the previous week, including
ﬁsh, seafood, meat, milk, vegetables and fruit, but
found no differences in consumption habits between
the two groups (data not shown).
Hygiene conditions and hygienic behaviours
A large proportion of households used a latrine in
their yard and shared it with other households (more
frequently in Carrefour). Soap and water were rarely
available at the latrine site, although this was not sig-
niﬁcantly associated with risk in either location. The
use of soap for hand washing and use of individual
dishes (rather than a communal serving dish) at
meals, was less frequent in cases than controls,
although statistical signiﬁcance was reached only in
Gonaives.
In both locations, compared to controls, cases more
frequently used non-chlorinated water for washing
dishes.
Exposure to information on cholera prevention
Radio was the most common means of receiving
information on cholera prevention, but no difference
was found between cases and controls in either
location. Controls more frequently reported exposure
to prevention information from training sessions in
Gonaives, at church in Carrefour and via television
in both locations (Table 2).
Social and economic status
In both Gonaives and Carrefour, the education levels
of the interviewee and his/her head of family were
lower in cases than in controls (same trend in both
locations, signiﬁcant only in Carrefour). Cases had
fewer household members than controls (same trend
in both locations, although signiﬁcant only in
Gonaives), and were less likely to own a television,
refrigerator and car (signiﬁcant in both locations).
Socioeconomic score was signiﬁcantly lower for
cases than for controls in both locations (Table 3).
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Multivariate analysis
In Gonaives the multivariate analysis indicated eating
meals outside the home [adjusted OR (aOR) 35·9],
owning pigs (aOR 10·3) and sharing latrines (aOR
3·5) to be the strongest andmost signiﬁcant risk factors.
The presence of E. coli in the family drinking water,
which approached the threshold of signiﬁcance in uni-
variate analysis, became signiﬁcant in the multivariate
analysis. Interactions between the presence of E. coli
and chlorine levels, between owning pigs and socioeco-
nomic level, and between participant’s age and the
presence ofE. coliwere explored, but nonewere statisti-
cally signiﬁcant. Receiving cholera prevention mess-
ages either via television (aOR 0·2) or through
training sessions (aOR 0·2) was protective (Table 4).
The multivariate analysis in Carrefour conﬁrmed as
signiﬁcant the main factors identiﬁed by univariate
odds ratios. Three signiﬁcant variables measuring
direct or indirect contact with someone suspected of
having cholera (sharing a latrine with someone suffer-
ing from diarrhoea, visiting a cholera patient, and car-
ing for someone suffering from diarrhoea or cholera)
were highly collinear and were therefore analysed sep-
arately in three models with the three variables inter-
changed. The aORs were 3·2 for sharing a latrine,
3·7 for visiting a cholera patient, and 3·8 for caring
for someone suffering from diarrhoea or cholera.
Using untreated water for washing dishes (aOR 3·2)
remained a signiﬁcant risk factor, while receiving cho-
lera prevention messages via television or in church
was protective in all three models (Table 5).
Table 1. Univariate conditional logistic regression in relation to direct and indirect contact with a cholera patient,
quality of drinking water and food consumption by study site, Haiti 2011
Gonaives Carrefour
Exposure (%)
OR 95% CI
Exposure (%)
OR 95% CIControls Cases Controls Cases
Direct and indirect contact
Cholera case in the household since
beginning of the epidemic
17·8 20·0 1·1 0·6–2·1 7·2 17·8 2·7* 1·2–5·8
Visiting someone suffering from
cholera
15·6 11·2 0·7 0·3–1·5 8·4 23·0 3·0** 1·5–6·2
Caring for someone suffering from
diarrhoea or cholera
13·3 4·4 0·3* 0·1–0·9 4·4 13·5 3·2* 1·3–8·3
Sharing latrine with someone
suffering from diarrhoea
16·9 32·5 2·1* 1·2–3·8 13·5 34·2 3·8*** 1·8–8·1
Quality of drinking water stored at home
Residual free chlorine in drinking
water >0·2 mg/l
15·6 11·5 0·7 0·3–1·5 60·7 63·2 1·1 0·6–1·9
Presence of non-E. coli coliforms 78·2 82·9 1·3 0·6–2·5 33·9 29·9 0·7 0·4–1·4
Presence of E. coli 21·2 31·7 1·8 0·9–3·2 20·2 18·2 0·8 0·4–1·7
Always chlorinate water before
drinking (self-reported)
48·9 34·4 0·5* 0·3–0·9 75·6 65·6 0·6 0·3–1·1
Ate a meal away from home at least
once in week before illness
14·4 42·2 7·6*** 3·3–17·4 28·3 47·8 2·5** 1·4–4·5
Places where meal was eaten
Restaurant 2·8 5·6 2·2 0·6–8·4 4·0 5·6 1·5 0·4–5·6
School† 4·4 14·4 15·6** 2·0–124·3 0·6 0·0 — —
Street vendor 2·8 8·9 3·2* 1·0–9·8 16·5 25·6 1·7 0·9–3·2
Market 1·7 12·2 19·1** 2·4–149·1 0·6 2·2 4·0 0·4–44·1
Parent’s/friend’s house 2·8 8·9 6·3* 1·3–30·7 4·0 7·8 2·0 0·7–5·7
Buying fresco from street vendor n.a. n.a. — — 27·4 42·7 2·0* 1·1–3·3
OR, Odds ratio; CI, conﬁdence interval; n.a., not available.
† In Gonaives the odds ratio for this variable could not be calculated due to the absence of pairing with unexposed cases.
The odds ratio presented here was calculated by randomly re-coding an exposed case as unexposed.
*P< 0·05, ** P<0·01, *** P<0·001 (two-tailed tests).
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Statistically signiﬁcant risk factors common to the
two locations were sharing latrines and low socioeco-
nomic level. Information on cholera prevention via
television was a common preventive factor.
DISCUSSION
Studies performed in the early phase of the cholera
epidemic in Haiti identiﬁed contaminated water as a
major risk factor in transmission of cholera [4–6].
Waterborne transmission was consistent with the
rapid and explosive spread of the epidemic across
Haiti and probably with the following peaks which
coincided with the rainy seasons. Our ﬁndings show
that, in addition to contaminated water, other factors
related to direct and indirect inter-human contacts
may play a major role in continued transmission
during the inter-peak periods.
Apart from the association with pig ownership,
which requires further investigation and clariﬁcation,
all other risk factors identiﬁed in our studies were
already known. Nevertheless, they provide potentially
valuable information for decision makers in Haiti.
In particular, we stress the importance of control
measures during lull periods, when prevention
efforts are typically scaled down and the population
tends to lose the perception of the risk of getting the
disease.
Table 2. Univariate conditional logistic regression for hygiene conditions and behaviours by study site, Haiti 2011
Gonaives Carrefour
Exposure (%)
OR 95% CI
Exposure (%)
OR 95% CIControls Cases Controls Cases
Type/location of toilets
Toilet inside house 4·8 7·2 Ref. 24·9 13·6 Ref.
Toilet/latrine in garden 1·2 0·0 — — 1·2 2·5 3·4 0·4, 26·8
Latrine in courtyard 86·7 79·5 0·7 0·2–2·1 67·1 71·6 1·8 0·9–3·8
Latrine belonging to neighbour 7·2 12·0 1·3 0·3–5·2 6·4 6·2 1·6 0·4–5·4
Shallow pit in yard 0·0 0·0 — — 0·6 4·9 11·9* 1·2–113·9
Other 0·0 1·2 — — 0·0 1·2 — —
Persons using the toilet/latrine
Only household members 74·1 72·8 Ref. 62·3 49·4 Ref.
Several households 25·9 25·9 1·0 0·5–1·9 36·0 45·6 1·8 1·0–3·3
Anybody 0·0 1·2 — — 1·7 5·1 5·8 1·0–33·4
Latrines were overﬂowing 21·7 30·8 1·3 0·7–2·4 4·3 8·8 1·9 0·6–6·3
Water available for hand washing at
site of latrines
5·1 4·4 0·8 0·3–2·7 8·6 2·3 0·3 0·1–1·2
Soap available for hand washing at
site of latrines
4·5 2·2 0·5 0·1–2·2 9·8 5·8 0·7 0·3–1·8
Use of soap for hand washing 83·1 68·5 0·4** 0·2–0·8 91·5 85·2 0·5 0·2–1·1
Use of individual place setting to eat 84·9 68·9 0·3** 0·1–0·6 91·3 86·7 0·6 0·3–1·4
Using untreated water to wash dishes 38·9 52·2 2·1* 1·2–3·8 19·6 35·6 3·0** 1·5–6·2
Sources of information on cholera prevention
Television 32·8 20·0 0·4** 0·2–0·8 61·7 42·2 0·4** 0·2–0·7
Radio 75·0 66·7 0·6 0·3–1·1 61·7 51·1 0·6 0·3–1·0
Door-to-door 48·9 54·4 1·4 0·7–2·5 27·8 28·9 1·1 0·6–1·9
Theatre 0·6 2·2 4·0 0·4–44·1 0·6 0·0 — —
Posters 2·8 2·2 0·8 0·2–4·1 11·7 10·0 0·8 0·3–2·1
Town crier/sound track 3·3 5·6 2·1 0·5–9·5 8·3 10·0 1·3 0·5–3·2
Training session 17·2 5·6 0·3** 0·1–0·7 20·6 16·7 0·7 0·4–1·5
School 19·4 17·8 0·9 0·4–1·9 8·3 10·0 1·3 0·5–3·2
Church 11·7 5·6 0·4 0·1–1·2 11·7 3·3 0·2* 0·1–0·8
Other sources of information 4·4 8·9 1·3 0·4–4·1 2·8 8·9 3·7* 1·1–12·3
OR, Odds ratio; CI, conﬁdence interval.
*P<0·05, ** P<0·01, *** P<0·001 (two-tailed tests).
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The quality of drinking water was far from optimal
in both locations. Self-reported chlorination of drink-
ing water was a protective factor in Gonaives, but
adequate chlorine concentration in home-stored
drinking water was not. This contradictory result
may have multiple explanations. It is possible that
the chlorination was incorrectly done, or that the pres-
ence of chlorine went undetected due to the delay
between chlorination and sample collection (the latter
information was not recorded). Alternatively, it might
reﬂect interviewees’ reluctance to admit that they had
not followed proper hygiene or clean water rec-
ommendations. In Carrefour highly chlorinated drink-
ing water was more frequent in households of cases
than controls, a ﬁnding that may reﬂect excessive
caution by family members after someone in the
household falls ill. In either case, it is clear that poor
water quality was common, as shown by the high pro-
portion of water samples found to be contaminated
with E. coli in households of both cases and controls,
and that the quality of drinking water needs to be
improved.
Direct and indirect contacts, such as helping or
visiting a person suffering from diarrhoea [12–14],
sharing latrines [15, 16] or a low socioeconomic status
[16, 17] are risk factors that have already been
described in other cholera epidemic or endemic con-
texts. In Haiti, it remains unclear whether the risk of
cholera via direct contact reﬂects a lack of means
(soap, chlorine, water), insufﬁcient knowledge of
essential hygiene measures, or both. The Haitian
Ministry of Public Health and Population, together
Table 3. Univariate conditional logistic regression for social and economic status by study site, Haiti 2011
Gonaives Carrefour
Exposure (%)
OR 95% CI
Exposure (%)
OR 95% CIControls Cases Controls Cases
Type of home dwelling
Concrete n.a. n.a. — — 80·6 63·3 Ref.
Wood or iron sheeting n.a. n.a. — — 13·9 21·1 2·3* 1·1, 5·1
Tent or plastic sheeting n.a. n.a. — — 5·6 15·6 3·4** 1·5, 8·3
Number of household members†
1–3 8·9 22·2 Ref. 15·2 21·3 Ref.
4–5 22·8 26·7 0·5 0·2–1·1 35·4 33·7 0·6 0·3–1·3
6–8 33·9 36·7 0·4* 0·2–1·0 31·5 30·3 0·6 0·3–1·4
59 34·4 14·4 0·2*** 0·1–0·4 18·0 14·6 0·5 0·2–1·3
Household owns
Goats 13·3 15·6 1·2 0·6–2·4 2·8 1·1 0·4 0·0–3·4
Pigs 3·9 16·7 5·5** 2·0–15·1 0·6 2·3 4·0 0·4–44·1
Chickens 25·0 21·1 0·8 0·5–1·5 19·6 18·0 0·9 0·5–1·8
Other animals 19·4 17·8 0·9 0·4–1·8 39·7 26·7 0·5* 0·3–0·9
Household owns at least one
Radio 77·8 70·0 0·7 0·4–1·2 73·3 60·0 0·5* 0·3–0·9
Television 71·1 46·7 0·4*** 0·2–0·7 68·3 53·3 0·5* 0·3–0·9
Refrigerator 21·7 11·1 0·4* 0·2–0·9 31·7 21·1 0·6 0·3–1·1
Oven 6·1 3·3 0·5 0·2–2·0 12·2 6·7 0·5 0·2–1·3
Washing machine 1·1 2·2 2·0 0·3–14·2 1·7 0·0 — —
Water storage tank 7·8 3·3 0·4 0·1–1·5 3·3 2·3 0·7 0·1–3·3
Car 14·4 3·3 0·2* 0·1–0·7 13·3 3·4 0·2* 0·1–0·8
Socioeconomic score‡ (mean) 1·45 1·13 0·5** 0·3–0·8 1·82 1·32 0·4*** 0·3–0·6
OR, Odds ratio; CI, conﬁdence interval; n.a., not available.
†Odds ratios for trend: Gonaives (0·83, 95% CI 0·75–0·92), Carrefour (0·94, 95% CI 0·85–1·04).
‡ Socioeconomic score includes educational level of the interviewee and of the head of the family as well as ownership of
radio, television, refrigerator, oven, washing machine, water storage tank, car and animals).
*P<0·05, ** P<0·01, *** P<0·001 (two-tailed tests).
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with other interested parties, distributed cleaning kits
to caregivers of patients admitted to CTCs to limit
transmission within patients’ homes; although well-
intentioned, this effort may have little impact since
most intra-household transmission would have
already occurred by the time of the distribution.
In our studies the investigation of household
latrines did not go beyond whether the latrine was
overﬂowing and whether soap and water were present,
so it remains unclear whether the observed elevated
risk was directly linked with contaminated latrines
or, again, with insufﬁcient knowledge of essential
hygiene measures. Nevertheless, as most households
lacked soap for hand washing, prevention efforts
should focus on making soap and chlorine available.
Considering that sharing a latrine with neighbours is
common in Haiti, outreach campaigns should speciﬁ-
cally address this issue by reinforcing the importance
Table 4. Multivariate analysis of risk factors associated with cholera illness in Gonaives, Haiti 2011
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Ate a meal away from home at least once in week
before illness
7·6*** 3·3–17·4 <0·001 35·9*** 7·9–163·4 <0·001
Household owns pigs 5·5** 2·0–15·1 0·001 10·3** 2·3–46·6 0·002
Sharing latrine with someone suffering from diarrhoea 2·1* 1·2–3·8 0·013 3·5* 1·3–9·5 0·016
Presence of E. coli in drinking water stored at home 1·8 0·9–3·2 0·074 3·5* 1·2–10·0 0·021
Chlorine level >0·2 mg/l in drinking water stored at home 0·7 0·3–1·5 0·376 0·5 0·2–1·9 0·341
Always chlorinate water before drinking 0·5* 0·3–0·9 0·019 0·3 0·1–1·0 0·060
Receiving information on cholera prevention via television 0·4* 0·2–0·8 0·015 0·2* 0·1–0·8 0·021
Receiving information on cholera prevention in training
session
0·3** 0·1–0·7 0·009 0·2* 0·0–0·9 0·035
Number of member in household (ref. 1–3 members)
4–5 0·5 0·2–1·1 0·099 0·5 0·2–1·7 0·291
6–8 0·4 0·2–1·0 0·044 0·7 0·2–2·6 0·595
59 0·2*** 0·1–0·4 <0·001 0·1** 0·0–0·5 0·004
Socioeconomic score 0·5** 0·3–0·8 0·001 0·5* 0·3–1·0 0·036
OR, Odds ratio; CI, conﬁdence interval.
*P<0·05, ** P<0·01, *** P<0·001 (two-tailed tests)
Table 5. Multivariate analysis of risk factors associated with cholera illness in Carrefour, Haiti 2011
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Sharing latrine with someone suffering from diarrhoea† 3·8*** 1·8–8·1 <0·001 3·2* 1·3–7·7 0·011
Using untreated water for washing dishes 3·0** 1·5–6·2 0·002 3·2** 1·4–7·3 0·006
Ate a meal away from home at least once in week before illness 2·5** 1·4–4·5 0·001 1·8 0·9–3·7 0·117
Presence of E. coli in drinking water stored at home 0·8 0·4–1·7 0·582 1·5 0·5–4·3 0·489
Chlorine level >0·2 mg/l in drinking water stored at home 1·1 0·6–1·9 0·845 1·0 0·5–2·4 0·920
Receiving information on cholera prevention via television 0·4** 0·2–0·7 0·002 0·4** 0·2–0·9 0·027
Receiving information on cholera prevention at church 0·2* 0·1–0·8 0·027 0·1** 0·0–0·5 0·003
Socioeconomic score 0·4*** 0·3–0·6 <0·001 0·5** 0·3–0·8 0·002
OR, Odds ratio; CI, conﬁdence interval.
†Two other variables measuring contacts with suspected cholera cases (visiting someone suffering from cholera and caring for
someone suffering from diarrhoea or cholera) were collinear with sharing the latrines with someone suffering from diarrhoea.
We built separate models replacing sharing the latrines with these two variables; the odds ratios were 3·7 (95% CI 1·2–11·9) for
visiting someone suffering from cholera and 3·8 (95% CI 1·5–9·5) for caring someone suffering from diarrhoea or cholera.
*P<0·05; ** P<0·01; *** P<0·001 (two-tailed tests).
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of cleaning latrines after use and of providing decon-
tamination of shared latrines.
Selling food and beverages in the streets and
markets, a common activity in developing countries
has also been identiﬁed as a key factor in cholera
transmission in other contexts [18–21]. In Gonaives
this factor was notable for both the strength of the
association and the high proportion of associated
cases suggesting that food consumed in the market
or at school was highly implicated in cholera trans-
mission. Since these studies were conducted, street
vendors in several Haitian cities (Dessalines, Gros
Morne) have been given information about cholera
transmission, along with supplies of chlorine, soap
and hand washing buckets, which were well-received
by both vendors and customers. These and other pre-
ventive measures should be strongly encouraged until
more permanent hygiene and sanitation measures are
in place.
In Carrefour, conditions speciﬁc to post-earthquake
victims, such as living in a tent or a dwelling made of
plastic sheeting, were associated with increased risk.
Early in the epidemic, displaced populations had rela-
tively sufﬁcient access to clean water and improved
sanitation. However, since then, some displaced
people have been relocated and aid agencies have
reduced their services inside the camps. Two surveys
by the Dinepa (National Water Board) Observatory
[22, 23] showed that already by the end of 2011
there had been an alarming decrease in access to
safe drinking water, and that there was poor mainten-
ance of latrines and hand-washing facilities in the sur-
veyed camps.
The association with owning pigs was highly
unexpected. Although V. cholerae has been detected
in stool samples of animals, including pigs [24], to
our knowledge this is the ﬁrst time that owning
animals has been associated with risk of contracting
cholera. Pig ownership may be a proxy indicator
for a risk factor we did not investigate and merits
further investigation. It may be worth including this
potential risk factor in further studies on cholera
transmission.
Both studies show that insufﬁcient practice of
essential hygiene measures is an important issue to
tackle in Haiti, but also that targeted information
campaigns can help reduce cholera incidence. Visual
messages on television, the persuasive appeal of a
church leader, and the personal motivation required
to attend a training session, may enhance the
likelihood that people will implement the suggested
hygiene measures. Prevention information through
various means was widespread in Haiti during
acute transmission phases, but gradually decreased as
the peak subsided. Prevention campaigns can effec-
tively make an impact to reduce cholera incidence
and should remain active during low transmission
periods.
These studies involve some limitations. One is
the low speciﬁcity of the Crystal VC test [25], leading
to inadvertent inclusion of some non-cholera
patients among cases. Another is that the selection
of controls was based on self-reports of no prior his-
tory of cholera. The two misclassiﬁcations above,
however, would only have weakened the results, i.e.
hidden weak associations such as using soap, a protec-
tive factor demonstrated by other studies [26, 27]. In
addition, we cannot exclude that some controls had
an asymptomatic form of cholera, which occurs fre-
quently [28, 29] and is potentially transmissible [30].
However, the risk factors we evaluated apply only to
symptomatic cholera.
We have presented evidence that in addition to
contaminated water, human-to-human and mediated
transmission through food handling or sharing
latrines, may play a substantial role in the mainten-
ance of V. cholerae during the lull between periods
of peak caseloads in Haiti. Reinforcing efforts to
raise public awareness of risk reduction measures
and to improve hygiene, clean food and safe water
practices are effective interventions for cholera control
that should be implemented also during lull periods.
Such interventions are, however, difﬁcult to
implement and maintain especially when the percep-
tion of the risk of getting the disease decreases.
Speciﬁc plans for low transmission periods should be
also foreseen as a promising approach to reducing
or eliminating circulating V. cholerae, thereby averting
the occurrence of future outbreaks in Haiti.
SUPPLEMENTARY MATERIAL
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Background
The number of reported cholera cases
worldwide, as well as the frequency and
scale of cholera epidemics, are increasing
[1]. Traditional prevention measures,
which focus on provision of safe water
and proper sanitation, are undoubtedly the
long-term solution for cholera control. But
for populations in many low-income coun-
tries these measures remain out of reach: in
Africa, 40% of families cannot access safe
water and 60% have no access to appro-
priate sanitation [2]. Furthermore, once a
cholera outbreak has started, these solu-
tions are unlikely to be implemented fast
enough or on a large enough scale to help
control the spread. Nationwide epidemics,
such as the recent one in Haiti—with over
600,000 cases and 7,000 deaths reported
within the first 2 years [3]—highlight the
urgent need for new tools and strategies.
Two oral cholera vaccines (OCVs) are
currently licensed and prequalified by
WHO: Dukoral (Crucell, Leiden, Nether-
lands), and Shanchol (ShanthaBiotechnics
Ltd., Basheerbagh, Hyderabad, India).
Both are given as a two-dose regimen
and were shown to be safe and to provide
sustained protection over several years [4];
Shanchol showed 66% efficacy over 3
years [5]. WHO recently updated its
guidelines on cholera outbreak response
to recommend considering OCV use in
epidemic situations (as well as in endemic
settings) [4].
However, ongoing questions and debate
about the feasibility, cost, timeliness, and
acceptability of reactive OCV campaigns
have discouraged their use [6,7]. Argu-
ments against using OCV during epidem-
ics have included: limited availability of
vaccine; logistical challenges of rapidly
transporting and delivering high volumes
of cold-chain–requiring vaccines in resource-
limited settings; difficulty achieving sufficient
coverage with a two-dose regimen; accep-
tance of vaccination by the population; high
vaccine cost; and fear of diverting limited
resources from other control measures [6,7].
Practical experience with OCV during
epidemics has therefore remained limited to
small-scale interventions in Asia [8–11].
Here we describe the implementation of
the first large-scale reactive OCV cam-
paign, conducted in Guinea between April
and June 2012, and the first use of OCV
Shanchol in Africa.
Cholera Context in Guinea
Guinea, a country on the West African
coast, regularly experiences cholera epi-
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Summary Points
N Oral cholera vaccines are safe and effective, and in 2010 were added to WHO
recommendations for cholera outbreak control. However, doubts about
feasibility, timeliness, and acceptability by the population, and the fear of
diverting resources from other preventive interventions, have discouraged their
use during epidemics.
N We report on the first large-scale use of oral cholera vaccine as an outbreak
control measure in Africa; this was also the first time Shanchol vaccine was used
in Africa.
N We administered 312,650 doses of vaccine during two vaccination rounds in
two coastal districts in Guinea. The feasibility, timeliness of implementation, and
delivery cost were similar to those of other mass vaccination campaigns.
N The campaign was well accepted by the population, and high vaccination
coverage was achieved despite the short time available for preparation, the
two-dose schedule, the remote rural setting, and the highly mobile population.
N Oral cholera vaccines are a promising new tool in the arsenal of cholera control
measures, alongside efforts to improve provision of safe water and sanitation
and access to cholera treatment.
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demics, with peaks occurring during the
rainy season in July–August. The last
major epidemic was in 2007, with 8,289
cases and 295 deaths [12]. However, in
2012 the first cholera cases were reported
in February, long before the rainy season.
As in previous epidemics, cases were first
reported from the islands north and south
of the capital, Conakry, in the Boffa and
Forecariah districts. These islands are
characterized by intense fishing activities
and trade, a highly mobile population,
limited access to health care, and poor
access to safe water or basic sanitation.
The early start of the outbreak, together
with a long inter-epidemic period and an
ongoing cholera epidemic in neighboring
Sierra Leone [13], suggested that a major
epidemic was imminent. Considering
these factors, the Ministry of Health of
Guinea, with support of Me´decins sans
Frontie`res (MSF) decided in April 2012 to
use OCV alongside already-implemented
treatment and prevention strategies (health
education; distribution of soap and chlo-
rine for household water treatment).
Implementation of the
Vaccination Campaign
Target population. The campaign
focused on the coastal and island popu-
lations of the above-mentioned districts,
which extend over about half the length of
the Guinean coast: first, a population of
163,000 people in Boffa district, and
46,000 people in parts of Forecariah
district (Kaback and Kakossa islands, and
some neighboring ports on the mainland).
Everyone older than 12 months presenting
at vaccination sites was eligible to receive
the vaccine during both vaccination rounds,
which were spaced 2–3 weeks apart.
Vaccine procurement, storage, and
transport. The bulk of the vaccine
supply (320,000 doses) was shipped direc-
tly from the manufacturer in India, and
50,000 additional doses from MSF stock in
Kampala, Uganda. The volume of the
transport containers of vaccine was 29 m3.
Vaccines were transported from Conakry’s
airport to the district capital in refrigerated
trucks and stored in the field in refrigerated
trucks or containers. Vaccines reached the
field within 2 weeks of the order date.
Vaccine was supplied in individual vials,
either in secondary packing of 35 vials or
in individual secondary packing inside
tertiary packing of 10 vials. One vaccine
vial in the 35-vial package had a volume of
13.5 cm3, about five times greater than a
dose of measles vaccine.
Vaccination teams. Forty-three teams
composed of community members (commu-
nity health workers, Guinean Red Cross
volunteers, etc.) were assembled. Each team
had a medical or paramedical leader and
four to eight members, plus up to 12 helpers.
Training for team leaders and members
included a practice vaccination session.
Choosing vaccination sites. Preli-
minary selection was done together with
district medical authorities, then refined in
consultation with community leaders. An
important criterion was to keep travel
distances short so that all family members,
including elderly people and mothers with
small children, could reach the sites easily.
Altogether there were 287 sites, one per
village or settlement (Figure 1).
Mobilizing the population. Due to
the emergency nature of the intervention,
the time period for social mobilization was
short. The information was transmitted
orally as described below; modern media
were not used, as local radio or television
are not available in the area and the mobile
network coverage is low. Public awareness
messaging included detailed information
about the rationale of the campaign, the
vaccine and the importance of two-dose
schedule, along with standard cholera control
messages regarding the necessity and availa-
bility of treatment and prevention measures.
Existing material was used to illustrate the
standard cholera control messages, but no
special material was designed for the vaccina-
tion due to the limited amount of time availa-
ble. Medical, administrative, and traditional
authorities were informed in advance. Each
community was visited 2 days before vaccina-
tion day by a health promoter, who provided
educational and awareness information via
village leaders. In more populated areas, local
outreach workers conducted door-to-door
mobilization.
Vaccination day. Each team had a
car (two in Boffa) or boat to reach the
vaccination sites. Vaccines were trans-
ported and used at ambient temperature
on vaccination day. Vaccines leftover at
the end of vaccination day were returned
to the cold chain and used first on the
following day. Before administration, the
vaccine vial monitor (VVM) was checked
for stability; the vial was shaken, opened,
and administered or self-administered under
observation (Figure 2). All VVM remained
valid during the campaign.
To facilitate ingestion of the vaccine, we
provided safe drinking water to each
vaccinee (pre-packed 33 cl sachets from a
Guinean manufacturer). Each vaccinee
also received a vaccination card during
the first round and was asked to bring the
card for the second dose. However, during
the second round we provided the vaccine
to those who had lost their card or were
not previously vaccinated.
In Forecariah, the second vaccination
round was accompanied by distribution of
preventive items (soap and chlorine solu-
tion for household water treatment),
targeting women of childbearing age.
Teams vaccinated an average of 703
persons daily, up to 1,830 vaccinations/
day/team. They spent several days in the
larger villages but covered several smaller
sites in one day. The vaccine wastage rate
was below 1%. A total of 46 non-severe
Figure 1. Vaccination team at work. Image credit: David Di Lorenzo.
doi:10.1371/journal.pmed.1001512.g001
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adverse effects were reported (mainly
diarrhea and vomiting).
Vaccination Coverage
Altogether 172,544 doses of vaccine
were administered during the first round
and 143,706 during the second. Based on
administrative population figures, cover-
age with at least one dose (either first or
second dose) was 92% in Boffa and 71% in
Forecariah, and with the complete two-
dose regimen was 68% in Boffa and 51%
in Forecariah. However, a household
survey conducted immediately after the
campaign (Francisco Luquero, personal
communication) found two-dose coverage
in both areas to be about 76%, and one-
dose coverage .90%. These differences
are likely to be due to overestimation of
actual population size by official figures.
Time and costs. The complete
campaign took 6 weeks from the decision
to proceed until completion of the second
round in Boffa (3-week interval between
doses) and 5 weeks in Forecariah (2-week
interval).
Cost per dose of vaccine delivered was
US$2.89, including $1.85 for the vaccine
itself and just over $1 for direct delivery
costs (especially transport of teams and
material, and payment for teams and
other staff). Table 1 lists all costs that were
factored into this calculation.
Evolution of the epidemic. We
were able to complete the vaccinations in
two affected areas before the start of the
seasonal cholera peak (Figure 3). The
campaign’s final outcomes will not be
known until ongoing vaccine effectiveness
and impact studies are completed; how-
ever, while the number of cholera cases
peaked in other parts of Guinea during the
rainy season, it remained at low levels in
vaccinated districts (Ministry of Health,
Cholera situation update, December 2012).
Lessons for the Future
This experience demonstrated that mass
campaigns with a two-dose OCV can be
conducted successfully at the beginning of
a cholera epidemic, even in a large,
difficult-to-access area in Africa with a
highly mobile population, and with little
time for preparation of the campaign and
social mobilization. Potential obstacles that
discouraged earlier campaigns either failed
to materialize or were quite manageable; in
particular, the population was eager to get
vaccinated during the outbreak, and logis-
tical issues were resolved.
Ironically, in many ways our campaign
was ‘‘over-resourced,’’ due to the antici-
pated obstacles. Vaccination teams in
Boffa were over-sized (half-sized teams in
Forecariah vaccinated the same number of
people per day), which increased trans-
portation needs. Transportation of water
sachets was logistically challenging; al-
though use of water is not necessary
according to the manufacturer, we pro-
vided it to facilitate the intake of the salty-
tasting vaccine. Vaccination cards were
used only to verify vaccination status
during the coverage survey. A simplified
strategy without use of water and vacci-
nation cards would reduce personnel and
transport needs, and related costs.
Another potential simplification relates
to vaccine vial presentation and packag-
ing. The single-dose vaccines are volumi-
nous, due partly to bulky secondary
packaging. Additionally, the vaccine vial
design is not ideal for oral use: single-dose
vials are tiny, with metallic caps that are
difficult to open.
There may also be potential to reduce
cold chain needs. Although the vaccine is
equipped with VVM 14 and considered
temperature-stable, current labeling re-
quires the vaccine to be stored in the cold
chain. Documentation of thermostability
is needed for future campaigns to be
conducted using vaccines at ambient
temperature.
Figure 2. Administration of the vaccine. Image credit: David Di Lorenzo.
doi:10.1371/journal.pmed.1001512.g002
Table 1. Direct costs of mass vaccination campaign.
Item Total (US$) % Total
Vaccine ($1.85/dose) 585,063 64.0%
Water sachets ($0.036/sachet) 11,385 1.2%
Airfreight for vaccines 47,719 5.2%
Transit cost for vaccines 9,574 1.0%
Cold chain (truck rental, reparation of container in Boffa) 26,505 2.9%
Vaccination, supervision and sensitisation teams payments 63,308 6.9%
Training for the teams 4,899 0.5%
Small vaccination material and stationary, vaccination cards 13,705 1.5%
Logistic material, site preparation, waste management 13,333 1.5%
Transport cost (cars, trucks, boats and fuel) 139,851 15.3%
Total 915,341 100.0%
Cost per dose delivered 2.89
Fixed administrative costs, MSF institutional costs, and costs linked to operational research are excluded.
doi:10.1371/journal.pmed.1001512.t001
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A single-dose vaccine would also greatly
simplify OCV campaigns. Studies in India
found that partial immune response is
achieved after a single dose [14], but
whether this response is sufficient to confer
clinical protection is not yet known.
Similarly, a herd protection effect of
Dukoral has been reported [15,16], but
its extent needs to be confirmed for
Shanchol in additional settings.
Perhaps the most serious obstacles to
wider use of reactive OCV campaigns are
cost and limited supply of Shanchol. These
constraints led us to drastically limit our
target population to a small subset of those
at risk; the full at-risk population includes
everyone living along the coast of Guinea,
including the capital (Conakry) with two
million inhabitants, areas that were highly
affected once the epidemic began. Fund-
ing for an OCV stockpile will be critical
for the timely implementation of larger
campaigns, an issue currently being ad-
dressed by WHO and its partners in an
effort to improve OCV access for coun-
tries facing cholera outbreaks [17].
Conclusion
Our experience demonstrates the feasi-
bility of implementing OCV mass cam-
paigns at the onset of major epidemics,
similar to the campaigns with other
vaccines used reactively (e.g., measles).
OCVs are a promising additional tool for
controlling cholera epidemics and should
help prevent many illnesses and deaths,
especially in settings with limited access to
health care and where immediate im-
provements in sanitary conditions are
improbable. In the near future, experience
implementing OCV campaigns should be
carefully documented, to provide future
guidance for its most effective use.
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Abstract
Background: Despite World Health Organization (WHO) prequalification of two safe and effective oral cholera vaccines
(OCV), concerns about the acceptability, potential diversion of resources, cost and feasibility of implementing timely
campaigns has discouraged their use. In 2012, the Ministry of Health of Guinea, with the support of Me´decins Sans
Frontie`res organized the first mass vaccination campaign using a two-dose OCV (Shanchol) as an additional control measure
to respond to the on-going nationwide epidemic. Overall, 316,250 vaccines were delivered. Here, we present the results of
vaccination coverage, acceptability and surveillance of adverse events.
Methodology/Principal Findings: We performed a cross-sectional cluster survey and implemented adverse event
surveillance. The study population included individuals older than 12 months, eligible for vaccination, and residing in the
areas targeted for vaccination (Fore´cariah and Boffa, Guinea). Data sources were household interviews with verification by
vaccination card and notifications of adverse events from surveillance at vaccination posts and health centres. In total 5,248
people were included in the survey, 3,993 in Boffa and 1,255 in Fore´cariah. Overall, 89.4% [95%CI:86.4–91.8%] and 87.7%
[95%CI:84.2–90.6%] were vaccinated during the first round and 79.8% [95%CI:75.6–83.4%] and 82.9% [95%CI:76.6–87.7%]
during the second round in Boffa and Fore´cariah respectively. The two dose vaccine coverage (including card and oral
reporting) was 75.8% [95%CI: 71.2–75.9%] in Boffa and 75.9% [95%CI: 69.8–80.9%] in Fore´cariah respectively. Vaccination
coverage was higher in children. The main reason for non-vaccination was absence. No severe adverse events were notified.
Conclusions/Significance: The well-accepted mass vaccination campaign reached high coverage in a remote area with a
mobile population. Although OCV should not be foreseen as the long-term solution for global cholera control, they should
be integrated as an additional tool into the response.
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Introduction
Provision of safe water and proper sanitation are without doubt
the long-term and only solution for cholera control [1,2].
However, controlling cholera globally is far from being achieved;
the disease burden is increasing with large-scale outbreaks
reported in the past several years, such as those in Haiti and
Zimbabwe [3]. Current outbreak response interventions focus on
case management and access to health care, as well as the
immediate provision of safe water and hygiene promotion [1].
However, current outbreak control activities have proven insuf-
ficient to avoid massive numbers of cases and deaths in recent
large-scale outbreaks. The adequate treatment of cases for
example, although crucial to decrease mortality, has a limited
impact in controlling disease spread [1,3]. Oral cholera vaccines
(OCV), which have the potential to reduce the number of cases
and minimize the spread of disease [4,5], could be an important
addition to the cholera response arsenal [1,6,7].
The World Health Organization (WHO) prequalifies the OCV
Dukoral (SBL Vaccine/Crucell, Sweden) and Shanchol (Shanta-
Biotechnics, Hyderabad, India). Both are killed whole cell V.
cholerae O1 vaccines; Shanchol also contains V. cholerae O139 and
Dukoral the recombinant cholera toxin B subunit. The two
vaccines share a good safety and efficacy profile with an estimated
protection of 60–85% for 2–3 years [1]. Although, recommended
by WHO (including in response to outbreaks since 2010) [8], their
use as public health tools has been limited. Specifically, questions
about the acceptability, feasibility, cost and potential diversion of
resources have discouraged the use of OCV for outbreak control
[9].
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In 2012, the Ministry of Health (MoH) of Guinea, with the
support of Me´decins Sans Frontie`res-Operational Centre Geneva
(MSF) organized the first cholera outbreak response in Africa
using an OCV in the Republic of Guinea (Guinea). This was also
the first time that Shanchol was used in a mass vaccination
campaign on the African continent. Cholera has been reported in
Guinea since 1970. The largest outbreak was in 1994 with more
than 30,000 cases and 670 deaths reported. The most affected
areas were the coastal prefectures and the islands (Maritime
Guinea, where the capital Conakry is located) [10]. From 2003 to
2007, cholera outbreaks were reported each year during the rainy
season (July–August) throughout the country with Maritime
Guinea remaining the most affected area. From 2008 to 2011,
only sporadic cases were reported [11].
In 2012, the first cholera cases were reported in Fore´cariah
(Maritime Guinea) before the rainy season. From February 2 to
March 8, a total of 147 cases and 13 deaths were reported. On
March 3, the first case was reported and confirmed in Conakry. A
cholera outbreak was also on going in neighbouring Sierra Leone,
with 13,934 cases and 232 deaths reported countrywide between
January and August 2012 [12]. The regional nature of the
epidemic, the early notification of cases before the peak of the
rainy season and the long interval without outbreaks, thereby
increasing the number of susceptible individuals due to lack of
prior exposure, all suggested the possibility of a large epidemic in
Guinea in 2012.
Case management, water, health education, hygiene and
sanitation interventions were implemented in response to the
outbreak. Non-selective mass vaccination campaigns were imple-
mented in the prefectures of Boffa and Fore´cariah (Figure 1). Two
doses of Shanchol, two weeks apart were offered from April 18 to
May 14, 2012 in Boffa and from May 27 to June 15, 2012 in
Fore´cariah (Figure 2). Overall, 316,250 vaccines were delivered by
43 teams (of 9 members in Boffa and 5 in Fore´cariah) in 287
vaccination sites (one per village or settlement). All individuals
Author Summary
Two safe and effective oral cholera vaccines are recom-
mended by the World Health Organization for cholera
prevention and control; however, concerns about the
acceptability, potential diversion of resources, cost and
feasibility of implementing timely campaigns has discour-
aged their use. In 2012, the Ministry of Health of Guinea,
with the support of Me´decins Sans Frontie`res, organized
the first mass vaccination campaign using a two-dose oral
cholera vaccine (Shanchol) as an additional control
measure to respond to an on-going nationwide epidemic.
This was also the first time that Shanchol was used in a
mass vaccination campaign on the African continent. High
coverage was reached within a few weeks, and the
campaigns were well accepted by the population. Syner-
gies between different axes in cholera control interven-
tions should be pursued as described here, and although
oral cholera vaccines should not be foreseen as the long-
term solution for global cholera control, they should be
integrated as an additional tool into the outbreak response
strategies.
Figure 1. Target areas by the non-selective mass vaccination campaigns, Guinea, 2012.
doi:10.1371/journal.pntd.0002465.g001
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older than 12 months were eligible for vaccination in both rounds.
Pregnant women were offered vaccine after a careful examination
of the risk and benefits (an on-going outbreak in a remote rural
place with limited access to health care and high cholera
associated mortality in the past) following the manufacture and
WHO recommendations [8]. Vaccines were stored under cold
chain, but were transported and used at ambient temperature on
vaccination days. Before administration, vaccine vial temperature
monitor was checked for stability and all remained valid.
Here, we present the results of household-based vaccination
coverage and acceptability surveys and surveillance of adverse
events.
Methods
Cross-Sectional Survey
All individuals older than 12 months, resident in the six sub-
prefectures bordering the sea in Boffa prefecture (Koba, Boffa-
centre, Douprou, Tougnifily, and part of Mankountan and
Tamita) and in the sub-prefectures of Kaback and Kakossa in
Fore´cariah prefecture were targeted for vaccination and were
eligible for inclusion in the survey (Figure 1).The coastal area of
Boffa combines both inland areas and several islands. Kaback and
Kakossa are two separate islands. Residents were defined as
persons living (sleeping and eating) in the area for at least the
previous two weeks. The adult population is mobile with men in
particular, leaving and returning to the area for fishing, agriculture
and trade.
A representative sample of the population in each survey site
(Boffa and Fore´cariah) was selected using cluster-based sampling
with population proportional to size [13]. To sample households
within the selected sectors, all households were enumerated. The
first household was selected with the aid of a random number table
and subsequent households were selected by proximity (first
household to the left). In the urban area of Boffa and in Kaback
Island in Fore´cariah, satellite-map based sampling was used to
select randomly the starting point of the cluster [14]. This
methodology was used in urban Boffa because of the large number
of households to enumerate and in Kaback Island because of the
absence of accurate population data per sector.
The sample size was calculated to obtain a representative
estimate of the proportion of residents who received two doses of
OCV by age group (1–4, 5–14, 15 years and older). Sample size
was calculated to ensure a sufficiently precise estimate for children
aged 1 to 4 years as this group was the smallest. We considered the
following assumptions: 70% of children would receive two doses of
vaccine, alpha error of 5%, absolute precision of 7% for Boffa and
10% for Fore´cariah, design effect (deff) of 3.0 for Boffa and 1.5 for
Fore´cariah (coverage was expected to be more homogenous in the
islands). Taking into account the results of the 2005 Demographic
and Health Survey [15], we expected 0.7 children 1–4 year old per
household (average of 6.1 individuals per household and 12% of
the population between 1 and 4 years). Assuming 10% of missing
data, we planned to visit 780 households (60 clusters of 13
households) in Boffa and 180 households (30 clusters of 6
households) in Fore´cariah. A household was defined as a group
of people sleeping under the same roof and sharing meals every
day for at least the previous two weeks.
Training and Data Collection
All surveyors and supervisors were recruited locally and
received a theoretical and practical training. Training consisted
of survey and interview methodology and a pilot implementation
of the questionnaire.
Teams conducted face-to-face interviews after consent. Survey
teams asked for the help of neighbours to trace absentees and re-
visit empty (but not abandoned) households later in the day. If
during the second visit the occupants could not be found or if they
refused to participate, that household was skipped.
A standardized pre-piloted questionnaire was used to collect the
following information: demographic data (age, sex, and household
size), vaccination status (card-confirmed and orally reported),
reasons for non-vaccination (open question), and acceptability data
(adverse events, taste and beliefs about the vaccine). Questions
concerning acceptability were only collected in Boffa (first site of
vaccination) in participants older than 15 years. Interviews were
conducted in the local language.
Surveillance of Adverse Events following Immunization
Surveillance of adverse events following immunization (AEFI)
was implemented at vaccination sites, health centres and health
posts in the target areas. An AEFI was defined as a medical
occurrence detected by the vaccination site supervisor or a
physician with an onset up to 14 days after receipt of a dose of
vaccine. During the awareness campaign and at the time of
vaccination, participants were told to report to a vaccination site
or a health centre if they felt ill after receiving the vaccine. The
following data were collected using a standardized form: age, sex,
Figure 2. Timeline of the cholera vaccination campaigns and implementation of the field surveys in Guinea in 2012. Months are
abbreviated as follows: F = February, A =April, M=May, J = June.
doi:10.1371/journal.pntd.0002465.g002
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pregnancy, history of allergies, vaccination date, consultation date,
date of onset of the symptoms, type of symptoms, and clinical
outcome (recovery, transfer or death).
Data Entry and Analysis
Our main outcome was the OCV coverage (single dose and full
course) in each of the target locations. Vaccine coverage was
calculated dividing the number of individuals reporting being
vaccinated by the survey population and expressed as a
percentage. Vaccination coverage estimates include both card-
confirmed and oral reporting. Secondary outcomes included
vaccine coverage by age group, sex and reasons for non-
vaccination. Crude vaccination coverage estimates and 95%
confidence intervals (95% CI) were obtained considering the
survey design. The design effect was calculated to estimate the loss
of precision due to the cluster based sampling strategy. Sampling
weights were calculated to account for differences in the cluster
size.
Data entry was performed using EpiData 3.1 (EpiData
Association, Denmark) and data analysis was performed using
Stata 12.0 (College Station, USA).
Ethical Considerations
The Ethical Review Board of Guinea and the MSF Ethical
Review Board approved the study protocol. Oral informed
consent was obtained from participants in all instances. All
children had consent given from a parent/guardian and all adult
participants provided their own consent. Oral informed consent
was requested since the study did not present any risk of harm to
subjects and did not involve procedures for which written consent
is normally required outside the research context. The procedure
was approved by the ethical review boards. The request of consent
was registered in a log-book. Privacy and confidentiality of the
data collected from participants was ensured both during and after
the conduct of the surveys. All treatment was provided free of
charge and participation was voluntary.
Results
The surveys were carried out May 20 to 25, 2012 in Boffa and
June 16 to 20, 2012 in Fore´cariah (Figure 2). In total, 851
households were visited in Boffa. Of these, 775 (91.1%) were
included in the survey, 45 households (5.3%) remained empty after
two visits, 3 households (0.4%) refused to participate and 23 (2.7%)
were not residents of Boffa. All 180 visited households were
included in Fore´cariah. Overall, 3,993 individuals were included
in Boffa and 1,255 in Fore´cariah (Figure 3). The median age of
participants was 15 years (inter-quartile-range (IQR): 5–30). There
were fewer males than females in the survey sample (47.6% and
44.1% males in Boffa and Fore´cariah respectively).
Oral Cholera Vaccine Coverage
Vaccination card retention was higher for children (81.7%) than
adults (74.8%), and higher for females (82.4%) than males (73.2%).
Overall, 89.4% [95%CI: 86.4–91.8%] and 87.7% [95%CI:
84.2–90.6%] were vaccinated during the first round and 79.8%
[95%CI: 75.6–83.4%] and 82.9% [95%CI: 76.6–87.7%] during
the second round in Boffa and Fore´cariah respectively. The two
dose (fully vaccinated) vaccine coverage (including card and oral
reporting) was 75.8% [95%CI: 71.2–79.9%, deff = 10.1] in Boffa
and 75.9% [95%CI: 69.8–80.9%, deff = 5.0] in Fore´cariah.
Considering incomplete vaccination, 93.3% [95%CI: 91.1–
95.0%, deff = 5.9] received at least one dose in Boffa and 94.9%
[95%CI: 91.8–96.9%, deff = 3.7] in Fore´cariah. The dropout rate
between the first and second dose was 15.2% [95%CI: 12.2–
18.7%] and 13.6% [95%CI: 9.7–18.7%] in each site respectively.
Vaccine coverage was lowest among adults in both prefectures
(Figure 4).
Vaccine coverage with two doses was similar among females
and males in Boffa (76.6% [95%CI: 71.9–80.7%] vs. 75.0%
[95%CI: 69.8–79.4%]), but higher among females in Fore´cariah
(79.4% [95%CI: 74.4–83.6%] vs. 71.4% [95%CI: 63.3–78.3%]).
Vaccine coverage among women in childbearing age (15–49 years
old) was statistically higher than among men of same age in
Fore´cariah (72.6% [95%CI: 65.4–78.8%] vs. 53.4% [95%CI:
41.6–64.8%], p,0.001), but not in Boffa (70.1% [95%CI: 63.8–
75.7%] vs. 64.3% [95%CI: 56.1–71.7%], p= 0.1). No major
differences were observed in vaccination coverage by sub-
prefecture (Table 1).
Regarding the awareness campaign, 95.7% of survey partici-
pants [95%CI: 94.2–96.8%] reported being aware of the
campaign. Among individuals not vaccinated, the main reason
was ‘‘absence during the campaign’’ for both the first and second
rounds. The second most reported reason was ‘‘not having time to
go for the vaccination’’ and the third, ‘‘sick during the campaign’’
(Table 2).AEFI was reported as the reason for non-vaccination by
0.9% of non-vaccinated individuals during the second round. A
small percentage of participants considered that the vaccine made
them feel sick (3.9% [95%CI 2.4–4.7%]). A large proportion of
participants reported that the taste of the vaccine was bad (77.6%
[95%CI 69.5–84.1%]). Among those vaccinated 1.4% [95%CI:
0.8–2.2%] reported spitting out or vomiting the vaccine. However,
98.9% [95%CI 97.8–99.5%] reported that they would be
vaccinated again in a future cholera campaign.
Surveillance of Adverse Events following Immunization
Overall, 48 patients (15 per 100,000 vaccinated) spontaneously
reported symptoms that were linked with the vaccine by the health
personnel and considered as AEFI with 35 (20 per 100,000
vaccinated) after the first round and 13 (9 per 100,000 vaccinated)
after the second round. In total, 29 were women (60%) and the
median age was 27 years (IQR: 16–36 years); 8 (17%) were children
1 to 4 years. Seven patients reported having a history of allergies
(15%). The cause of the allergy was specified for two patients
(quinine and chloroquine). The average delay between vaccination
and symptom onset was 24 hours with a median delay of 7 hours
(IQR: 1–24 hours). One quarter reported the symptoms in the
following hour after vaccination. Symptoms reported (n= 139) were
mainly gastro-intestinal: 28 (20%) diarrhea, 22 (16%) vomiting, 14
(10%) stomachache and 12 (9%) nausea. In addition, 15 patients
(11%) reported fever and general weakness. No patient was
transferred to a hospital and no deaths were reported.
Discussion
The high coverage and good acceptability of the campaigns,
conducted in a rural mobile population in Guinea, is encouraging.
The percentage of people reporting AEFIs was low and almost all
participants reported that they would be vaccinated in a future
campaign. However, more evidence is needed about the feasibility
of reactive campaigns from densely populated urban scenarios
where cholera burden is high and cholera outbreaks evolve faster
[16–20]. Also the acceptability of target campaigns in such a
context should be assessed from a political, public health and
community point of view. Determining the short-term protection
given by the first dose is a clear priority as an effective one-dose
regimen would facilitate the ease and timeliness of reactive
campaigns in all contexts.
Oral Cholera Vaccines as Response to Outbreaks
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There are several key limitations of note. Despite the short time
span between the vaccination campaign and the data collection for
the surveys, we were not able to card-confirm vaccination status
for 25% of participants and as a result some information bias may
be present. Considering those individuals as not-vaccinated (worst-
case scenario), two-dose coverage would decrease to 61% in Boffa
and 64% in Fore´cariah. Second, the precision of estimates was
better than expected because the number of participants recruited
was higher (linked with the household size composition) than
originally planned. However, population estimates in the surveyed
areas are likely to be inaccurate. In most areas, no major
differences were observed between administrative and survey
coverage, but in Kaback an important deviation was observed.
Inaccuracies in the population data could have caused some
imbalances in the allocations of clusters; as described, we tried to
avoid this problem using spatial sampling in Kaback.
An additional limitation concerns the use of a quantitative
approach to explore campaign acceptability. Although reasons for
non-vaccination were specifically collected using an open question,
we cannot exclude the possibility that the population may not have
understood certain awareness and education messages. A quali-
tative assessment would aid in understanding better reasons for
non-vaccination, elucidate possible solutions and provide a better
understanding of the perception of the vaccination campaigns by
the population.
There are few examples where OCVs have been used as public
health tools. Dukoral was used pre-emptively in refugee camps in
Uganda and Darfur [21,22] and in endemic areas (Zanzibar and
Figure 3. Study flow chart: Number of households visited, number of households included, number of individuals in the targeted
age group (older than 12 months of age) residing in the households included in the survey and final number of individuals
included in the study.
doi:10.1371/journal.pntd.0002465.g003
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Figure 4. Vaccine coverage by age group of the cholera mass vaccination campaign in Boffa (panel A) and Fore´cariah (panel B)
prefectures, first round, second round and two doses (fully vaccinated), April–June 2012.
doi:10.1371/journal.pntd.0002465.g004
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Mozambique) [23,24]. Shanchol has been recently used in Haiti in
a pilot campaign [25]. To our knowledge there are only two
published examples of reactive campaigns using OCV, and both
were conducted in Asia [26,27] using vaccines not prequalified by
the WHO. The coverage and acceptability of these campaigns
varied depending on the setting and the approach (pre-emptive vs.
reactive). High coverage was obtained in Uganda, Darfur and
Micronesia [21,22,26] and lower coverage was obtained in
Table 1. Vaccine coverage by sub-prefecture of the cholera mass vaccination campaign in Boffa and Fore´cariah prefectures, first
round, second round and two doses (fully vaccinated), April–June 2012.
First round Second round Full coverage (two doses)
n/N (%)* [95% CI] n/N (%)* [95% CI] n/N (%)* [95% CI]
Boffa prefecture
Boffa (n = 850) 773/847 (91) [82–96] 692/847 (82) [74–89] 655/847 (78) [68–86]
Douprou (n = 535) 477/534 (88) [81–93] 428/534 (79) [70–86] 411/534 (76) [67–83]
Koba (n = 957) 835/949 (88) [83–92] 672/947 (71) [62–80] 645/946 (69) [59–77]
Mankountan (n = 577) 535/577 (93) [88–96] 506/577 (89) [82–93] 484/577 (84) [76–90]
Tamita (n = 203) 190/203 (93) [85–97] 165/202 (80) [71–87] 160/202 (78) [66–86]
Tougnifili (n = 811) 725/811 (88) [77–94] 676/811 (83) [73–89] 636/811 (77) [64–86]
Fore´cariah prefecture
Kaback (n = 754) 657/744 (87) [84–90] 605/744 (80) [72–86] 565/744 (74) [67–81]
Kakossa (n = 501) 447/501 (88) [80–93] 451/501 (88) [76–93] 88/501 (78) [68–86]
*The vaccine coverage estimates were weighted considering the study design and the confidences intervals were adjusted by the design effect.
doi:10.1371/journal.pntd.0002465.t001
Table 2. Reason for non-vaccination among individuals not vaccinated, Boffa and Fore´cariah prefectures, April–June 2012.
1st round 2nd round
N=521 N=952
Reason n % n %
Impossibility to go to the vaccination site
Absent during the campaign 411 78.89 672 70.59
The person did not have the time to be vaccinated 30 5.76 81 8.51
Sick during the campaign 24 4.61 42 4.41
The person was hospitalized at the time of vaccination 3 0.58 3 0.32
Lack of information
Not informed about the campaign 17 3.26 28 2.94
The person did not know the date of the campaign 3 0.58 26 2.73
The person did not know the place of vaccination 1 0.19 2 0.21
The caregiver thought that the child was too young 8 1.54 8 0.84
The person thought that he/she was too old 4 0.77 4 0.42
The person thought that one dose was enough 0 0.00 2 0.21
Logistic constraints
Vaccination site considered too far 3 0.58 5 0.53
No vaccines available at the vaccination site 0 0.00 8 0.84
Waiting time too long 0 0.00 8 0.84
Refusals
Cultural beliefs 1 0.19 1 0.11
Bad experience with previous vaccinations 1 0.19 8 0.84
Adverse events during the first round 0 0.00 8 0.85
The vaccine was considered dangerous 0 0.00 1 0.11
Other 11 2.11 34 3.57
No explanation 4 0.77 11 1.16
doi:10.1371/journal.pntd.0002465.t002
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Mozambique, Zanzibar and Vietnam [23,24,27]. In Guinea we
obtained 76% coverage for two doses and 93% of the population
received at least one dose, which represents, to our knowledge, one
of the highest coverage reached [21–24,26,27]. The high coverage
obtained is a promising outcome considering that this was one of
the largest campaigns conducted in terms of number of doses
administered, the specificities of the population (rural and mobile),
and the short time available for preparation of the campaign,
which has been one of the major arguments against outbreak
response with OCV. There are several factors that likely
influenced the population to participate in the campaign: first,
the campaign was conducted in response to an outbreak and the
possibility of even partial protection against a frightening disease
was motivating. Second, the population may have been reassured
by the involvement of the MoH, public health authorities and
MSF; as an example, the vaccination campaign was inaugurated
in Boffa with the presence of the Minister of Health. This
involvement was also crucial to mobilize human resources and to
organize the campaign considering the local specificities. Finally,
both the awareness campaign and the vaccination strategy itself
(decentralized with sites organized in each village or settlement)
involved the communities. This aimed to ensure awareness and
provide vaccination opportunities to remote places and difficult to
reach population which likely contributed to this high coverage.
Vaccination activities started early in the morning and finished
late in the afternoon to maximize the opportunities for workers in
the main fishing ports. Despite these efforts, the lowest coverage
was obtained in adult males.
Significant differences where observed by sex in Fore´cariah,
especially in individuals between 15–49 years old. The vaccination
campaign in Fore´cariah coincided with an intense period in
agriculture activities, which was a barrier for the participation in
the campaign, especially for the male adults. In addition, the Red
Cross Society of Guinea distributed soap and a bottle of chlorine
solution to women of childbearing age in Fore´cariah during the
second round of vaccination, which likely increased the coverage
in this group. Distribution of soap and chlorine was one of the
control measures implemented by the MoH in response to the
outbreak in the affected places, but this activity was successfully
integrated in Fore´cariah within the vaccination sites. This suggests
that synergies among different preventive approaches is an
element to consider in future campaigns both to provide a more
comprehensive message on cholera prevention and to improve the
vaccine coverage itself.
The number of AEFI reported through the surveillance system
was low, without severe AEFI reported. Only a small proportion of
non-vaccinated individuals during the second round of vaccination
reported AEFI as a cause of non-vaccination. This result is
coherent with previous publications on vaccine safety where mild
symptoms (mostly not requiring medical attention) have been
reported [28,29]. The proportion of vaccinated individuals
reporting AEFIs was lower in our study than in the cluster
randomized clinical trial conducted in Kolkata (15 vs. 76 per
100,000) [28]. This difference is probably explained by: first, our
surveillance system was passive compared with the active case
finding implemented in Kolkata; and second, access to health care
was likely more difficult in the vaccinated area in Guinea (remote
rural area) than in the urban context of Kolkata.
With respect to the proportion of vaccinees vomiting or spitting
out the vaccine after intake, we found a higher percentage than
previously documented with Dukoral (no data available for
Shanchol) [23]. For administration of Dukoral, the vaccine has
to be diluted in water containing a buffer solution. Although
administration with water is not necessary for Shanchol, we
offered water after vaccine intake. Most vaccinated individuals did
not like the taste of the vaccine and offering water may have
contributed to fewer incomplete vaccine courses. Additional
information should be collected in future campaigns using
Shanchol, considering that providing water considerably increased
the logistic complexity of the campaign.
In order to facilitate the use of OCV as an additional tool,
WHO and partners are in the process of creating a vaccine
stockpile dedicated to outbreak response [30]. Here, we showed
that high coverage can be reached within a few weeks, even in
rural areas, and that the campaigns were well accepted by the
population. Good documentation of these interventions is essential
to elucidate the strategies leading to successful outcomes as well as
key implementation barriers. Synergies between different axes in
cholera control interventions should be pursued and other
examples of integrated cholera response than the one presented
here should serve also to determine the best use of vaccines for
cholera prevention and control.
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Abstract
Background: During the 2012 cholera outbreak in the Republic of Guinea, the Ministry of Health, supported by Me´decins
Sans Frontie`res - Operational Center Geneva, used the oral cholera vaccine Shanchol as a part of the emergency response.
The rapid diagnostic test (RDT) Crystal VC, widely used during outbreaks, detects lipopolysaccharide antigens of Vibrio
cholerae O1 and O139, both included in Shanchol. In the context of reactive use of a whole-cell cholera vaccine in a region
where cholera cases have been reported, it is essential to know what proportion of vaccinated individuals would be reactive
to the RDT and for how long after vaccination.
Methodology/Principal Findings: A total of 108 vaccinated individuals, selected systematically among all persons older
than one year, were included at vaccination sites and 106 were included in the analysis. Stools samples of this cohort of
vaccinated participants were collected and tested with the RDT every day until the test was negative for two consecutive
visits or for a maximum of 7 days. A total of 94.3% of cholera vaccine recipients had a positive test after vaccination; all
except one of these positive results were reactive only with the O139 antigen. The mean time to become negative in those
with an initial positive result after vaccination was 3.8 days, standard deviation 1.1 days.
Conclusions/Significance: The RDT Crystal VC becomes positive in persons recently vaccinated against cholera, although
almost exclusively to the O139 antigen. This reactivity largely disappeared within five days after vaccination. These results
suggest that the test can be used normally as soon as 24 hours after vaccination in a context of O1 epidemics, which
represent the vast majority of cases, and after a period of five days in areas where V. cholerae O139 is present. The reason
why only O139 test line became positive remains to be investigated.
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Introduction
Cholera is an acute diarrhoeal infection caused by ingestion of
the bacterium Vibrio cholerae. Two serogroups– O1 and O139 – are
responsible for cholera epidemics. While V. cholerae O1 causes the
majority of outbreaks over the world, O139 – first identified in
Bangladesh in 1992 – is confined to South-East Asia [1], where its
incidence has declined over the years [2]. Globally, O139 accounts
for a small minority of cholera cases [3], and local transmission has
never been reported in Africa or America. Rapid identification of
initial cases of cholera in the early phase of an epidemic is critical
for implementation of a timely public health response [4] to
control the spread and duration of the outbreak. Currently,
cholera diagnosis relies on the microbiological identification of the
pathogen by stool culture, which remains the gold standard to
confirm the diagnosis [5]. However, this procedure requires
laboratory infrastructure, adequate transport procedures and
trained staff [5]. As rapid diagnostic tests (RDT) require less time,
a minimum laboratory infrastructure and basic technical skills,
they are used to confirm cholera outbreaks in places where high
laboratory standards are difficult to obtain [6].
In 2003, the Institut Pasteur developed a cholera RDT based on
the qualitative detection of lipopolysaccharide (LPS) antigen of
both Vibrio cholerae O1 and O139 serogroups from stool specimens.
This test uses one-step, vertical-flow immunochromatography
principle and monoclonal antibodies against the core and O-
specific polysaccharides of each serogroup for capture and
detection of antigens [7,8]. The O1 specific antigenic determinant
is common to Ogawa and Inaba serotypes [8,9] and the one for
O139 is common to both O139 capsular polysaccharide and LPS.
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This cross-reactivity between O139 LPS and capsular polysac-
charide explains that antibodies react with both encapsulated and
non-encapsulated V. cholerae O139 strains [10]. The RDT is
produced by Span Diagnostics (Surat, India) under the trade name
Crystal VC [5]. Several evaluations have shown good sensitivity,
ranging from 92% to 100% [7,11–12]. In contrast, the specificity
was lower and most evaluations in field conditions have shown
specificities from 71% to 77% when compared with culture as the
gold standard [4,11–13]. Nevertheless, the use of culture as gold
standard may underestimate specificity, and re-analysis of the data
using statistical methods for evaluation with an imperfect gold
standard showed that the specificity could be around 85% [14].
After these evaluations, the manufacturer SPAN changed the test
presentation (order of the lines and addition of a dilution buffer),
but the test in this new version has not been formally evaluated.
This test is widely used for epidemiological purposes during
outbreaks.
In 2012, the Republic of Guinea faced an O1 cholera epidemic,
with the first cases notified in the prefecture of Fore´cariah in
February. In light of the ongoing cholera epidemic and the 2009
World Health Organization (WHO) recommendations calling for
the consideration of oral cholera vaccines as a part of the epidemic
response [15], the Ministry of Health and Public Hygiene
(MHPH) of Guinea supported by Me´decins Sans Frontie`res –
Operational Center Geneva (MSF-OCG), implemented a vacci-
nation campaign in the prefectures of Boffa and Fore´cariah. The
vaccine Shanchol (Shantha Biotechnics, India), prequalified by the
WHO, contains killed bacteria V. cholerae O1 and O139 and, given
in two doses 14 days apart, provides nearly 70% protection for at
least 2 years after vaccination [16]. A total of 7,531 cases including
138 deaths (case fatality ratio of 1.8%) were reported to the
MHPH of Guinea between the beginning of the epidemic and its
end, which was declared on 6 February 2013, after six consecutive
weeks without any new case notification [17].
Given that the RDT Crystal VC detects the LPS antigens of V.
cholerae O1 and O139 in feces, which are also contained in the oral
vaccine Shanchol, we hypothesized that the stools of vaccinated
individuals could become positive by the rapid test due to the
vaccine only, in the absence of viable bacteria. In a reactive
campaign during an outbreak, positive test results due to the
vaccine could interfere with the use of the tests in suspected
cholera cases. The aim of this study was to estimate the proportion
of positive results of the test Crystal VC in recipients of the cholera
vaccine Shanchol at different time points after vaccination and the
mean time to become negative (in those with an initial positive
result for O1 or O139) after vaccination.
Methods
Ethics statement
The study protocol was approved by the Ethical Review Board
(ERB) of Guinea and the MSF ERB. Written informed consent
was obtained from adults or from the guardians of participants less
than 18 years of age. Privacy and confidentiality in the data
collected from the participants were ensured both during and after
the conduct of the study.
Setting, population and study design
The study took place in Kabak (Fore´cariah Prefecture, Guinea)
during the second round of the mass vaccination campaign carried
out by the MHPH/MSF in June 2012. The study population
corresponded to the population targeted by the vaccination
campaign (all residents of Kabak aged one year and above).
Individuals were included if they were vaccinated and accepted to
participate. They were excluded if they had watery diarrhea on
inclusion (to exclude potential cholera cases) and/or a high
probability of not being present for all the follow-up visits. The
cohort of vaccinated participants meeting study criteria was
followed-up prospectively.
We estimated that 96 individuals were needed to achieve a
minimum precision of 10% around a proportion of 50% of
positive RDT, as there were no data on the prevalence of positive
tests in the vaccinated population. We increased the sample size to
106 to account for an expected 10% of loss to follow-up. A
systematic sampling method (one every 10 individual) was used in
every vaccination site.
Recruitment and follow-up procedures
Participants were recruited in 4 of the 31 vaccination sites,
selected arbitrarily, as vaccination sites were not thought to have
any influence on the study outcomes. Demographic information
was collected at inclusion through a face-to-face interview (mainly
in Soussou, the local language) and information on stool
production and basic clinical symptoms during follow-up visits
using an individual standardized case report form (CRF).
Participants were asked to collect stool in a pot provided by the
study team. Participants’ homes were visited daily to collect stool
specimens, complete a follow-up form and to provide them with a
new pot for the next stool. We transported the stools to the
laboratory and tested them with the RDT. Laboratory technicians
completed the information with the RDT results. Follow-up was
considered finalized when 2 consecutive negative RDT results
were obtained or after 7 days.
Field use of the rapid diagnostic test
The stool samples were tested with the RDT at Kabak Health
Center following the manufacturer’s instructions by a laboratory
technician trained to the use of the test. Crystal VC tests used were
manufactured in 2011 and 2012 by Span Diagnostics Ltd., India
(catalogue reference number 161C101-10). A small portion of
stool was mixed with a buffer and 200 mL (4 drops) of the mix was
placed in a test tube. The dipstick test was left in the tube for
20 minutes before reading. If only the control line appeared, the
Author Summary
The rapid diagnostic test (RDT) Crystal VC detects
lipopolysaccharide antigens from V. cholerae O1 and
O139 in stool samples, which are also present in the oral
cholera vaccine Shanchol. It is important to take into
consideration the possibility of a positive result to the RDT
due to vaccination and not to cholera in recently
vaccinated individuals. During a large mass cholera
vaccination campaign in Kabak (Guinea) in 2012, we
conducted a study to estimate the proportion of positive
results to the RDT in recipients of the oral cholera vaccine
at different time points after vaccination. The results of this
study show that ingestion of the cholera vaccine led to a
positive RDT, although almost exclusively to the O139
antigen, in the majority of vaccinated people. From the
fifth day after vaccination, only a small minority of
vaccinated individuals remained positive for the RDT and
none of the specimens tested the seventh day of follow-up
were positive. Our findings provide the first data on the
use of the RDT Crystal VC in vaccinated people. This test
should be used carefully during the first week after
reactive mass oral cholera vaccination campaigns in areas
where V. cholerae O139 is present.
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test was negative. If 2 or 3 lines appeared, the test was positive for
either V. cholerae O139, O1, or both. If the control line was absent,
the test was considered invalid and repeated once.
Laboratory control of the rapid diagnostic test
Ten by ten dilutions of the Shanchol vaccine were prepared
using the dilution buffer provided in the RDT kit. Undiluted and
diluted vaccine solutions up to a 109-fold dilution were tested with
the RDT following the manufacturer’s recommendations.
A bacterial suspension adjusted to an optical density at 600 nm
(OD600 nm) of 0.8 was prepared in the dilution buffer provided in
the RDT kit from an overnight culture of V. cholerae O1 and O139
strains. Such an OD value was previously estimated to correspond
to 26108 V. cholerae/mL by colony counting of 10-fold serial
dilutions spread on agar plates and incubated over night at 37uC.
This initial solution was used to prepare solutions at 26107 and
26106 bacteria/mL using the dilution buffer provided in the kit,
undiluted and diluted solutions were tested with the RDT
following the manufacturer’s recommendations.
Data analysis
Qualitative variables were described through their frequency
and percentages. Continuous variables were described through
their mean, median, standard deviation (SD) and percentiles (P25
and P75). We calculated the proportion of positive results for O1 or
O139 for each day of follow-up including in the numerator the
number of positive results and in the denominator the sum of the
total number of tests performed and the number of cases for whom
follow-up was stopped after obtaining two consecutive negative
results. Missing data (absent or no stool sample) were excluded
from this calculation. The 95% exact confidence intervals (95%CI)
of the proportion estimate were calculated. To estimate the mean
time to obtain a negative RDT result after vaccination (time to
become negative) we counted the number of days needed to obtain
a first negative result in the group of people who obtained
previously a positive result for O1 or O139 after vaccination.
Statistically significant differences by gender and age were assessed
with a linear regression model. A p value,0.05 was considered
significant.
Data were entered in an EpiData version 3.1 database
(EpiData, Odense, Denmark) and analyzed using Stata version
11 (StataCorp, College Station, Texas, USA).
Results
Recruitment and follow-up
A total of 108 individuals were recruited during 2 days in 4
vaccination sites. Two individuals were excluded from the analysis
(one was absent during all follow-up visits and for the other, follow-
up was stopped accidentally by the study team).
Follow-up of the remaining 106 participants is described in
Figure 1. Participants were followed for a median time of 5 days
(minimum of 2 and 7 as maximum). Almost half of them (49.1%)
were followed for 4 (23.6%) or 5 days (26.4%).
Participant’s characteristics, symptoms and delay in stool
collection and testing
Among the 106 participants, 79.2% (84) were females and the
median age was 25 years (P25-P75=2–80). The majority of
participants were older than 15 (84.8%) and the proportion of
children under five was 5.7%.
In total, 18 participants declared having diarrhea during follow-
up, and two reported vomiting. Other symptoms such as
constipation, stomachache or headache were declared by 37
participants.
The average delay was 3.9 hours (SD=4.4) between stool
production and collection and 6.6 hours (SD=5.9) between stool
collection and performance of the RDT (including collection and
transport of samples to the laboratory) by the laboratory
technicians. As a result, there was an average delay of 10.5 hours
(SD=6.6) between stool production and performance of the RDT.
Proportion of positive tests after vaccination
Of the 106 participants, 100 (94.3%) became positive with the
O139 line after vaccination and 6 never had a positive result. On
the first day of follow-up (day 1) 71.1% were positive. On day 3,
almost half of the tests remained positive (49.5%) and on day 5 and
6 this percentage decreased below 3% (Table 1).
Figure 1. Study participants, exclusions and follow-up results, Kabak, 2012.
doi:10.1371/journal.pntd.0002366.g001
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Only one participant became positive with the O1 line (together
with the O139 line) on the first day of monitoring, and both lines
became negative subsequently.
Time to become negative
Of the 100 participants with at least one positive result, five
could not be tested on day 7 as they were absent or did not
produce stools, although they had a positive result with their last
specimen collected (Figure 1). Among these 5 participants, 3 had
their last positive stool on day 3, 1 on day 4 and 1 on day 5. For
the remaining 95 cases with O139 positive tests, we calculated the
time to become negative after vaccination.
For all participants, the mean time to become negative after
vaccination was 3.8 days (SD=1.1) and the median time was 4
days (P25-P75=3–5). For males, the mean time to become negative
after vaccination was 4.3 days (SD=1.4) and 3.6 (SD=1) for
females (p = 0.03), with a median of 4 days for both males and
females. A linear regression model showed that a longer time to
become negative was associated to an older age (p = 0.002) and to
male sex (p = 0.012) (Table 2).
Laboratory testing of the rapid diagnostic test
The Crystal VC RDT gave positive results for both O1 and
O139 when the strip was inserted directly into the vaccine solution
prior to ingestion, and remained positive up to 104-fold dilutions of
the vaccine. At a 105-fold dilution, only the O139 line remained
positive and none of them were positive at higher dilutions
(Table 3).
The RDT gave a positive signal with the O1 test line at bacterial
concentration of 26108 and 26107, but was negative at 26106
bacteria/mL, while all dilutions of V. cholerae O139 culture tested
down to 26106 bacteria/mL were positive for the O139 line
(Table 3).
Discussion
To our knowledge, this is the first study showing that healthy
individuals vaccinated with the oral vaccine Shanchol become
positive with the cholera rapid test Crystal VC in the first days
following vaccination. The proportion of vaccinated individuals
Table 1. Rapid diagnostic test results in vaccinated participants by day of follow-up, Kabak, 2012.
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day7
A. Tests performed 97 97 90 76 46 23 6
a.1. Positive result (+) 69 80 47 20 2 1 0
a.2. Negative result (2) 28 17 43 56 44 22 6
B. Follow-up stopped after 2(2) 0 0 5 17 42 67 85
C. Absent 1 0 0 1 1 4 5
D. No sample available 8 9 11 12 17 12 10
Total1 106 106 106 106 106 106 106
Proportion2 of positives (%) 71.1 82.5 49.5 21.5 2.3 1.1 0.0
95%CI of the proportion 61.5–79.9 73.4–89.4 39.1–59.9 13.7–31.2 0.3–8.1 0.0–6.0 0.0–4.03
1The total is the sum of A+B+C+D.
2The proportion is the result of the formula (a.1/(A+B))*100.
397.5% Confidence Interval, one-sided.
doi:10.1371/journal.pntd.0002366.t001
Table 2. Linear regression model of time to become negative
by age and sex, Kabak, 2012.
Coefficient
95% Confidence
Interval p
Age1 0.020 (0.008–0.032) 0.002
Sex2 0.669 (0.153–1.186) 0.012
1The coefficient shows the increase in days in the time to become negative per
year of age.
2The coefficient shows the increase in days in the time to become negative for
males compared to females.
doi:10.1371/journal.pntd.0002366.t002
Table 3. Rapid diagnostic test results performed in vaccine
and bacterial suspension dilutions, Pasteur Institute, 2012.
Control
line
Line
T1 O139
Line
T2 O1
Vaccine dilutions
Tube 1 (10-fold dilution) +++ +++ +++
Tube 2 (102-fold dilution) +++ +++ +++
Tube 3 (103-fold dilution) +++ +++ ++
Tube 4 (104-fold dilution) +++ ++ +
Tube 5 (105-fold dilution) +++ + 2
Tube 6 (106-fold dilution) +++ 2 2
Tube 7 (107-fold dilution) +++ 2 2
Tube 8 (108-fold dilution) +++ 2 2
Tube 9 (109-fold dilution) +++ 2 2
O1 and O139 strains dilutions +++
O1 - Tube 1 (26108bacteria/mL) +++ 2 +++
O1 - Tube 2 (26107 bacteria/mL) +++ 2 ++
O1 - Tube 3 (26106 bacteria/mL) +++ 2 2
O139 - Tube 1 (26108 bacteria/mL) +++ +++ 2
O139 - Tube 2 (26107 bacteria/mL) +++ +++ 2
O139 - Tube 3 (26106 bacteria/mL) +++ ++ 2
Intensity of the positive line: (+) very weak positive; (++) weak positive; (+++)
positive.
Negative result: (2).
doi:10.1371/journal.pntd.0002366.t003
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positive for the Crystal VC test after vaccination was high (94.3%)
for the O139 component of the test, but low with the O1
component. This proportion of O139-positive tests decreased
rapidly to half on the third day after vaccination and to one-fifth
on the fourth day of follow-up. The median duration required to
have a negative result for those cases presenting a previous positive
test was 4 days.
Almost all positive tests (except for one) were positive only for
O139 line, despite the fact that the Shanchol vaccines contains the
two strains V. cholerae O1 and O139, with a higher amount of O1
(1500 Elisa units of V. cholerae O1 LPS and 600 Elisa units of V.
cholerae O139 LPS for a dose of 1.5 mL) [18]. This could be due to
a higher sensitivity of the RDT for the O139, as suggested by the
results of sensitivity against bacterial cultures showing that the
O139 line was reactive with higher bacterial dilutions than the O1
line. Such results were already reported by Nato et al. [7] when
evaluating the initial version of the RDT, but are in contradiction
with those observed by Mukherjee et al. [13] with the first version
of the Crystal VC test, which was reactive at 106 bacteria/mL for
V. cholerae O1 and 107 bacterial/mL for V. cholerae O139. These
differences of analytical sensitivity between the different versions of
the RDT emphasize the need for a proper diagnostic performance
evaluation of each new version of the test.
Including pre-vaccination stool status of our study population as
well as unvaccinated participants could have provided useful
information on the magnitude of potential false positive reactions
due to factors unrelated to vaccination, i.e. non-specific reactions,
which could have been expected considering the reported
moderate specificity of the test [4,11–13], or positivity due to
asymptomatic carriers. The sharp increase and subsequent
decrease in the proportion of O139 positive tests after vaccination
are not in favour of such assumptions and suggest that the positive
results were due to the vaccine alone. Of the 75 tests done after
day 5, only three (4%) were positive for O139, and overall only
one test was positive for O1 which is lower than the number of
false positives that could be expected based on the test specificity.
However, it should be noted that this study was conducted in
people without cholera symptoms while the previous evaluations
were conducted in suspected cholera cases.
There are several limitations worth noting. First, women and
adults were overrepresented in our study sample. Although women
were more vaccinated than men were during the vaccination
campaign carried out in Kabak, the proportion of women in our
study (79.3%) was clearly higher than the vaccinated population
(59.5%) [19]. This is likely due to the fact that the majority of men
presented early at the vaccination site and were more likely to be
excluded given their potential absence for work during the follow-
up period. However, although there was a small difference in the
mean time to become negative between men and women (4.3 days
vs. 3.6), the median was the same for both sexes (4 days) thereby
not likely affecting the results presented here. The median age in
the study was 25 years compared to 15 for the vaccinated
population [19]. Considering that the time to become negative was
longer for the older participants, it is likely that we slightly
overestimated the time to become negative. Nonetheless, the
differences by age were small in magnitude (0.2 days per 10 years
of age) and they do not change the interpretation of the results
neither our recommendations regarding the use of the cholera
RDT in vaccinated areas. Second, we could not conclude on five
cases who had a positive result with their last specimen collected,
and for whom further samples could not be collected because they
were absent or unable to produce stool samples. When designing
the study, we decided to limit the follow-up period to 7 days, based
on the expected time for gastrointestinal transit of the killed
bacteria. Although extending the follow-up of participants until
they became negative for the rapid test would have been useful for
concluding on these 5 individuals, we consider that this limit was
reasonable in the absence of any other data. In addition, even if we
consider that these five people were still positive at day 7, the
percentage of positive tests would be still low (5.2%), lower than
the expected for non-cholera cases considering the specificity of
the test. Third, we did not perform culture to exclude participants
with possible cholera or asymptomatic carriage of V. cholerae.
Although initially planned in the protocol for participants with
diarrhea or with a positive RDT at the end of follow-up (day 7), no
culture was performed since symptoms were found unreliable and
none of the specimens tested on the seventh day of follow-up were
positive. Finally, specimens were tested on average ten hours after
stool production and without the possibility of storage at 4uC due
to the lack of electricity in Kabak. This delay seems reasonable
given the difficulties to collect the samples immediately after
production, although it is unclear the degree to which antigens
degrade during this period, which could potentially affect the
RDT results.
The results of the study confirm our hypothesis that the rapid
test Crystal VC can become positive in persons recently vaccinated
against cholera, although only with the O139 line, probably linked
to its higher analytical sensitivity. However, tests become negative
rapidly and five days after vaccination the proportion of positive
tests among vaccinated is less than 3%. As the current global
pandemic is almost exclusively caused by Vibrio cholerae O1, our
results suggest that the current Crystal VC kit can be used
normally as soon as 24 h after receiving Shanchol in a context of
V. cholerae O1 epidemic, and after a period of five days in areas
where V. cholerae O139 is present. Other cholera rapid diagnostic
tests based on the LPS detection are available in the market [20]
and could also become positive in recently vaccinated individuals.
Thus, an evaluation of other tests or future versions of the Crystal
VC test is recommended if they are to be used in the context of
oral cholera vaccination campaigns. Finally, we strongly recom-
mend that the diagnostic performances of the current modified
version of the Crystal VC test be evaluated with respect to the
different sensitivities of the O1 and O139 lines.
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Annex 2. Data collection form: feasability assessment 
Vacciantion Site   
Vaccination Session*   
Time spent for preparation of the session   
Session duration   
Time spent for closing of the vaccination point   
Daily number of doses being administered    
     Per gender   
     Per age-group (2-4, 5-14, >=15)   
     Per hour    
Number of personal in charge of the vaccination point per category   
   Screening   
   Animators   
   Vaccination cards   
   Preparators   
   Vaccinators   
   Cleaners   
   Registers   
   Community memebers   
   Med responsable   
   Log responsable   
   Coordinator   
Logistics for consumable   
   Cool boxes   
   Vaccine vials   
   Litres of water   
Quantity of non-consumable items   
   Chairs   
   Tables   
   Benches   
  
  * Vaccination session = one day session on each vaccination point  
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Annex 3. Vaccine coverage and acceptability questionnaire 
A DONNEES ENQUETEURS 
A1 DATE DE L’ENQUETE : __/__/2012   A2 NUMERO DE L’EQUIPE : ________ 
A3 
SOUS-PREFECTURE :  
BOFFA-CENTRE 1 [_]   DOUPROU 2 [_]  KOBA 3 [_]    TAMITA 4 [_]  TOUGNIFILI 5 [_]   MANKOUNTAN  6 [_]       
  
A4 VILLAGE : ____________________ A5 N° DE GRAPPE : __________ 
A6 N° DE LA MAISON : C _ _ _ 
A7 NOMBRE DE PERSONNE RESIDANT DANS LA MAISON :  [          ] 
 
B. VACCINATION CONTRE LA POLIOMYELITE 
Pendant le pèlerinage et juste après, une campagne de vaccination contre la polio a été organisée à Boffa. Elle 
concernait tous les enfants âgés de moins de 5 ans. Des vaccinateurs passaient de maison à maison (de porte à 
porte) et donnaient un médicament dans la bouche des enfants. (Présenter la boîte à image).  
B1. Des vaccinateurs sont-ils passés dans cette maison ?  Non  [  ]  Oui  [  ]  Ne sait pas  [  ] 
B2. Combien d’enfants de moins de 1 an résident dans cette maison ?  [       ] 
 
Id 
Age Sexe Vacciné contre la polio? 
(en mois) Homme=0  / Femme=1 Non = 0  / Oui = 1  / Ne sait pas =9 
Enfants de 
moins de 1 an 
1.1    
1.2    
1.3    
1.4    
B3. A part lui/elle/eux, combien d’enfants de moins de 5 ans résident dans cette maison ?  [       ] 
 
Id 
Age Sexe Vacciné contre la polio? 
(en années) Homme=0  / Femme=1 Non = 0  / Oui = 1  / Ne sait pas =9 
Enfants âgés de 
1 à 4 ans 
2.1    
2.2    
2.3    
2.4    
2.5    
2.6    
2.7    
C. VACCINATION CONTRE LE CHOLERA 
La semaine passée, une campagne de vaccination contre le choléra a été organisée à Boffa par le Ministère de la Santé avec l’appui de Médecins sans 
Frontières. Elle concernait toutes les personnes à partir de 1 an. Il fallait se rendre dans un site de vaccination où on remplissait une carte de vaccination avant 
de recevoir un médicament dans la bouche. (Présenter la boîte à image).  
Une campagne similaire avait été organisée avant le pèlerinage.  
C.1. Des personnes résidant dans cette maison sont-elles allées se faire vacciner ? Aucune 1 [  ]   Certaines  2  [   ]  Toutes 3  [   ]  Ne sait pas 9  [   ] 
Si certaines ou toutes sont allées se faire vacciner, pourriez-vous aller chercher les cartes de vaccination ? 
Si la personne ne sait pas répondre à cette question, demandez si un autre adulte de la maison peut répondre à cette question. Si aucun autre adulte ne sait 
répondre à cette question, demandez si vous pouvez repasser plus tard.   
 
C.2. Pour les enfants âgés de 1 à 4 ans (reporter l’âge et le sexe depuis le tableau B3, prenez les autres informations en discutant avec les parents des enfants puis vérifiez 
sur la carte si possible). 
 
Id 
Age Sexe 
Vacciné 
contre le 
choléra ? 
 
 
Nombre 
de doses 
reçues 
1er tour 
du 18/04/2012 au 23/04/2012 (avant pèlerinage) 
2ème tour 
du 09/05/2012 au 14/05/2012 (après le pèlerinage) 
dose 
reçue ? 
Vérifié 
sur 
carte ? 
Date de 
vaccination 
Avez-
vous 
recraché 
ou vomi 
? 
Raisons 
non 
vaccination 
2eme 
dose 
reçue ? 
Vérifié 
sur 
carte ? 
Date de 
vaccination 
Avez-vous 
recraché ou 
vomi ? 
Raisons de non 
vaccination 
(en 
années) 
Homme=0 
Femme=1 
Non = 0  
Oui = 1  
NSP =9 
0 = 0 
1 =1 
2 = 2 
>2 = 3  
NSP = 9 
Non=0 
Oui=1 
NSP=9 
Non=0 
Oui=1 
jj / mm / aa 
Non = 0  
Oui = 1  
NSP =9 
Voir codes 
(NA si 
vacciné) 
Non=0 
Oui=1 
NSP=9 
Non=0 
Oui=1 
jj / mm / aa 
Non = 0 Oui 
= 1 NSP =9 
Voir codes 
(NA si vacciné) 
2.1        __ / __ /12     __ / __ /12   
2.2        __ / __ /12     __ / __ /12   
2.3        __ / __ /12     __ / __ /12   
2.4        __ / __ /12     __ / __ /12   
2.5        __ / __ /12     __ / __ /12   
2.6        __ / __ /12     __ / __ /12   
2.7        __ / __ /12     __ / __ /12   
2.8        __ / __ /12     __ / __ /12   
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C.3. Pour les enfants âgés de 5 à 14 ans (prenez les informations en discutant avec les parents des enfants, puis vérifiez sur la carte si possible). 
 
Id 
Age Sexe 
Vacciné 
contre le 
choléra ? 
Nombre 
de doses 
reçues 
1er tour 
du 18/04/2012 au 23/04/2012 (avant pèlerinage) 
2ème tour 
du 09/05/2012 au 14/05/2012 (après le pèlerinage) 
Dose 
reçue ? 
Vérifié 
sur  
carte ? 
Date de 
vaccination 
Avez-vous 
recraché ou 
vomi ? 
Raisons de 
non 
vaccination 
Dose 
reçue ? 
Vérifié 
sur 
carte ? 
Date de 
vaccination 
Avez-vous 
recraché ou 
vomi ? 
Raisons de 
non 
vaccination 
(en 
années) 
Homme=0 
Femme=1 
Non = 0  
Oui = 1  
NSP =9 
0 = 0 
1 =1 
2 = 2 
>2 = 3  
NSP = 9 
Non=0 
Oui=1 
NSP=9 
Non=0 
Oui=1 
jj / mm / aa 
Non = 0  
Oui = 1  
NSP =9 
Voir codes 
(NA si 
vacciné) 
Non=0 
Oui=1 
NSP=9 
Non=0 
Oui=1 
jj / mm / aa 
Non = 0  
Oui = 1  
NSP =9 
Voir codes 
(NA si 
vacciné) 
3.1       __ / __ /12     __ / __ /12   
3.2       __ / __ /12     __ / __ /12   
3.3       __ / __ /12     __ / __ /12   
3.4       __ / __ /12     __ / __ /12   
3.5       __ / __ /12     __ / __ /12   
3.6       __ / __ /12     __ / __ /12   
3.7       __ / __ /12     __ / __ /12   
3.8       __ / __ /12     __ / __ /12   
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C.4. Pour les adultes (15 ans et plus) (prenez les informations de la carte si possible, sinon en discutant avec les personnes concernées ou le responsable du ménage s’ils 
sont absents). 
Id 
Age Sexe 
Vacciné 
contre le 
choléra ? 
Nombre 
de doses 
reçues 
1er tour 
du 18/04/2012 au 23/04/2012 (avant pèlerinage) 
2ème tour 
du 09/05/2012 au 14/05/2012 (après le pèlerinage) 
Dose 
reçue ? 
Vérifié 
sur  
carte ? 
Date de 
vaccination 
Avez-vous 
recraché ou 
vomi ? 
Raisons de 
non 
vaccination 
Dose 
reçue ? 
Vérifié 
sur 
carte ? 
Date de 
vaccination 
Avez-vous 
recraché ou 
vomi ? 
Raisons de non 
vaccination 
(en 
années) 
Homme=0 
Femme=1 
Non = 0  
Oui = 1  
NSP =9 
0 = 0 
1 =1 
2 = 2 
>2 = 3  
NSP = 9 
Non=0 
Oui=1 
NSP=9 
Non=0 
Oui=1 
jj / mm / aa 
Non = 0  
Oui = 1  
NSP =9 
Voir codes 
Non=0 
Oui=1 
NSP=9 
Non=0 
Oui=1 
jj / mm / aa 
Non = 0  
Oui = 1  
NSP =9 
Voir codes 
4.1       __ / __ /12     __ / __ /12   
4.2       __ / __ /12     __ / __ /12   
4.3       __ / __ /12     __ / __ /12   
4.4       __ / __ /12     __ / __ /12   
4.5       __ / __ /12     __ / __ /12   
4.6       __ / __ /12     __ / __ /12   
4.7       __ / __ /12     __ / __ /12   
4.8       __ / __ /12     __ / __ /12   
4.9       __ / __ /12     __ / __ /12   
4.10       __ / __ /12     __ / __ /12   
4.11       __ / __ /12     __ / __ /12   
4.12       __ / __ /12     __ / __ /12   
Annexes | 227 
 
D. ACCEPTABILITE DU VACCIN CONTRE LE CHOLERA 
 
D.1. Pour les enfants âgés de 1 à 14 ans (reporter l’âge et le sexe depuis les tableaux B3 et C3, prenez les autres informations en discutant avec les parents des enfants ou 
leur responsable). 
 
 
Id 
Age Sexe 
Effets indésirables 
 1er tour 2ème tour 
 
Malade? Symptômes ? 
Consultation 
? 
Malade? Symptômes ? 
Consultation 
? 
 
(en 
année
s) 
Homme
=0 
Femme=
1 
Non = 0  
Oui = 1  
NA=8 
NSP =9 
Codes, séparés par une 
virgule 
Non = 0  
Oui = 1  
NA=8 
NSP =9 
Non = 0  
Oui = 1  
NA=8 
NSP =9 
Codes, séparés par une 
virgule 
Non = 0  
Oui = 1  
NA=8 
NSP =9 
Enfants âgés de 1 
à 4 ans 
2.1         
2.2         
2.3         
2.4         
2.5         
2.6         
2.7         
2.8         
Enfants âgés de 5 
à 14 ans 
3.1         
3.2         
3.3         
3.4         
3.5         
3.6         
3.7         
3.8         
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D.3. Pour les adultes (15 ans et plus) présents, poser leur les questions suivantes : 
 
 
Id 
Age Sexe Présent? 
Effets indésirables Acceptabilité Complè
-tement 
protégé 
avec 1 
dose ? 
Complè-
tement 
protégé 
avec 2 
doses ? 
1er tour 2ème tour Entendu 
parler 
campagn
e ? 
Effet sur 
la santé ? 
Rendre 
malade ? 
Goût ? 
Vacciné à 
nouveau 
? Malade? 
Symptôme
s ? 
Consulta
-tion ? 
Malade? 
Symptômes 
? 
Consulta
-tion ? 
(en 
année
s) 
Homme
=0 
Femme=
1 
Non = 0 
Oui = 1 
Non = 0  
Oui = 1  
NA=8 
NSP =9 
Codes, 
séparés par 
une virgule 
Non = 0  
Oui = 1  
NA=8 
NSP =9 
Non = 0  
Oui = 1  
NA=8 
NSP =9 
Codes, 
séparés par 
une virgule 
Non = 0  
Oui = 1  
NA=8 
NSP =9 
Non = 0  
Oui = 1  
NSP =9 
Pas 
d'effet=0 
Mauvais 
effet=1 
Bon effet = 
2  
NSP = 9 
Non = 0  
Oui = 1  
NSP =9 
Mauvais=0 
Bon = 1  
Pas 
d'opinion=8  
Pas vacciné = 9 
Non = 0  
Oui = 1  
NSP =9 
Non = 0  
Oui = 1  
NSP =9 
Non = 0  
Oui = 1  
NSP =9 
4.1                 
4.2                 
4.3                 
4.4                 
4.5                 
4.6                 
4.7                 
4.8                 
4.9                 
4.10                 
4.11                 
4.12                 
 
Annex 4. Notification form of adverse events following immunization 
 
 
CENTRE/POSTE DE SANTE 
Nom du Centre santé/Poste de 
vaccination 
 
Village / Sous-prefecture  
Date de la consultation           __ / __ / 2012 
Nom et prénom de la personne remplissant la feuille : ___________________________ 
 
IDENTIFICATION DE LA PERSONNE SOUFFRANT D’EFFETS INDESIRABLES 
Nom  
Prénom  
Sexe Homme  H [  ]      Femme  F [  ] 
Si femme, enceinte ?  Oui 1 [  ]  Non 0 [  ]  Ne sait pas  9 [  ] 
Date de naissance/Age _ _ / _ _ / _ _ _ _                             Age    _______ ans 
Carte de vaccination Oui 1 [  ]  Non 0 [  ]  
 
Nom du 
Vaccin 
Date de 
vaccination 
Heure de 
vaccination 
Dose (1er/ 
2ème) 
Numéro de 
lot 
Date 
d’expiration 
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RENSEIGNEMENTS MEDICAUX 
La personne a-t-elle des antécédents allergiques ?  Oui 1 [  ]  Non 0 [  ]  Ne sait pas  9 [  ]  
Si oui, à quoi la personne est-elle allergique ?   
Date et heure où les symptômes ont débuté ?  
La personne présente-t-elle les symptômes suivants ? (Cochez les symptômes et indiquer sévérité) 
- réaction allergique    - démangeaisons    - Douleur à la gorge   
- Déshydratation   - bouche sèche    - toux    
- Douleur abdominale   - fièvre > 38°C   - Fatigue   
- diarrhée    - ulcère oral    - Étourdissement   
- vomissement    - éruption cutanée   - Maux de tête   
- nausées    - Modification de la 
couleur des urines 
  - autres 
Décrire les symptômes : 
 
 
 
Pour le cas sévères (grade 3, 4 et 5) une feuille supplémentaire sera remplie par le Dr. Soumah 
RESULTATS 
Résultat : Résolu 1 [  ]  Traitement ambulatoire 2 [  ]  Transféré  3 [  ]   Décédé  4 [  ] Inconnu 5 [  ] 
Si décédé, date de décès : _ _ / _ _ / _ _ _ _     Autopsie : oui  [  ]   Non  [  ]  Inconnu  [  ] 
Si la personne a été transférée, indiquez où ?  
RELATION AVEC LE VACCIN :  
Non lié 1 [  ]  Improbable 2 [  ]  Possible 3 [  ]   Probable 4 [  ] Très probable 5 [  ] Données insuffisantes 6 [  
] 
 
Investigation nécessaire : Oui  [   ]  Non  [  ]   ; Si oui, date des investigations _ _ /_ _ /_ _ _ _ 
Résultats des investigations : 
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Annex 5. Informed consent : case-control study 
 
 
Feuille d’information pour les cas se présentant dans une structure de prise en charge du choléra dans la zone 
d’étude.   
 
Nous travaillons en collaboration avec le Ministère de la Santé et de l’Hygiène publique de République de 
Guinée. Nous menons une étude sur le choléra, qui est une maladie commune dans ce pays.  
 
Le choléra cause de nombreux cas de diarrhées sévères chez les enfants et les adultes en Guinée. Un vaccin 
contre le choléra donné par voie orale (par la bouche) est maintenant qualifié par l’Organisation Mondiale de la 
Santé et disponible. Des études menées dans d’autres pays ont permis de démontrer que ce vaccin protégeait 
contre le choléra, sans effet secondaire. Le Ministère de la Santé et de l’Hygiène publique de République de 
Guinée, en collaboration avec des organisations internationales, a réalisé une campagne de vaccination de masse 
contre le choléra dans cinq sous-préfectures de la préfecture Boffa. Nous souhaiterons maintenant évaluer les 
résultats de cette campagne de masse.  
 
Nous vous demandons votre permission pour vous inclure, ou inclure l’enfant sous votre responsabilité, dans 
cette étude. Vous (ou l’enfant sous votre responsabilité) avez été sélectionné car vous (ou l’enfant sous votre 
responsabilité) habitez dans une des sous-préfectures ayant bénéficié de la campagne de vaccination et êtes 
venus consulter ce centre de traitement à cause de diarrhées aqueuses survenues pendant ou après la campagne 
de vaccination. 
 
Si vous acceptez de participer, un échantillon de vos selles (ou des selles de l’enfant sous votre responsabilité) 
sera prélevé. Cet échantillon sera testé pour le choléra. Ceci sera complètement gratuit. Cette procédure est une 
procédure de routine pour le diagnostic du choléra. Vous (ou l’enfant sous votre responsabilité) serez traité selon 
les guides standards de prise en charge des cas de diarrhées. Nous vous poserons ensuite quelques questions 
vous concernant (ou concernant l’enfant sous votre responsabilité) comme par exemple le village où vous (ou 
l’enfant sous votre responsabilité) vivez, la source où vous prenez l’eau pour boire, le nombre de personnes 
vivant dans votre ménage, ou si vous avez reçu le vaccin contre le choléra lors de la campagne de masse. Vos 
réponses à ces questions nous aideront à évaluer les facteurs de risque et de protection contre le choléra. Les 
résultats de cette étude nous permettront d’améliorer les connaissances sur ce vaccin, et d’augmenter son 
utilisation en Guinée et dans d’autres pays. 
 
Le questionnaire devrait durer environ 30 minutes. En participant à cette recherche, vous ne vous exposez à 
aucune sensation douloureuse.  
 
Nous vous informerons du résultat du test diagnostic réalisé sur l’échantillon de selles que nous aurons prélevé 
pour savoir si vos diarrhées (ou celles de l’enfant sous votre responsabilité) sont dues ou non au choléra. Vous  
n’aurez aucune dépense financière liée à votre participation à l’étude, et vous ne recevrez pas d’argent. Toutes 
les informations que vous donnerez resteront confidentielles. Epicentre archivera les questionnaires dans un 
endroit sécurisé fermé à clef et les données ne pourront être utilisées que pour ce projet.  
 
Vous (ou l’enfant sous votre responsabilité) n’êtes pas obligé de participer à ce projet de recherche, et votre refus 
n’aura pas de conséquence sur votre prise en charge et votre traitement. Vous (ou l’enfant sous votre 
responsabilité) bénéficierez du même traitement dont vous auriez bénéficié en participant à l’étude.  
 
Vous (ou l’enfant sous votre responsabilité) pouvez choisir d’interrompre votre participation à ce projet de 
recherche à n’importe quel moment pour quelque raison que ce soit, sans perdre aucun de vos droits en tant que 
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patient. Votre traitement (ou celui de l’enfant sous votre responsabilité) n’en sera aucunement affecté. 
  
Si vous avez la moindre question, vous pouvez nous la poser maintenant ou plus tard. Si vous souhaitez poser 
une question plus tard, vous devrez contacter Dr. Melat Haile, téléphone X1. 
 
Ce projet de recherche a été revu et approuvé par le Comité national de bioéthique de République de Guinée, 
dont la tâche est de s’assurer que les personnes participant à cette recherche sont protégés. Si vous souhaitez en 
savoir plus sur ce comité d’éthique, contactez Dr. Apha Amadou Diallo, téléphone X2. 
 
 
Certificat de consentement 
 
J’ai été invité(e) (ou l’enfant dont je m’occupe a été invité) à participer à la recherche sur le choléra. J’ai lu les 
informations fournies ci-dessus ou quelqu’un me les a lues. J’ai eu la possibilité de poser des questions à ce sujet, 
et toutes les questions que j’ai posées ont trouvé une réponse satisfaisante. J’accepte volontairement de participer 
(ou que l’enfant dont je m’occupe participe) comme sujet d’étude et j’ai compris que j’ai le droit de me retirer de 
cette étude à n’importe quel moment sans que cela n’affecte d’aucune manière ma prise en charge médicale (ou 
celle de l’enfant dont je m’occupe). 
 
 
Nom du sujet                                                                      Date et Signature du sujet 
 
 
___________________________   ___________________________  
    ___/___/___ (jj/mm/aa) 
  
 
Si la personne n’est pas lettrée 
 
Nom d’un témoin lettré                               Date et Signature du témoin 
(si possible, cette personne devra être choisie par  
le participant  et ne pas avoir de connexion  
avec l’équipe de recherche) 
 
___________________________   ___________________________  
    ___/___/___ (jj/mm/aa) 
        
 
Nom du chercheur                              Date et Signature du chercheur 
___________________________   ___________________________  
    ___/___/___ (jj/mm/aa) 
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Annex 6. Vaccine effectiveness (case-control study) questionnaire 
 
 IDENTIFICATION DE LA STRUCTURE DE SOIN 
X1 NOM DE LA STRUCTURE : ___________________________ 
X2 VILLE / VILLAGE : ________________________ 
X3 DATE DE REMPLISSAGE DU QUESTIONNAIRE : ……/……./ 2012 (jj/mm/aaaa) 
X4 Personne en charge du remplissage __________________________ 
 
PERSONNE CAS 
SUSPECT DE CHOLERA 
C [_]  PERSONNE QUI N’A JAMAIS 
ATTRAPPE LE CHOLERA DEPUIS 
FEVRIER 2012 
T [_] 
X
5 
CODE CAS  [         ]  X7 Témoins communautaires : 
Pour le Cas (code)  [        ]  Témoin A-D [___] 
X
6 
COORDONNÉES GPS DONNÉES : 
 
LAT: N  ..................................... 
 
LONG : W …………......................... 
 X8 COORDONNÉES GPS DONNÉES : 
 
LAT: N  .......................................... 
 
LONG : W …………........................... 
 
 IDENTIFICATION (à remplir pour les CAS et les TEMOINS) 
A1 NOM : …………………………………………………………….. 
A2 SEXE :  HOMME H[_]    FEMME F[_] A3 AGE   [             ] ANS 
A4 SOUS-PREFECTURE : 
BOFFA-CENTRE 1[_]    DOUPROU 2[_]   KOBA 3[_]    TAMITA 4[_]  TOUGNIFILI 5[_]       MANKOUNTAN  6[_]          
A5 VILLAGE ......................................   
A7 ADRSESE (N° ET RUE OU POINTS DE REPERE): _________________________________ 
______________________________________________________________________ 
Si la personne est malade de choléra, remplissez le tableau B à la page 2 
Si la personne est non malade de choléra, remplissez le tableau C à la page 3 
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 (CAS) 
 
B PERSONNE CAS SUSPECT DE CHOLERA                                            
 INFORMATIONS RECUEILLIES A LA CONSULTATION DU CENTRE DE SANTE 
B1 Numéro du cas dans le registre [                                     ] 
B2 Date d’admission au centre de sante ……../……../………. 
B3 Date du début de la diarrhée ……../……../………. 
B4 Type de diarrhée: Aqueuse 1[_] 
 Sanglante 2[_] 
 Autre 3[_] ………………………………… 
B5 Déshydratation : Pas de déshydratation (A) A[_]     
                                 Un peu déshydraté (B) B[_]      
 Déshydratation sévère (C) C[_] 
                                 Ne sait pas N[_] 
B6 Le malade est encore au centre de santé:    Non 0[_]    Oui 1[_] 
B7 Si « Non », date de sortie : …....../…......./............... 
  
  
VERIFICATION D’AUTRES INFORMATIONS D’ELIGIBILITE AUPRES DU MALADE : 
  Oui Non 
B8 Viviez-vous dans un village de la préfecture de Boffa avant  
le 18 / 04 / 2012 ? 
[_] [_] 
B9 Aviez-vous au moins 1 an au 22 / 04 / 2012 ? [_] [_] 
B10 Avez-vous eu au moins trois selles aqueuses en 24 heures avant de vous 
rendre au centre de santé ? 
[_] [_] 
B11 La diarrhée a-t-elle commencé après le 25 / 04 / 2012 ? [_] [_] 
B12 Acceptez-vous de participer ? [_] [_] 
 
ATTENTION : 
Continuez le questionnaire UNIQUEMENT SI la personne choisie comme cas a répondu « OUI » à TOUTES 
les questions en haut. 
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 (TEMOINS) 
 
C PERSONNE QUI N’A JAMAIS ATTRAPE LE CHOLERA DEPUIS FEVRIER 2012                 
  
Vérifier si la tranche d’âge de la personne non malade que vous allez interroger (témoin) est bien du 
même sexe et de la même tranche d’âge que la personne malade (cas) à laquelle elle est appariée : 
C1 Sexe du cas : Homme H[_]    Femme F[_]     
C2 Sexe du témoin : Homme H[_]    Femme F[_]     
C3 Tranche d’âge du cas: 1-4[_]   5-9[_]   10-19[_]   20-29[_]   30-39[_]   40-49[_]   plus de 50 ans [_] 
C4 Tranche d’âge du témoin 1-4[_]   5-9[_]   10-19[_]   20-29[_]   30-39[_]   40-49[_]   plus de 50 ans [_] 
  
  
Vérification d’autres informations d’éligibilité : 
  Oui Non 
C5 Viviez-vous dans un village de la préfecture de Boffa avant  
le 18 / 04 / 2012 ? 
[_] [_] 
C6 Aviez-vous au moins 1 an au 22 / 04 / 2012 ? [_] [_] 
C7 Avez-vous souffert de diarrhées aqueuses aigües en 2012 ?  [_] [_] 
C8 Etes-vous allé dans un centre de santé en 2012 pour des diarrhées aqueuses 
aigües? 
[_] [_] 
C9 Si non, si vous aviez eu des diarrhées aqueuses aigües, seriez-vous allé dans un 
centre de santé ? 
[_] [_] 
 
ATTENTION : 
Continuez le questionnaire UNIQUEMENT SI cette personne choisie comme témoin a répondu « OUI » aux 
questions C5, C6 et C9 en haut et « NON» aux questions C7 et C8. 
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(CAS ET TEMOINS) 
D STATUT SOCIO-ÉCONOMIQUE  
D1 Quelle est votre profession ?  
Commerçant 1[_]    Marchand 2[_]   Cultivateur 3[_]   Ecolier/Elève 4[_]   Extracteur sel  5[_]    
 Pêcheur 6[_]    Ménagère 7[_]   Pas de travail 8[_]   Autre 9[_]  ………………… Ne sait pas 99[_]   
D2 Quel est le niveau d’études du chef du foyer ? 
Aucun 0[_]       Primaire  1[_]         Secondaire 2[_]                Universitaire 3[_]      Ne sait/rappelle pas 9[_] 
D3 Votre famille possède-t-elle : 
Radios     Non 0[_]    Oui 1[_]    Ne sait pas 9[_]   
Vélo         Non 0[_]    Oui 1[_]    Ne sait pas 9[_]   
Téléphone portable     Non 0[_]    Oui 1[_]    Ne sait pas 9[_]   
Générateur   Non 0[_]    Oui 1[_]    Ne sait pas 9[_]       
Télévisions    Non 0[_]    Oui 1[_]    Ne sait pas 9[_]   
Frigo              Non 0[_]    Oui 1[_]    Ne sait pas 9[_]   
Cuisinière/Four (électrique ou gaz)    Non 0[_]    Oui 1[_]    Ne sait pas 9[_]   
Bateau/Pirogue       Non 0[_]    Oui 1[_]    Ne sait pas 9[_]   
D4 Combien de personnes vivent dans le foyer ?  _______ personnes 
D5 Combien d’enfants de moins de 5 ans ?_______ Combien d’enfants entre 5 et 15 ans ? ______ 
D8 Combien d’enfants entre 5 et 15 ans vont à l’école ? _______ 
E CONDUITE VIS-A-VIS DU SOIN 
E1 Distance par rapport au centre de santé en km ___________________ 
E2 Combien de temps vous faut-il pour aller au centre de santé ?   ______________________ 
E3 Par quel moyen de transport  
A pied 1[_]  Moto 2[_] Voiture 3[_] Transport public 4[_] Autre 5[_], préciser   _______________ 
E4 Si vous aviez une diarrhée, où iriez-vous chercher des soins ?  
Lister dans l’ordre les endroits cités par la personne : 
_____________________________________________________________________________________________
___________________________________________________________ 
F HISTORIQUE DU CHOLÉRA & DES CONTACTS A RISQUE 
F1 En ce moment, y a-t-il des cas de choléra (ou symptômes similaires) dans la maison ? 
Non 0[_]    Oui 1[_]    Ne sait pas 9[_] 
F2 Dans les 7 derniers jours, y a-t-il eu des cas de choléra (ou symptômes similaires) dans votre entourage 
(voisins, amis, collègues…) ? 
Non 0[_]    Oui 1[_]    Ne sait/rappelle pas 9[_] 
F3 Dans les 7 derniers jours, avez-vous voyagé ou reçu une visite de la part des personnes provenant d’une 
autre localité ? Non 0[_]    Oui 1[_]    Ne sait/rappelle pas 9[_] 
F4 Dans les 7 derniers jours, avez-vous participé à un enterrement ou retrait de deuil de quelqu’un suspect 
de choléra ? Non 0[_]    Oui 1[_]    Ne sait/rappelle pas 9[_] 
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G APPROVISIONNEMENT EN EAU ET TRAITEMENT DE L’EAU 
G1 Dans quelle source d’eau vous approvisionnez-vous le plus souvent ? 
(Ne suggérez pas la réponse, une seule réponse possible) 
a. Pompe / Forage                                              1[_] 
b. Puits protégé (avec renforcement en ciment et un seul sceau)      2[_] 
c. Puits traditionnel (ouvert au ciel sans protection)                            3[_] 
d. Eau d’une source naturelle (rivière, mare…)                                  4[_] 
e. Autre : ___________________________                                      5[_] 
f. Ne sait pas                                                                                       9[_] 
G2 Dans les 7 derniers jours, avez-vous pu traiter votre eau de boisson ? 
Non 0[_]    Au moins une fois 1[_]  Tous les jours 2[_]   Ne sait pas 9[_]   
G3 A la maison, le récipient utilisé pour stocker l’eau à boire est-t-il fermé par un couvercle ou par un 
bouchon ?  Non 0[_]    Oui 1[_]    Ne sait pas 9[_] 
H NOURRITURE CONSOMMEE DANS LES 7 DERNIERS JOURS 
H1 Dans les 7 derniers jours, avez-vous mangé de la nourriture vendue ou préparée dans un endroit 
publique (restaurant, sur la route) ? 
Jamais 0[_]    Au moins une fois 1[_]    Tous les jours 2[_]  Ne sait pas 9[_] 
I PRATIQUES D’ HYGIENE 
I1 Avez-vous du savon/cendres (pour le lavage des mains) à la maison en ce moment ? 
  Non 0[_]    Oui 1[_]    Ne sait/rappelle pas 9[_] 
I2 D’habitude, quand vous lavez-vous les mains ? 
(Ne suggérez pas la réponse et mettez une croix seulement aux réponses citées par le participant. Plusieurs 
réponses possibles.) 
Je ne me lave pas les mains  [_]    Aucune réponse [_] 
 
Avant de manger [_]    Après avoir mangé [_]    Après avoir été aux toilettes [_]    Après vous être occupé 
d’un enfant qui avait été aux toilettes [_]     
Avant de faire la cuisine [_]    Autre [_]  ………………………………….   
J TOILETTES/LATRINES 
J1 Ou est-ce que vous faites le plus souvent vos besoins ? 
Latrine privée 1[_]    Latrine partagée 2[_]    Fosse dans la cour 3[_]    Par terre 4[_]     
Dans la nature 5[_]    Autre 6[_]  …………………………………….       Ne sait pas 9[_]      
J2 Qui d’autre se sert des Toilettes/Latrines/Fosse que vous utilisez ? 
Uniquement le foyer 1[_]    Plusieurs foyers 2[_]    N’importe qui 3[_]    Ne sait pas 9[_]   
J3 Quelqu’un qui partage vos latrines a-t-il eu le choléra ou toute autre diarrhée au cours du dernier mois ?  
Non 0[_]    Oui 1[_]    Ne sait pas 9[_] 
J4 Les latrines sont-elles débordées ? 
Non 0[_]    Oui 1[_]    Pas possible de le voir 9[_] 
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K STATUT VACCINAL 
K1 Avez-vous été vacciné contre le choléra ? Non 0[_]    Oui 1[_]  Ne sait pas 9[_] 
 Si oui, demandez à voir la carte de vaccination. 
K2 Combien de doses avez-vous reçu ? 0 0[_]    1 1[_]    2 2[_]   Plus de 2 3[_]    NSP 9[_] 
  
1ère dose 
K3 1ère dose reçue ? Non 0[_]    Oui 1[_]    Ne sait pas 9[_] 
K4 Vérifié sur la carte de vaccination ? Non 0[_]    Oui 1[_]     
K5 Date de vaccination pour la 1ère dose : __ / __ / 2012      Ne sait pas [    ] 
K6 Lieu de vaccination pour la 1ère dose : _____________________ 
K7 Avez-vous recraché ou vomi en prenant la 1ère dose ? Non 0[_]    Oui 1[_]    Ne sait pas 9[_] 
  
2ème  dose 
K8 2ème dose reçue ? Non 0[_]    Oui 1[_]    Ne sait pas 9[_] 
K9 Vérifié sur la carte de vaccination ? Non 0[_]    Oui 1[_]     
K10 Date de vaccination pour la 2ème dose : __ / __ / 2012 
K11 Lieu de vaccination pour la 2ème dose : _____________________ 
K12 Avez-vous recraché ou vomi en prenant la 2ème dose ? Non 0[_]    Oui 1[_]    Ne sait pas 9[_] 
K13 D’après vous, une personne ayant reçu deux doses de vaccins contre le choléra peut-elle encore être 
malade du choléra ? Non 0[_]    Oui 1[_]    Ne sait pas 9[_] 
 
 
 
 
INFORMATIONS SUR LES ENQUETEURS 
 
 
Nom: …..................................................................   Signature: …………………………………… 
 
 
 
INFORMATIONS SUR LES SUPERVISEURS 
 
 
Nom: …..................................................................   Signature: ……………………………………  
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Annex 7. Characteristics of the case-patients and control-subjects: vaccine 
effectiveness study 
Table 1. Characteristics of the case-patients and control-subjects included in the vaccine effectiveness 
study, Boffa and Forécariah, Guinea, 2012 
 
Controls Cases 
  n (%) n (%) P value 
Profession 
    
0.18 
Trader 29 (18.1) 8 (20.0)
 Farmer 37 (23.1) 16 (40.0) 
 Pupil / student 29 (18.1) 3 (7.5) 
 Fisherman 10 (6.3) 3 (7.5) 
 Housewife 10 (6.3) 1 (2.5) 
 Unemployment 22 (13.8) 6 (15.0) 
 Other 23 (14.4) 3 (7.5) 
 Head of the household's educational degree 
    
0.13 
Non 43 (27.2) 13 (32.5)  
Primary 5 (3.2) 4 (10.0) 
 Secondary 21 (13.3) 2 (5.0) 
 University 5 (3.2) 0 (0.0) 
 Literate 84 (53.2) 21 (52.5) 
 Radio 113 (70.6) 27 (67.5) 0.68 
Bicycle 82 (51.2) 19 (47.5) 0.64 
Telephone 128 (80.0) 27 (67.5) 0.10 
Generator 36 (22.5) 6 (15.0) 0.28 
Television 36 (22.5) 6 (15.0) 0.27 
Fridge 1 (0.6) 0 (0.0) 0.50 
Boat 26 (16.3) 9 (22.5) 0.29 
Household size 
    
0.06 
0-4 members 34 (21.3) 17 (42.5)  
5-7 members 40 (25.0) 7 (17.5) 
 8-12 members 49 (30.6) 9 (22.5) 
 >12 members 37 (23.1) 7 (17.5) 
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  Controls  Cases  
  n (%) n (%) P value 
Proportion of children attending school in the 
household     0.60 
None of them 29 (17.6) 4 (9.8)  
Less than half 63 (38.2) 17 (41.5) 
 More than half 54 (32.7) 13 (31.7) 
 All of them 19 (11.5) 7 (17.1) 
 Distance to the closet health center 
    
0.15 
     Need of transport  51 (29.7) 17 (39.5)  
Walking distance 121 (70.3) 26 (60.5) 
 Other cholera cases in the household 6 (3.5) 2 (4.7) 0.69 
Travelling or receiving a visit in the last week 35 (20.3) 11 (25.6) 0.34 
Participation in a burial ceremony 2 (1.2) 1 (2.3) 0.23 
Water source 
    
0.11 
Pump 84 (48.8) 20 (46.5)  
Protected well 39 (22.7) 14 (32.6) 
 Unprotected well 6 (3.5) 2 (4.7) 
 Water from natural source 42 (24.4) 7 (16.3) 
 Other 1 (0.6) 0 (0.0) 
 Treatment of the drinking water 43 (25.4) 11 (25.6) 0.66 
Recipient to store drinking water with a lid 170 (98.8) 43 (100.0) 0.35 
Eating food in a public space 
    
0.21 
Never 117 (68.0) 28 (65.1)  
Sometimes 27 (15.7) 10 (23.3) 
 Soap available in the household 113 (65.7) 31 (72.1) 0.29 
Washing hands before eating 144 (83.7) 37 (86.0) 0.83 
Washing hands after eating 87 (50.6) 22 (51.2) 0.69 
Washing hands after going to the toilet 93 (54.1) 25 (58.1) 0.47 
Washing hands after cleaning a baby after 
defecation 16 (9.3) 3 (7.0) 0.59 
Washing hands before cooking 23 (13.4) 6 (14.0) 0.91 
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  Controls  Cases  
  n (%) n (%) P value 
Usual place of defecation     0.12 
Latrine 81 (50.6) 17 (42.5)  
Pit in the yard 56 (35.0) 14 (35.0) 
 In the ground 23 (14.4) 9 (22.5) 
 Sharing the latrine 
    
0.71 
Just for the household 31 (22.3) 6 (18.8)  
Several households 59 (42.4) 13 (40.6) 
 Anybody 49 (35.3) 13 (40.6) 
 Sharing the latrine with someone suffering 
from cholera 5 (3.7) 6 (20.0) 0.001 
Flooding latrine 13 (9.5) 4 (12.9) 0.54 
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Annex 7. Characteristics of the non-cholera watery diarrhea case-patients and 
control-subjects: inicator bias analysis. 
Table 2. Characteristics of the non-cholera watery diarrhea case-patients and control-subjects 
included in the indicator bias analysis, Boffa and Forécariah, Guinea, 2012. 
 
Controls Cases   
 n (%) n (%) P value 
Profession 
    
0.50 
Trader 22 (12.8) 8 (18.6)  
Farmer 48 (27.9) 9 (20.9) 
 Pupil / student 19 (11.0) 3 (7.0) 
 Fisherman 5 (2.9) 2 (4.7) 
 Housewife 26 (15.1) 8 (18.6) 
 Unemployment 36 (20.9) 11 (25.6) 
 Other 16 (9.3) 2 (4.7) 
 Head of the household's educational degree 
    
0.24 
Non 34 (19.9) 13 (31.0)  
Primary 16 (9.4) 3 (7.1) 
 Secondary 11 (6.4) 4 (9.5) 
 University 5 (2.9) 3 (7.1) 
 Literate 105 (61.4) 19 (45.2) 
 Radio 123 (71.5) 28 (65.1) 0.30 
Bicycle 91 (52.9) 21 (48.8) 0.55 
Telephone 124 (72.1) 31 (72.1) 1.00 
Generator 27 (15.7) 11 (25.6) 0.20 
Television 23 (13.4) 13 (30.2) 0.03 
Fridge 1 (0.6) 1 (2.3) 0.35 
Boat 31 (18.0) 8 (18.6) 0.71 
Household size 
    
0.61 
0-4 members 23 (13.5) 3 (7.0)  
5-7 members 41 (24.1) 9 (20.9) 
 8-12 members 57 (33.5) 15 (34.9) 
 >12 members 49 (28.8) 16 (37.2) 
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  Controls  Cases  
  n (%) n (%) P value 
Proportion of children attending school in the 
household     0.13 
None of them 33 (22.9) 14 (37.8)  
Less than half 42 (29.2) 11 (29.7) 
 More than half 51 (35.4) 8 (21.6) 
 All of them 18 (12.5) 4 (10.8) 
 Distance to the closet health center 
    
0.10 
  Need of transport  107 (66.9) 31 (77.5)  
Walking distance 53 (33.1) 9 (22.5) 
 Other cholera cases in the household 4 (2.5) 3 (7.5) 0.15 
Travelling or receiving a visit in the last week 42 (26.3) 13 (32.5) 0.41 
Participation in a burial ceremony 3 (1.9) 0 (0.0) - 
Water source 
    
0.98 
Pump 63 (39.4) 17 (42.5)  
Protected well 21 (13.1) 5 (12.5) 
 Unprotected well 10 (6.3) 2 (5.0) 
 Water from natural source 47 (29.4) 11 (27.5) 
 Other 19 (11.9) 5 (12.5) 
 Treatment of the drinking water 34 (21.3) 5 (12.8) 0.15 
Recipient to store drinking water with a lid 158 (98.8) 40 (100.0) 0.35 
Eating food in a public space 
    
0.02 
Never 72 (45.0) 11 (28.2)  
Sometimes 49 (30.6) 20 (51.3) 
 Soap available in the household 78 (49.1) 16 (40.0) 0.30 
Washing hands before eating 143 (89.4) 33 (82.5) 0.22 
Washing hands after eating 24 (15.0) 4 (10.0) 0.37 
Washing hands after going to the toilet 72 (45.0) 17 (42.5) 0.77 
Washing hands after cleaning a baby after 
defecation 12 (7.5) 1 (2.5) 0.20 
Washing hands before cooking 21 (13.1) 5 (12.5) 0.90 
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  Controls  Cases  
  n (%) n (%) P value 
Usual place of defecation     0.28 
Latrine 61 (35.5) 15 (34.9)  
Pit in the yard 81 (47.1) 17 (39.5) 
 In the ground 30 (17.4) 11 (25.6) 
 Sharing the latrine 
    
0.17 
Just for the household 73 (48.7) 13 (38.2)  
Several households 48 (32.0) 11 (32.4) 
 Anybody 29 (19.3) 10 (29.4) 
 Sharing the latrine with someone suffering from 
cholera 9 (7.1) 5 (16.7) 0.23 
Flooding latrine 11 (7.4) 4 (11.8) 0.39 
 
 
 
 
 
 
 
Annex 9. Vaccine coverage by age and sex of the cholera mass vaccination campaign in Boffa and Forécariah 
prefectures. 
 
Figure 1: Vaccine coverage by age and sex of the cholera mass vaccination campaign in Boffa and Forécariah prefecture, first 
round, second round and two doses (fully vaccinated), April-June 2012. 
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Annex 10. Geographical distribution of the vaccine coverage in Boffa and Forécariah prefectures. 
 
Figure 2: Vaccine coverage by age and sex of the cholera mass vaccination campaign in Boffa and Forécariah prefecture, first round, second 
round and two doses (fully vaccinated), April-June 2012. 
 
* The estimates of the spatial distribution of the vaccine coverage were obtanied applying a Gaussian kernel function to the point 
estimate of each cluster. The analysis were conducting using the package “spatstat” of R software v.2.10. 
